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ABSTRACT 
Beta-thalassaemia is a common genetic disorder in Malaysia. It is a haemolytic 
anaemia which is caused by mutations within the β-globin gene complex, affecting 
the synthesis of β-globin chains. This will result in excessive free α-globin chains 
causing α-globin chain toxicity. Erythropoiesis is also impaired leading to chronic 
anaemia. Beta-thalassaemia major babies may appear healthy at birth. However, 
symptoms such as jaundice and anaemia will start to develop as they reach six 
months of life. They require frequent transfusions to maintain haemoglobin levels 
which lead to iron-overload. Although chelation therapy is recommended, the 
patients are still under oxidative stress. Patients need to be monitored during their 
therapy to prevent any organ damage and mortality due to oxidative injuries. The 
current sampling method used to diagnose and monitor the β-thalassaemia major 
patients involved the use of venous blood. The sampling method is invasive and 
requires a phlebotomist to perform the procedure with minimal pain to paediatric 
patients. Assessment of non-invasive methods as alternative sampling procedure will 
be advantageous for the molecular and biochemical analysis of β-thalassaemia. The 
present study aims to genotype purified DNA extracted from non-invasive samples 
including mouthwash, saliva and buccal cytobrush samples and to assess the 
biochemical markers from saliva samples. Samples were collected from                    
β-thalassaemia major patients in University Malaya Medical Centre and healthy 
individuals. DNA was extracted using two alkaline lysis DNA extraction methods 
followed by organic purification to compare the concentration and purity. The 
purified DNA was amplified using various DNA amplification methods available to 
detect β-globin gene mutation present in the Malaysian population. Saliva samples 
were assessed for total non-enzymatic antioxidant capacity, level of protein and lipid 
peroxidation, activity of glutathione peroxidase (GPx), level of uric acid (UA) and 
iv 
cytokines tumor necrosis factor-α (TNF- α) and interleukin-6 (IL-6). Biochemical 
parameters were further analysed using parametric and non-parametric statistical 
analysis. Saliva samples provided highest amount of purified DNA compared with 
mouthwash and buccal cytobrush samples. In contrast, the DNA purity was the 
highest from mouthwash samples. DNA extraction Method 2, which used higher 
concentration of lysis agents and additional purification steps compared with Method 
1, provided purified DNA with better reproducibility. The surface area of sample 
collection site and the amount of leukocytes may have contributed to the high 
purified DNA concentration while the amount of mucin contributed to the purity. 
The level of GPx was higher in β-thalassaemia major patients. Strong correlation 
was also observed between ferric reducing antioxidant power (FRAP) assay and UA. 
When the β-thalassaemia major patients group was further sub-divided, there was a 
notable difference in the level of AOPP between genetic classification of                 
β-thalassaemia and the level TNF-α between ethnicity and age groups. Better 
chelation due to combination therapy, compliance, education and patient 
management may have helped in improving the oxidative stress status in                 
β-thalassaemia major patients. In conclusion, mouthwash and saliva can provide 
high quality purified DNA for reproducible molecular analysis and biochemical 
parameters in saliva samples are within detectable limits for biochemical assays. 
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ABSTRAK 
Beta-talasemia merupakan penyakit genetik yang lazim di Malaysia. Ia 
merupakan penyakit anemia hemolitik yang disebabkan oleh mutasi di kompleks gen   
β-globin, yang memberi kesan kepada penghasilan rantaian β-globin. Kecacatan ini 
mengakibatkan lebihan rantaian α-globin terbebas dan keracunan α-globin. 
Eritropoesis turut terganggu lalu menyebabkan anemia yang berpanjangan. Bayi     
β-talasemia kelihatan sihat ketika lahir. Namun, tanda-tanda seperti jaundis dan 
anemia mula kelihatan apabila bayi mencecah umur enam bulan. Mereka 
memerlukan pemindahan darah yang kerap untuk mengekalkan tahap hemoglobin, 
yang akhirnya membawa kepada masalah lebihan zat besi. Walaupun rawatan kelasi 
disarankan, masalah tekanan oksidatif masih dapat diperhatikan pada pesakit. 
Mereka perlu dipantau sepanjang rawatan bagi mengelakkan kerosakan organ dan 
kematian akibat kecederaan oksidatif. Kaedah pengambilan sampel yang masih 
digunakan kini untuk mendiagnos dan memantau pesakit melibatkan pengambilan 
darah vena. Kaedah ini adalah invasif dan memerlukan ahli flebotomi untuk 
melakukannya dengan kesakitan minima terhadap pesakit pediatrik. Penilaian 
terhadap sampel tidak invasif pastinya akan memberi faedah dalam analisis 
molekular dan biokimia β-talasemia. Kajian ini bertujuan untuk menganalisa DNA 
dari sampel kumuran, air liur dan kesatan mulut dan menganalisa penanda biokimia 
dalam air liur. Sampel dikutip dari pesakit β-talasemia major di Pusat Perubatan 
Universiti Malaya dan individu sihat. DNA diasingkan menggunakan dua kaedah 
lisis beralkali diikuti penulenan menggunakan pelarut organik bagi membandingkan 
kepekatan dan ketulenannya. DNA tertulen diganda dengan pelbagai kaedah untuk 
mengesan mutasi gen β-globin yang lazim dalam populasi Malaysia. Air liur 
dianalisa untuk mengesan jumlah kapasiti antioksida bukan enzimatik, tahap 
peroksidaan protein dan lemak, aktiviti glutation peroksidase (GPx), tahap asid urik 
vi 
(UA) dan sitokin ‘tumor necrosis factor-α’ (TNF-α) dan ‘interleukin-6’ (IL-6). 
Parameter biokimia dinilai dengan ujian statistik parametrik dan bukan parametrik. 
Air liur menghasilkan DNA berkepekatan tinggi berbanding kumuran dan kesatan 
pipi. Sebaliknya, DNA paling tulen diperoleh dari sampel kumuran. Kaedah 
pengasingan DNA ke-2, yang menggunakan agen lisis berkepekatan lebih tinggi dan 
penambahan langkah penulenan berbanding kaedah pertama, menghasilkan DNA 
tertulen yang lebih mudah disalin semula. Luas permukaan kawasan pengambilan 
sampel dan kandungan leukosit mungkin memberi kesan terhadap kepekatan DNA 
manakala kandungan musin mempengaruhi ketulenan DNA. Tahap aktiviti GPx 
lebih tinggi di kalangan pesakit β-talasemia major. Hubungan kukuh dapat 
diperhatikan antara ‘ferric reducing antioxidant power’ (FRAP)  dan UA. Apabila 
kumpulan pesakit β-talasemia major dipecahkecilkan, terdapat perbezaan ketara 
pada tahap AOPP mengikut klasifikasi genetik β-talasemia dan tahap TNF-α 
mengikut kumpulan etnik dan umur. Rawatan kelasi yang lebih baik melalui terapi 
gabungan, kesesuaian, pengetahuan terhadap terapi dan pengurusan pesakit mungkin 
membantu memperbaiki status tekanan oksidatif di kalangan pesakit β-talasemia 
major. Kesimpulannya, sampel kumuran dan air liur mampu membekalkan DNA 
berkualiti tinggi bagi analisis molekular dan kepekatan parameter biokimia dalam air 
liur berada di tahap yang mampu dikesan bagi analisa biokimia.  
 
. 
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CHAPTER 1: INTRODUCTION 
Thalassaemia is a public health problem in Malaysia. About 4.5% of the 
Malaysian population are β-thalassaemia carriers and the estimated prevalence of  
β-thalassaemia major children is 2.1 in 1000 births (George, 2001). Until 2009, 
4541 patients were registered in the Malaysian Thalassaemia Registry, with more 
than 3000 patients identified with Haemoglobin E (HbE)/β-thalassaemia and          
β-thalassaemia major (Abdul Wahab et al., 2011).  
Beta-thalassaemia occurs when there are point mutations, additions or deletions 
in the β-globin gene complex which is located on the short arm of chromosome 11. 
The effects of mutation on gene transcription result in reduced or absence of          
β-globin chain production. The reduced amount of β-globin chain production 
indirectly increases the level of unpaired α-globin chains. Insoluble free α-globin 
chains adhere easily to the cellular membranes of red blood cells and disrupt the 
integrity of the cell membranes. Red blood cells thus become more fragile and lead 
a shortened life span (Weatherall & Clegg, 2001).  
Beta-thalassaemia carriers present as asymptomatic to mildly anaemic 
individuals. This asymptomatic manifestation causes β-thalassaemia carriers to not 
realise that they are carriers of a genetic disorder. Couples with β-thalassaemia have 
a 25% risk of producing a β-thalassaemia major child.  
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Beta-thalassaemia major babies appear to be normal in the early months of life. 
The effects of reduced or zero β-globin chain synthesis is not prominent as yet, 
since the most dominant haemoglobin for oxygen circulation in the early months of 
life is foetal haemoglobin (HbF). The symptoms begin to appear after the adult 
haemoglobin (HbA) replaces the HbF, at around six months of life.                    
Beta-thalassaemia major babies develop jaundice, are anaemic, and require regular 
blood transfusions for survival. Molecular characterisation for β-thalassaemia 
mutations in parents who are carriers and prenatal diagnosis are performed to avoid 
the birth of thalassaemia major children (Cao & Kan, 2012).  
The most common approach to obtain DNA for molecular analysis is blood 
sample collection. The most common site for blood drawing is the median cubital 
vein in the elbow. A skilful phlebotomist is required to perform the collection safely 
without causing discomfort or side effects such as haematoma and nerve injury 
(Rayegani & Azadi, 2007; Stitik et al., 2001). Paediatric thalassaemia major patients 
are often frail and their veins collapse easily, thus making blood collection more 
difficult. Another option for blood collection is from the dorsal metacarpal vein but 
this is generally uncomfortable for the patients.  
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Recent studies involving non-invasive sampling for molecular and biochemical 
studies have gained popularity. Besides being painless, the procedure is simple and 
can be carried out by the patients or subjects themselves. Previous studies showed 
that the analytes in saliva were significantly correlated to that in serum or plasma 
(Sculley & Langley-Evans, 2002), and that DNA was successfully isolated from 
buccal cells for genomic studies (Lum & Marchand, 1998). The common            
non-invasive samples include mouthwash, saliva, and buccal swab.  
The presence of oxidative stress in disease conditions has been well documented 
(Kassab-Chekir et al., 2003; Livrea et al., 1996). However most of these studies 
were based on blood oxidative stress indices levels. The assessment and evaluation 
of oxidative stress particularly in β-thalassaemia major patients is very crucial as 
they are susceptible to oxidative damage induced by iron overload. Regular 
assessment of oxidative stress status will be useful in the clinical management and 
proper intervention in order to improve the quality of life, reduce complications and 
mortality in β-thalassaemia patients.  
A study on oxidative stress indices level on β-thalassaemia major patients 
attending blood transfusion in University of Malaya Medical Centre was previously 
carried out. The level of advanced oxidative protein products (AOPP), lipid 
hydroperoxide (LOOH), and enzyme activities such as glutathione peroxidase 
(GPx) and catalase were measured in plasma and peripheral blood mononuclear cell 
lysate (Kuppusamy & Tan, 2011).  
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The use of non-invasive techniques to obtain biological samples for DNA 
evaluation and biochemical assessment in paediatric patients will be well received 
by both patients and their parents. This study will establish techniques to effectively 
extract DNA from mouthwash, saliva and buccal cells for genotyping purposes and 
to assess the oxidative stress levels in thalassaemia major patients. 
1.1 Objectives  
The objectives of this study are:  
1.1.1 Genotyping of DNA from non-invasive samples  
i. To optimise and establish DNA extraction techniques from mouthwash, 
saliva and buccal swab samples from β-thalassaemia major patients 
ii. To determine and compare the concentrations and purities of extracted 
DNA from the different samples  
iii. To carry out molecular characterisation of DNA extracted from 
mouthwash, saliva and buccal cells using different DNA amplification 
techniques.  
1.1.2 Assessment of biochemical markers in saliva samples  
i. To estimate oxidative stress levels via measurement of lipid 
hydroperoxide, advanced oxidation protein products, ferric reducing 
antioxidant power, uric acid and glutathione peroxidase activity.  
ii. To determine salivary inflammatory markers TNF-α and IL-6.  
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CHAPTER 2: LITERITURE REVIEW 
2.1 Cooley’s anaemia  
Thalassaemia was first reported by Thomas Benton Cooley in 1925, following 
observation of four anaemic paediatric patients with hepatosplenomegaly and 
discoloration of the skin and sclera (white eye). Blood analysis showed that these 
patients presented with nucleated red blood cells, leukocytosis and resistance of red 
cells towards hypotonic lysis. The patients also presented with enlargement of facial 
and cranial bones described as “mongoloid appearance”. These patients with 
Cooley’s anaemia were later confirmed with homozygous β-thalassaemia (Cooley & 
Lee, 1925).  
The term thalassaemia originated from the Greek words - ‘thalassa’ which means 
‘the sea’, referring to the Mediterranean Sea and ‘emia’ which means ‘blood’. This 
‘sea blood’ referred to the high frequency of thalassaemia found in populations in 
the Mediterranean region. The thalassaemia genes are widely distributed among the 
Mediterranean population, including the populations in the Middle East and 
Southeast Asia.  
In the early times, thalassaemia major patients did not survive even to the first 
decade of life. With the introduction of blood transfusion treatments, thalassaemia 
major patients can now live up to their third decade of life and longer by 
maintaining normal haemoglobin (Hb) levels (Piomelli et al., 1969; Prabhu et al., 
2009).  
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2.2 Basics of red blood cells synthesis  
2.2.1 Haematopoiesis and erythropoiesis in normal individuals  
Haematopoiesis takes place during the first few weeks of gestation in the yolk 
sac of embryos. Starting from the sixth week until the sixth to seventh month          
in utero, production of blood cells is predominated by the liver and spleen and 
continues until the second week after birth.  
The bone marrow takes over the process of haematopoiesis beginning from the 
sixth to seventh week after birth. During infancy, the bone marrow is involved in 
production of blood cellular components and production is more focused in the 
central skeleton and proximal ends of femurs and humeri towards adulthood. This is 
due to the progression of fatty/yellow marrow replacement starting in early 
childhood and involving marrow in the long bones (Hoffbrand & Pettit, 2000).  
In a normal state, human erythrocytes are produced and develop to maturity in 
the red bone marrow. Differentiation of pluripotential stem cells to anucleated 
erythrocytes are regulated by various growth factors such as erythropoietin. 
Erythropoietin controls the erythrocyte production by maintaining the number of 
circulating erythrocytes (Besa et al., 1992).  
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2.2.2 Beta-globin gene cluster and haemoglobin synthesis  
The β-globin gene complex is located on the short (p) arm of chromosome 11 
(Figure 2.1a). The cluster is approximately 34 kb long and consists of five 
functional globin genes, located from  the 5’ to 3’ end; epsilon (ε)-, gamma-G (Gγ)-,             
gamma-A (
Aγ)-, delta (δ)-, and β-globin genes. The genes located in this cluster are 
involved in production of globin chains of the β-globin family, and pair with the 
globin chains from the α-globin family to form functional haemoglobin (Weatherall 
& Clegg, 1979). The β-globin gene is 1.606 kb in length and consists of 3 exons and 
2 introns (Figure 2.1b).  
(Adapted from Thein (1998); Weatherall & Clegg (2001)) 
 
Figure 2.1a & b The β-globin gene complex on chromosome 11 and the             
β-globin gene  
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Haemoglobin molecules are tetrameric structures, made up of two pairs of 
different globin molecules attached together with one haem molecule in each globin 
chain. The genes present in the cluster are arranged according to the order of 
expression at different stages of life (Hoffbrand & Pettit, 2000). Table 2.1 
summarises the type of haemoglobin present in human throughout the different 
stages of life.  
 
Table 2.1 Haemoglobin synthesised at various stages of human life 
Stage  Haemoglobin  Globin chain 
Embryonic  
(Up to 6 weeks) 
Hb Gower I ζ2ε2 
Hb Gower II  α2ε2 
Hb Portland I  ζ2γ2 
Hb Portland II (minor Hb) ζ2β2 
Hb Portland III (minor Hb) ζ2δ2 
Foetal  HbF α2γ2 
Adult  HbA (97%) α2β2 
 HbA2 (2% - 3%) α2δ2 
 HbF (<1%) α2γ2 
(Reference: Bunn & Forget (1986); Weatherall & Clegg (2001)) 
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Starting from the thirteenth week of gestation, β-globin chain synthesis has 
already started with the production of adult haemoglobin (HbA) which comprises of 
two α-globin chains and two β-globin chains (α2β2). Production increases gradually 
in utero until it reaches 20 - 40% of the total haemoglobin in the foetal circulation at 
birth, while HbF (α2γ2) still functions as the main circulating haemoglobin 
(Turgeon, 2005).  
After birth, the HbA level continues to increase while HbF reduces as HbA starts 
to take over the oxygen transport function. After 6 months of birth, HbA is the main 
functioning haemoglobin for cellular respiration and comprises over 95% of the 
total adult haemoglobin (Hoffbrand & Pettit, 2000).  
In order to function properly, the amount of β-globin chains produced needs to 
correspond to the amount of α-globin chains. Disturbance in α- or β-globin chain 
synthesis will result in globin chain imbalance and produce abnormal haemoglobin. 
The abnormal haemoglobin will not be able to transport oxygen effectively and will 
lead to physiological problems in the affected individuals (Besa et al., 1992).  
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2.3 Beta-thalassaemia  
Beta-thalassaemia is a condition where productions of functional β-globin chains 
are reduced or absent. This leads to a condition of excessive amounts of free          
α-globin chains, which will precipitate in the form of inclusions. The inclusions 
damage the erythroid precursor cells, indirectly reducing the efficacy of 
erythropoiesis leading to anaemia (Cao et al., 2000 ; Weatherall & Clegg, 2001).   
2.3.1 Cause of β-thalassaemia 
Beta-thalassaemia is mainly caused by point mutations. This includes single base 
substitutions, deletions and insertions within the β-globin gene (Weatherall & 
Clegg, 2001).  
The effect of gene mutations depends on the location of the point mutation. For 
example, changes at the promoter site may reduce the β-globin chain synthesis by 
altering the mRNA transcription rate. On the other hand, mutations altering splicing 
sites may lead to improper mRNA translation and totally disrupt β-globin chain 
synthesis.  
Beta-thalassaemia can also be caused by gene deletions. Large size deletions 
such as Filipino β-deletion and Thai (3.5 kb) deletions remove the entire β-globin 
gene. Thus, β-globin chains are not synthesised and this results in anaemia (Lynch 
et al., 1991; Motum et al., 1993; Ziffle et al., 2011).  
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2.3.2 Pathophysiology of β-thalassaemia 
A reduction of β-globin chain synthesis results in excessive amount of free        
α-globin chains, which is insoluble and will precipitate intracellularly. The 
precipitations will disturb DNA synthesis and halt mitosis of the precursor cells. 
Degradation products of α-globin chains can disturb cellular membranes and cause 
cells to be removed from circulation. Indirectly, this affects the efficiency of 
erythropoiesis (Weatherall & Clegg, 2001).  
Erythropoietin levels are significantly elevated when haemoglobin levels drop to      
7 g/dL or are reduced as a response to anaemia (Hammond et al., 1962). Its action 
towards precursor cells in bone marrow stimulates production of erythrocytes. 
However, since erythropoiesis is ineffective, production is continuously stimulated 
to overcome hypoxia due to anaemia. Indirectly, the stimulation leads to bone 
marrow expansion and deformity, especially in facial bones (thalassaemia facie) 
(Hoffbrand & Pettit, 2000).  
The spleen acts as a filter to remove defective blood cells and foreign bodies 
(Chen & Weiss, 1973; Kashimura & Fujita, 1987; Moghimi, 1995; Wandenvik & 
Kutti, 1988). The overproduction of defective erythrocytes due to excess free         
α-globin chains may cause the spleen to overwork and leads to splenomegaly. With 
all the formed elements trapped in the spleen due to congestion, anaemia may 
become more severe, and thrombocytopaenia and neutropaenia may occur.  
Other health problems associated with β-thalassaemia major include expansion 
of plasma volume due to marrow expansion, iron overload, hepatomegaly, bone 
disease, and increased risk of blood-borne infections (Weatherall & Clegg, 2001).   
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2.3.3 Clinical classification of β-thalassaemia 
Beta-thalassaemia is commonly classified according to the clinical 
manifestations presented by the patients. There are three classes of                          
β-thalassaemia – β-thalassaemia minor, intermedia and major.  
The minor form of β-thalassaemia usually presents as asymptomatic or mild 
anaemia. Another term commonly used to address β-thalassaemia minor is                      
β-thalassaemia trait or carrier. Identification of a β-thalassaemia minor individual is 
through haematological screening and since only one of the β-globin genes is 
affected, the reduction of β-globin chain synthesis is not severe enough to cause 
severe anaemia. There is a group termed as ‘silent’ carriers and these patients 
appear asymptomatic and have normal haematology indices. They are heterozygotes 
for the thalassaemia mutations and are only identified by molecular screening. 
The major form is the most severe manifestation of β-thalassaemia. With both         
β-globin genes affected, β-globin chain production is severely impaired or 
terminated. Patients usually start to present severe anaemia at the age of six months 
and require monthly blood transfusions. Insufficient production of HbA leads to 
elevation of HbF and slight increase in HbA2.  
Beta-thalassaemia intermedia is a condition where the patient does not present 
anaemia as severe as the major form, but still requires occasional blood transfusions 
to maintain the haemoglobin level at around 7 g/dL. The ‘intermedia’ term is mainly 
used in clinical practice as the disorder involves a different treatment regime based 
on the patient phenotype (Weatherall & Clegg, 2001).  
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2.3.4 Genetic classification of β-thalassaemia  
Genetic classification of thalassaemia refers to the extent of reduction of globin 
chain synthesis. In β-thalassaemia, the main genotypes are β0-thalassaemia and             
β+-thalassaemia (Weatherall & Clegg, 2001).  
In β0-thalassaemia, β-globin chain synthesis does not occur. There is absence of 
HbA production. Individuals who are homozygous or compound heterozygotes 
exhibit β0-thalassaemia phenotype. HbA is at zero percent and HbF can increase up 
to 98% (Telen & Kaufman, 1999).  
On the other hand, β+-thalassaemia shows a reduced amount of β-globin chain 
production. Homozygotes or heterozygotes that possess one of the many                     
β+-thalassaemia mutations show HbA production, but at a reduced level. There is 
also β++-thalassaemia where the defects in β-globin production are less severe 
compared to β+-thalassaemia.  
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2.4 Detection of β-thalassaemia  
2.4.1 Haematological study for detection of β-thalassaemia  
Globin chain accumulation and inadequate amount of haemoglobin production 
lead to destruction of erythrocytes and anaemia with hypochromasia and 
microcytosis. Peripheral blood film is used to observe the presence of abnormality 
in erythrocyte appearance and cell counting. Beta-thalassaemia patients usually 
present peripheral blood films with microcytic and hypochromic red blood cells, 
anisopoikilocytosis and presence of codocytes (target cells). In β-thalassaemia 
major patients, an abundance of nucleated red blood cells can be observed in the 
stained peripheral blood preparations.  
Haematological indices such as mean corpuscular volume (MCV), mean 
corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin concentration 
(MCHC) are evaluated and compared with values from normal individuals. Values 
of MCV and MCH are affected by cellular size and haemoglobin concentration, 
respectively. Thus, microcytosis and hypochromasia produce an impact on both 
index levels (Turgeon, 2005). The value of MCHC may be slightly reduced or 
remain at a normal level since both haemoglobin and haematocrit are reduced and 
produce a slight effect on the ratio. A comparison of values of the haematological 
indices is presented in Table 2.2.  
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Table 2.2 Comparison of haematological indices between normal individuals 
(male and female), β-thalassaemia carriers and β-thalassaemia major 
patients 
Haematological Indices 
Normal β-thalassaemia 
carrier 
β-thalassaemia 
major Male Female 
Haemoglobin            
(Hb, g/dL) 
15.9±1.0 14.9±0.9 
Male:  
11.5-15.3 
Female:  
9.1-14.0 
<7.0 
Mean corpuscular 
volume (MCV, fL) 
89.1±5.01 87.6±5.5 <79 50-70 
Mean corpuscular 
haemoglobin (MCH, pg) 
30.9±1.9 30.2±2.1 <27 12-20 
(Reference: Galanello et al. (1979)) 
 
However, microcytic and hypochromic anaemia does not always indicate 
thalassaemia. Various underlying factors may also lead to these symptoms – 
anaemia of chronic disease, iron deficiency anaemia and sideroblastic anaemia 
(Dacie & Lewis, 1994). Thus, subsequent testing must be carried out depending on 
the preliminary results obtained on cellular appearance and haematological indices. 
A general scheme of investigation carried out for microcytic anaemia screening and 
expected findings is represented in Figure 2.2.  
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(Reference: Besa et al. (1992); Dacie & Lewis (1994)) 
  
Figure 2.2 Investigation scheme for thalassaemia and abnormal haemoglobins  
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2.4.2 Specific haematology tests  
Determination of iron status is carried out on subjects with MCV levels lower 
than 80 fL and MCH less than 27 pg. This includes determination of serum ferritin 
level, total iron binding capacity and estimation of soluble transferrin protein. 
Performing these tests is crucial to rule out iron deficiency anaemia, since iron 
deficiency may also lower the HbA2 level and mask the presence of β-thalassaemia 
in the subjects (Bates & Bain, 2006).  
Further investigation to detect haemoglobin subtypes are carried out using 
haemoglobin electrophoresis on cellulose acetate at alkaline pH (pH 8.2 - 8.6). In 
alkaline pH, haemoglobin molecules have a net negative charge and will move 
towards the anode of the electrophoresis system. Haemoglobin variants have 
different net charges, causing the molecules to migrate at different rates. This 
indirectly allows differentiation of variants present in the subject’s blood. This 
method can be used to detect the presence of HbE and Hb Lepore (Kohn, 1969; 
Turgeon, 2005).  
Quantitation of HbA2 is confirmed by high performance liquid chromatography 
(HPLC) and microcolumn chromatography. Estimation of HbF levels can be carried 
out by haemoglobin denaturation at alkaline pH or through HPLC. Elevated levels 
of HbA2 and HbF suggest that the subject may have β-thalassaemia. The 
haemoglobin subtype levels in β-thalassaemia patients are summarised in Table 2.3.  
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Table 2.3 Haemoglobin subtype fractions in normal individuals, β-thalassaemia 
carriers and major patients 
Haemoglobin 
subtypes 
Normal 
β-thalassaemia 
carrier 
β-thalassaemia major 
β+/β+ or β+/β0 β0/β0 
HbA 96% - 98% 92% - 95% 10% - 30% 0% 
HbA2 2% - 3% >3.5% 2% - 5% 2% - 5% 
HbF <1% 0.5% - 4% 70% - 90% 95% - 98% 
(Reference: Telen & Kaufman (1999)) 
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2.5 Sample collection for genomic DNA and biochemical studies  
2.5.1 Sampling for analysis of β-thalassaemia  
Common sample used for molecular analysis of thalassaemia is collected from 
venous blood. Leukocytes present in the blood are harvested and extracted to obtain 
high quality DNA for molecular analysis. High quality DNA yield and purity is an 
advantage since it can be used for multiple molecular analyses with optimal 
amplification. These factors are important to ensure rapid and cost effective 
molecular analysis.  
Plasma samples are used for a wide array of biochemical analysis. Since blood 
carries nutrients and metabolites throughout the human body, any abnormal 
accumulation of metabolites can be observed in plasma or serum samples. This 
includes enzyme activity, intermediate and end-products of metabolism.  
However, the skill requirement in phlebotomy can limit sample collection by 
researchers in the field. Adverse effect such as haematoma due to blood leakage to 
surrounding tissue, infection from needle prick, discomfort and even nerve injury 
can be acquired if the procedures are not carried out accordingly or by a trained 
technologist (Hold et al., 1995; Rayegani & Azadi, 2007; Stitik et al., 2001). 
Subjects especially children are often reluctant to cooperate when it comes to blood 
sample collection due to their previous experience in phlebotomy. Collection of 
non-invasive samples is more convenient for researcher and patients. With sufficient 
information and guidance on sample collection, the process can be done with 
minimal supervision. The non-invasive process is painless and more comfortable to 
the patients.  
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2.5.2 Stratified squamous epithelium of oral cavity as the source of DNA  
Stratified squamous epithelium is the most widely present stratified epithelium 
on the human body. It forms the skin and the mucous membrane of the upper 
digestive system, cornea, vagina and anal canal (Junqueira & Carneiro, 2003). It 
consists of multiple layers of epithelial cells resting on a basement membrane, with 
various shapes from cuboidal or columnar at the bottom to irregular and flat 
squamous cells at the outermost layer (Applegate, 2002).  
The basal layer lying on the top of the basement membrane is the most active in 
mitotic activity. Addition of cell numbers through mitosis pushes the cells upwards, 
changing the cell configuration and making them flatter than the ones present at the 
bottom. The cells move farther from the blood vessels and receive fewer nutrients 
and lose mitotic activity. Later the cells start to lose their nuclei, died and 
desquamated from the tissue.  
This tissue can be further divided into two - keratinised and non-keratinised 
stratified squamous epithelium. Keratinised stratified squamous epithelium is found 
in thick and thin skin. The basal layer (stratum basale/germinativum) mainly 
consists of keratinocytes. These cells will grow older and move up to the outermost 
layer of the epithelium (stratum corneum) and undergo keratinisation, which 
provides a dry and rough barrier. The nuclei and organelles of the cells are 
hydrolysed and disintegrated. The cytoplasm is then filled with keratin and form a 
barrier on the epidermal surface (Eroschenko, 2008).  
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The non-keratinised variant is found in moist surface such as upper digestive 
tract. The upper digestive tract includes the inner cheeks, palate and oesophagus. 
Just like the keratinous type of this epithelium, this tissue sheds the outermost layer 
daily due to abrasion and replaces them with newer cells from the lower strata. 
However, due to lack of keratinocytes, the cells do not undergo keratinisation as 
they age. The outermost cellular layer which consists of mature cells still maintains 
the nuclear structure and the organelles (Junqueira & Carneiro, 2003).  
Due to the intact nuclear structure in the outermost layer of non-keratinised 
stratified squamous epithelium, it is possible to collect buccal cells to obtain 
genomic DNA. Collection of the sloughed off buccal cells can be carried out 
indirectly through collection of mouthwash and saliva, or directly through swabbing 
using cotton swab or cytological brushes.  
2.5.2.1 Collection of epithelial cells from mouthwash 
Previous studies have shown that DNA from human buccal cells has been 
successfully isolated and amplified for genomic studies. Collection of buccal cells 
from mouthwash involves rinsing the subject’s mouth with a suitable solution for a 
given time. The mouthwash is then expectorated into a container and processed to 
collect the cells by centrifugation (King et al., 2002; Lum & Marchand, 1998). 
Solutions such as antiseptic mouthwash solution, sterile water or isotonic solution 
such as 0.85% - 0.9% normal saline is utilised as the suspension medium (Garcia-
Closas et al., 2001; Mulot et al., 2005).  
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Collection is performed after a resting period if the subjects have just finished 
eating, smoking, drinking, or brushing teeth (Aidar & Line, 2007; de Vries et al., 
2006). Collection of samples directly after eating may increase the amount of 
contaminants originating from food particles. This might affect the purified DNA 
when the undigested particles are not properly removed during purification. On the 
other hand, sample collection right after brushing teeth may reduce the number of 
collected cells (Feigelson et al., 2001). Thus, a lag between brushing teeth and 
sample collection is given to allow the recovery of sloughed off cells.  
Antiseptic mouthwash solution acts as both mechanical and chemical agents for 
mouth cleansing and bactericidal agent. Thus, the number of oral normal flora 
vegetative cells can be reduced, and prevent the DNA degradation due to their 
metabolic activity (Pandeshwar & Das, 2014). In spite of that, the usage of 
antiseptic mouthwash, even the alcohol-free mouthwash is not encouraged for 
children due to their tendency to swallow the solution.  
The burning sensation due to the presence of alcohol also serves as a limitation 
of usage of antiseptic mouthwash as a suspension medium. Additional rinsing is 
needed to completely remove the solution. In addition, leaving the                 
alcohol-containing mouthwash residue in the oral cavity can be carcinogenic to the 
epithelial cells lining the oral cavity (Lachenmeier et al., 2008).  
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Sterile water or other isotonic solution is another option for mouthwash solution. 
The use of these solutions is safer and more acceptable especially to children since 
the solutions used are non-toxic. These solutions may only remove the bacteria by 
mechanical means. Thus, an initial rinsing with tap water or the same solution is 
added to reduce the oral bacteria load (King et al., 2002). Addition of DNA 
preservative such as ethylenediamine tetraacetic acid (EDTA) and proper storage 
will keep the DNA integrity until the extraction is performed (Aidar & Line, 2007; 
Lahiri & Schnabel, 1993).  
2.5.2.2 Collection of epithelial cells from saliva 
Whole saliva consists of fluid and cellular component. The cellular components 
are composed of normal flora of the oral cavity, epithelial cells and also leukocytes 
that have migrated through the gingival crevices (Kaufman & Lamster, 2000; 
Kumar et al., 2014; Pandeshwar & Das, 2014; Schiott & Loe, 1970). The friction 
between the oral cavity and the teeth and tongue desquamate the epithelial cells 
from the oral cavity and transfer them into the salivary fluid. Salivary fluid can be 
collected by expectoration of stimulated or unstimulated saliva (Dizgah & Hosseini, 
2011; Sculley & Langley-Evans, 2002; Zalewska et al., 2014).  
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To expectorate unstimulated saliva, the subject needs to sit down calmly and 
prevent him/herself from making any movement in the oral cavity and from 
swallowing the fluid (Dizgah & Hosseini, 2011; Zalewska et al., 2014). Saliva is 
pooled in the mouth and then spitted out from the subject’s mouth into a container. 
The cells present in the fluid are later collected by centrifugation process. 
Unstimulated saliva collection process may require a long time to complete. The 
process can also be stunted if the subject does not rehydrate before the collection 
procedure was performed.  
Stimulation of saliva can be carried out by introducing external material into the 
subject’s mouth such as a piece of paraffin wax, cotton roll or chewing gum (Ash et 
al., 2014; Dizgah & Hosseini, 2011). The material will be expectorated out at the 
same time during the collection. Further processing such as centrifugation will 
separate the sample from the inducing material prior to DNA extraction. The other 
way of inducing is through the use of chemical such as citric acid or chewing 
motion (Zalewska et al., 2014). This method takes less time since the saliva flow 
rate is increased. Nevertheless, improper rehydration may halt the process as in 
unstimulated saliva collection.  
Other than extracting DNA from the whole saliva sample, treated cards made of 
filter paper pre-treated with antibiotics can be used to collect the cellular component 
for the saliva. After the subject has expectorated the salivary fluid into a sterile 
container, the treated card is then placed into the saliva. The card is then air-dried 
and stored until DNA extraction is performed. The card can be separated into a 
number of pieces and DNA can be extracted using various methods and in multiple 
batches (Milne et al., 2006; Mulot et al., 2005).  
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2.5.2.3 Collection of epithelial cells using buccal swabs and cytobrushes 
The use of buccal swabs or cytobrushes to collect the buccal cells is well 
accepted for non-invasive sampling for molecular studies. The most common tool 
used for the method is cotton swabs (Bennet et al., 2000; Cheng et al., 2010; Milne 
et al., 2006). Other than that, another option for buccal cells collection is by using 
sterile cytological brushes (Aldave et al., 2004; King et al., 2002; Said et al., 2014).  
The collection involves performing a few firm strokes on the oral mucosa for a 
given time. The swabs are then air-dried or stored in sterile stabilising buffer or 
saline solution (Hansen et al., 2007; Swinfield et al., 2009; Zhou et al., 2012). The 
soft swab and bristles in cotton swabs and buccal cytobrush made the procedure 
comfortable and convenient to use. However, despite being economical, cells tend 
to get trapped between the cotton fibers or bristles. The trapped cell may be 
excluded from the extraction procedure and this may result in reduction of DNA 
recovery after the extraction process.  
Various tools are also introduced for buccal cells collection, such as foam tipped 
applicator stick and tongue depressor (Burger et al., 2005; Hansen et al., 2007; 
Moore et al., 2001). Collection of samples using a foam-tipped applicator stick 
involves collection of saliva present around the cheek and gum line. The use of 
foam-tipped applicator sticks is usually paired with antibiotic and stabiliser treated 
cards, where the foam is squeezed onto the card to retrieve as much as cells and 
saliva that is collected in the foam. For tongue depressors, this involves scraping the 
buccal cells from cheek and transferring the device into storage buffer or solution.  
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Contamination by microbial DNA from oral cavity normal flora cannot be 
avoided completely in all of the buccal cell collection methods mentioned above. 
Proper procedure planning such as initial mouth rinsing can indirectly help to 
reduce the amount of microbial DNA present in the sample and produce better 
results in determining DNA concentration and purity for molecular analysis.  
2.5.3 Saliva as an alternative biological fluid  
Fluid components of whole saliva are composed of – gingival crevicular fluid 
(GCF), liquid released from salivary glands, serum, traces of blood from intra-oral 
bleeding and additional fluids of bronchial and nasal origin (Kaufman & Lamster, 
2000; Sculley & Langley-Evans, 2002).  
The GCF is the transudate and exudates of the gingival (gum) tissue interstitial 
fluid (Alfano, 1974; Brill & Krasse, 1958; Griffiths, 2003; Uitto, 2003). The fluid is 
released through the gingival crevices present between the teeth and the gum line. In 
normal physiological conditions, the fluid is the filtrate from capillaries in the gum 
tissue released to the oral cavity under the influence of osmotic gradient. In 
pathological conditions, the increased permeability of the capillary wall increases 
the amount of interstitial fluid. The increased amount of interstitial fluid indirectly 
increases the GCF flow rate.  
 
 
 
 
 
 
27 
The GCF contains a mixture of components from blood, host tissue and 
subgingival plaque. This includes small organic molecules, protein, cytokines and 
enzymes originating from the host and the bacteria present in the oral cavity 
(Delima & Van Dyke, 2003). Thus, it can be concluded that the GCF has the 
composition of serum. However, the concentration may be reduced due to dilution 
by the salivary gland secretions.  
Other investigators have conducted antioxidant level measurements in salivary 
samples in patients with medical conditions, such as type 2 diabetes mellitus, renal 
failure, hypertension and heart disease (Al-Rawi, 2011; Bibi et al., 2008 ; Soukup et 
al., 2012; Wolfram et al., 2005). Salivary uric acid concentration was reported to be 
similar to that of serum, while other antioxidants such as ascorbic acid were present 
at a lower concentration (Sculley & Langley-Evans, 2002).  
Collection of samples can be carried out using the same methods performed for 
collection of buccal cells from saliva – collection of whole saliva whether 
stimulated or unstimulated, direct collection from specified salivary gland and 
collection of GCF from gingival crevices (Michishige et al., 2006). Although 
stimulated saliva can be used for biochemical analysis, unstimulated saliva provides 
more accurate observations (Sculley & Langley-Evans, 2002).  
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2.6 Molecular analysis of β-thalassaemia 
Confirmation of β-thalassaemia is carried out by molecular studies to specify the    
β-globin gene mutation(s) involved. Genotyping of β-thalassaemia for diagnosis and 
research purpose is commonly carried out by the Amplification Refractory Mutation 
System (ARMS), gap-polymerase chain reaction (gap-PCR), PCR-restriction 
fragment length polymorphism (PCR-RFLP) and reverse dot-blot hybridisation. 
2.6.1 Detection of point mutations using the Amplification Refractory 
Mutation System  
In 1989, the Amplification Refractory Mutation System (ARMS) was introduced 
in place of normal PCR for confirmation of the mutation status for α1-antitrypsin 
deficiency patients. The system allows rapid analysis of known point mutations 
present in genomic DNA sequences (Newton et al., 1989). It was later applied for 
molecular analysis in carrier detection and prenatal diagnosis for various genetic 
disorders including α- and β-thalassaemia (George & Tan, 2010; Old et al., 1990; 
Tan et al., 2004; Wee et al., 2009).  
The primers in ARMS are designed such that a mismatch at the 3’ end will not 
allow the amplification process to continue. The mutant primers are designed with 
the 3’-nuclotide complementary to the point mutation present on the DNA 
sequence. This makes the ‘mutant’ primers refractory (resistant) to PCR on ‘normal’ 
DNA templates. The same basis is applied for normal primers, where the               
3’-nucleotide is complementary to the normal DNA sequence. 
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The ARMS primers need to be paired with a second primer, called common 
primer, to generate allele-specific amplification products. As an indicator of DNA 
amplification, two internal control primers are included in every reaction. These 
primers will amplify DNA sequences located in other regions of the DNA template 
that is not directly related to the point mutations. Amplification of the internal 
control indicates that the reaction mixture has been prepared correctly and DNA 
amplification has taken place.  Figure 2.3 shows the basis of ARMS and the primer 
design.  
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(Adapted from Kitching & Seth (2005)) 
 
 
 
 
Figure 2.3 Basic concept of primer designed for ARMS and their behaviour 
with different DNA templates  
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In some instances, a single 3’-nucleotide mismatch will still allow DNA 
amplification to progress. Purine/pyrimidine mismatches are less refractory when 
compared with purine/purine and pyrimidine/pyrimidine mismatches when extended 
with Taq DNA polymerase. Non-specific amplification may thus arise due to this 
and lead to false-positive results. To remove the problem, adding one more 
mismatches before the 3’ end may cause the primer/template complexes to 
destabilise. The primers are thus more refractory and specific when compared with 
only a single mismatch at the 3’ end.  
Provided that the amplification product sizes are different and can be 
distinguished after gel electrophoresis, presence of both wild type and mutant alleles 
can be detected in a single reaction (Chen et al., 2007). Figure 2.4 represents the 
schematic diagram of a single-tube ARMS for mutant and wild type allele 
identification.  
Combined-ARMS (C-ARMS) has also been developed to detect two different 
mutations in a single PCR reaction. Two to three primers with mutant sequences are 
combined in a single-tube reaction mixture. In this procedure, the ARMS primers 
need to share the common primer, or they can be paired with different common 
primers that will not hybridise with each other. This allows rapid and more        
cost-effective prenatal diagnosis compared with individual ARMS reactions (Tan et 
al., 2001; Thedsawad et al., 2012; Wee et al., 2009).  
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The amplification products are of different molecular weight and 
thus distinguishable from one another. Amplification product on (1) 
normal individual: A + C; (2) carriers or compound heterozygous 
individual:    A + B + C; (3) β-thalassaemia major: A + B 
(Adapted from Chen et al. (2007))  
 
Figure 2.4 Example of primer design for single-tube ARMS for detection of 
mutant and normal allele of one point mutation involving substitution 
of a single base from G to T 
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2.6.2 Detection of large size deletions by gap-PCR  
Beta-thalassaemia can be caused by large deletions in the β-globin gene 
sequence. However, amplification using normal PCR is difficult to detect the 
presence of the genes of interest due to annealing time constraints and limited 
amount of nucleotides and reagents. When the deletion breakpoints are known,  
gap-PCR can be performed to detect deletions of large gene sequences by utilising 
primers flanking the deleted region (Clark & Thein, 2005).  
The primers are designed to specifically anneal to the complementary sense and 
antisense sequences on either ends of the deleted sequence. Presence of the gene 
sequence in a normal individual renders the sequence resistant to DNA 
amplification. Thus, there is no product yield from templates with undeleted 
sequences. However, the presence of a deletion will shorten the gene sequence and 
allow amplification to occur as the primers are brought close together. Significant 
copies of amplified gene sequence are thus produced and confirmed through gel 
electrophoresis.  
To detect the presence of the normal sequence, a third primer or another pair of 
primers can be included to amplify the sequence present within the deleted region. 
The observation of an amplified product after gel electrophoresis confirms the 
presence of the normal sequence. A combination of these primers will enable the 
laboratory to determine whether the patient is homozygous or heterozygous for the 
specified deletion in a single PCR reaction. A diagrammatic representation of     
gap-PCR is shown in Figure 2.5  
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Figure 2.5 Positions of forward and reverse primers designed for analysis of       
large-sized deletions using gap-PCR 
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2.6.3 Detection of mutation by PCR-Restriction Fragment Length 
Polymorphism (PCR-RFLP) 
Restriction endonuclease is an enzyme produced by prokaryotic organisms as a 
mechanism of defence against viral invasion. The enzymes recognise the particular 
sequence termed as a restriction site and cleave the DNA strand. The most 
commonly used enzymes are type II enzymes which cleave the DNA at the 
recognition site itself (Berg et al., 2002). A report in 1989 states that 50% of 
mutations in the β-globin gene in the Mediterranean region creates or removes 
restriction endonuclease sites in the β-globin gene sequence (Pirastu et al., 1989).  
Detection of mutations involving PCR-RFLP begins with the amplification of 
DNA sequences containing the mutations. The amplicon obtained is then treated 
with restriction endonuclease that is able to recognise the creation or removal of a 
restriction site in the amplified DNA product. Confirmation of restriction enzyme 
analysis is carried out using gel electrophoresis.  
PCR-RFLP is an inexpensive method with no requirements of high-technical 
instrumentation. However, the time constrains due to multiple electrophoretic 
separation steps and the possibility that several SNPs may affect the same restriction 
site can limit the usability of this procedure (Rasmussen, 2012).  
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2.7 Oxidative stress  
Oxidative stress is a condition caused by imbalance of pro-oxidant and 
antioxidant in the biological system (Halliwell & Gutteridge, 1999). Pro-oxidants 
induce oxidative stress by forming reactive oxygen species or suppressing the 
activity of antioxidants. While antioxidants serve as molecules which protect the 
biological system from being oxidised and produce more free radicals.  
Free radicals are molecules or molecular fragments containing one or more 
unpaired electron in the outermost molecular orbital (Halliwell & Gutteridge, 1999). 
The unsatisfied electron valence pair made the molecules highly reactive. Free 
radicals readily react with macromolecules such as protein, lipids and DNA, 
damaging the molecules.  
Free radicals are produced in normal and pathological condition. Aerobic 
organisms use oxygen to oxidise molecules for metabolism. Even though oxidative 
phosphorylation in eukaryotic cells manage to fully utilise oxygen without 
producing intermediary molecules, trace amount of reactive oxygen species (ROS) 
formation is unavoidable (Berg et al., 2002).  
Antioxidants as cellular defence mechanism will try to delay or prevent oxidation 
of target substrates. The prevention is carried out by stopping the chain reaction or 
converting the free radicals into less injuring molecules, before being excreted or 
utilised by the cell itself (Ghone et al., 2008).  
Increase in pro-oxidant activity may lead to various macromolecular damage and 
tissue damage (Low, 2005). Living organisms may counteract reactive species by 
having complex antioxidant systems. However, the accelerated production of 
reactive species depletes cellular antioxidants rapidly and this will result in 
oxidative stress.  
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2.7.1 Oxidation of macromolecules  
Oxidation of macromolecules such as DNA, lipid and protein usually involves 
abstraction of hydrogen atom by radicals such as hydroxyl radicals (•OH)              
(Berlett & Stadtman, 1997; Cooke et al., 2003; Gutteridge, 1995). The molecules 
produced after hydrogen atom abstraction may become the new reactive molecules, 
continuing the oxidation chain reaction.  
2.7.1.1 Oxidation of lipid  
Lipid peroxidation can occur through enzymatic or non-enzymatic pathway, with 
non-enzymatic pathway being initiated with or without free radicals (Niki et al., 
2005). Main target for peroxidation is polyunsaturated fatty acids which contain 
double covalent bonds. Presence of double covalent bond weakens the           
carbon-hydrogen bond of the adjacent carbon atom. This factor facilitates the 
removal of hydrogen atom from the methyl group (Gutteridge, 1995). Membrane 
phospholipids which are rich in polyunsaturated fatty acids are very susceptible to 
lipid peroxidation.  
2.7.1.2 Oxidation of protein 
Protein oxidation occurs with the same basics; abstraction of α-hydrogen atom by 
•OH which initiates chain reactions that further oxidise the amino acid residues. All 
amino acid residues are prone to oxidation by •OH. The most susceptible amino 
acid residues are aromatic amino acids such as tryptophan and tyrosine. However, 
some damages are reversible, such as the oxidative damage which occurs on sulphur 
containing residues like methionine (Berlett & Stadtman, 1997).  
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2.7.1.3 Oxidation of DNA 
Oxidation of DNA strands may cause structural changes, leading to mutations 
and cellular destruction. Abstraction of hydrogen atom usually happens at methyl 
group on sugar base of nucleotide (Cadet & Douki, 1999; Cooke et al., 2003). 
Cellular replication and repairs cannot be carried out due to this disruption. Cell will 
be wasted and marked for destruction by macrophage.  
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2.7.2 Oxidative stress in β-thalassaemia  
2.7.2.1 Iron overload 
Majority (67%) of the body iron storage is in haemoglobin, followed by ferritin 
and haemosiderin which add up to 27% of the storage. Almost all (up to 95%) of the 
iron for haemoglobin synthesis originate from the old erythrocytes. The remaining 
is obtained through diet (Besa et al., 1992).  
Due to the rapid destruction of the red blood cells and hypertransfusion, the iron 
storage in the patient’s body exceeds ferritin storage and detoxification capacity 
limit. Multiple transfusions increase transferrin saturation and later give rise to free 
iron species that is unbound to transferrin. This non-transferrin-bound iron (NTBI) 
is taken up by parenchymal cells such as hepatocytes and myocardium readily if 
compared with transferrin-bound iron (Hershko, 2010; Prabhu et al., 2009).  
Hypoxia condition favours the production of superoxide anion (O2•
-
) due to 
‘slowed down’ electron transport chain (Misra & Fridovich, 1971). Increased 
amount of O2•
-
 can induce separation of iron from its carrier protein. Free iron 
(Fe
2+
) will participate in Fenton and Haber-Weiss reaction, inducing the production 
of •OH (Gutteridge et al., 1981). Peroxides formed through the reaction will start 
cross-linking with macromolecules, reducing their functionality or making the 
molecules totally non-functional (Figure 2.6).  
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(Reference: Haber & Weiss (1932); Koppenol (2001))  
Oxidation targeted on red blood cells give rise to serious problems, since the 
absence of nuclei in red blood cells means they cannot initiate cellular repair by 
themselves. Lipid peroxidation might disfigure the cells while protein oxidation can 
produce protein clusters on the membrane, making it prone to be targeted as 
abnormal and removed from circulation (Prabhu et al., 2009). Oxidation can worsen 
thalassaemia patient’s condition, since haemolysis can be enhanced and indirectly 
increase the level of iron in circulation.  
Other than that, the excess iron also affects the endocrine system leading to 
reduced endocrinal function (Galanello et al., 2010). This can be observed in female 
patients where their puberty and physical development was delayed due to 
hypogonadotropic hypogonadism (Roussou et al., 2013).  
 
 
 
 
Figure 2.6 Production of •OH through Fenton and Haber-Weiss reaction 
involving iron  
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2.7.2.2 Iron chelation therapy  
Accumulation of iron in parenchymal tissue already started at the first year of 
regular transfusion. Normal homeostasis in human cannot control the excessive iron 
present in the system. To reduce the amount of iron accumulated in the body, it need 
to be removed therapeutically, such as through iron chelation therapy (Hershko, 
2010). Chelated iron is later excreted through urine and faeces.  
Deferoxamine (DFO) was introduced in 1960’s as a subcutaneous chelating 
agent. Chelation therapy is usually started after serum ferritin level has exceeded 
1000 µg/L. Patients need to infuse 20 to 60 mg/kg of body weight DFO for 8 to     
12 hours a day, 5 to 7 days a week (Hershko et al., 2003). Daily parenteral infusion 
might cause discomfort and the expensive cost of the drugs and equipment might 
limit the usage in several developing countries (Prabhu et al., 2009).  
Deferiprone (DFP) is introduced as an oral iron chelator, and usually prescribed 
in combination with DFO (Olivieri et al., 1992). DFP is reported to have better 
efficacy in chelating iron. However, side effects such as arthropathy, 
agranulocytosis, neutropaenia, and gastrointestinal disturbance have also been 
reported (Cohen et al., 2003 ).  
Newer oral iron chelators such as deferasirox (DFS), commercially known as 
Exjade has been introduced and approved for use in various countries including 
Malaysia. It was reported in short-term trial that it is able to remove iron from heart 
(Cohen, 2006). However, long-term report is still limited. Other oral chelator such 
as deferitrin is still in development (Eckes, 2011).  
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2.7.2.3 Cytokine associated to hypoxia  
Tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) are pleiotropic 
cytokines which have various biological activities. TNF-α is produced by various 
types of immune and non-immune cells in response to various stimuli, such as viral 
and parasitic infection, bacterial endotoxin, enterotoxin, nitric oxide, hypoxia and 
oxygen radicals (Wang et al., 2003).  
On the other hand, IL-6 is produced by lymphoid and non-lymphoid cells and 
plays a role in immunological reactivity regulation, acute-phase response, 
inflammation, oncogenesis and haematopoiesis. In haematopoiesis, IL-6 triggers the 
dormant progenitor cells to exit G0 phase and enter cell cycle (Kishimoto, 2003).  
Hypoxia and overproduction of oxygen radicals may also induce the production 
of TNF-α in the circulation. TNF-α will also cause the secretion of other cytokines 
including IL-6 (Beyaert & Fiers, 1998). Persistence of the hypoxic condition and the 
continuous overproduction of radicals might cause overproduction of TNF-α. Even 
though TNF-α is supposed to induce apoptotic cell death of tumor cells, 
overproduction of TNF-α will exhibit its pro-inflammatory effects. This might lead 
to hypotension, diffuse coagulation and widespread tissue damage (Wang et al., 
2003).  
Overproduction of IL-6, on the other hand plays a role in autoimmune diseases 
(Beyaert & Fiers, 1998). Previous studies showed that excess production of IL-6 
impairs erythropoietin, disrupting erythroid development and increasing the severity 
of anaemia (Raj, 2009).  
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2.8 Methods of assessing oxidative stress  
2.8.1 Ferric reducing antioxidant power   
Ferric reducing antioxidant power assay measures the ferric reducing ability of 
metabolites in the sample. The colorimetric assay measures the level of overall           
non-enzymatic antioxidants present. In acidic condition, ferric                           
2,4,6-tripyridyl-triazine complex (Fe
3
-TPTZ) will react with antioxidant present in 
the sample. Reaction will reduce Fe
3+
 to Fe
2+
, which the complex formed with 
TPTZ and produced intense blue colour (Benzie & Strain, 1996). 
2.8.2 Advance oxidation protein products 
Advanced oxidation protein products (AOPP) is produced during oxidative stress 
by chlorinated oxidants such as chloramines or hypochlorous acid reaction. The 
oxidative stress marker was detected in abundance in individuals with kidney failure 
(Li et al., 2007; Witko-Sarsat et al., 1996). The assay reported by Witko-Sarsat 
(1996) involves measuring sample absorbance after mixing with potassium iodide 
(KI) in acidic condition in comparison to chloramine-T level.   
2.8.3 Lipid hydroperoxide assay   
There are various assays present to assess lipid peroxidation. However, there is 
no single assay that can be used to thoroughly explain the overall reaction that 
occurs (Halliwell & Chirico, 1993). One of the methods described is measurement 
of lipid hydroperoxide (LOOH), which is an intermediate of lipid peroxidation. 
LOOH indicates whether the primary reaction is initiated by singlet oxygen or 
oxyradicals (Girotti, 1998).  
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Colorimetric assay previously described in 1990 used 1-methyl-2-phenyl-indole 
(MPI) as chromogen (Esterbauer & Cheeseman, 1990). MPI prepared in acetonitrile 
is mixed with samples to react in acidic condition at 45°C. Presence of LOOH is 
observed by the presence of blue-coloured chromophore, which can be measured 
spectrophotometrically.  
2.8.4 Glutathione peroxide activity 
Glutathione peroxidase (GPx) is another method assessing lipid peroxidation. It 
reacts with H2O2 and oxidise glutathione from its reduced form (GSH) to oxidised 
form (GSSG). Addition of glutathione reductase and NADPH will reduce GSSG 
back to GSH, while oxidising NADPH to NADP
+
. Changes in absorbance occurred 
due to reduced amount of NADPH which can be monitored by spectrophotometry. 
The decreasing absorbance rate is directly proportional to the GPx activity in the 
sample (Forman & Boveris, 1982). 
2.8.5 Uric acid level  
Uric acid (UA) is a major antioxidant present in human blood and may protect 
against aging and oxidative stress. Human have a high basal level of plasma UA 
level. However, elevated UA level may lead to various conditions such as 
cardiovascular diseases (Johnson et al., 2007).  
Measurment of UA can be carried out through colorimetric method by measuring 
the reduction of chromogenic substance by uric acid. However, the method is not 
specific as it measures substances other than UA itself. Using the enzyme uricase to 
convert UA to allantoin produce more specific result even though it cost more than 
the former method (Barr, 1990).  
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2.8.6 Enzyme-linked immunosorbent assay  
Enzyme-linked immunosorbent assay (ELISA) is a variant of immunoassay used 
to detect analytes in biological samples. Innovation of ELISA from the commonly 
used radioimmunoassay allows quantitative detection of antibody or antigen in the 
sample without using expensive and radioactive labelling (Lequin, 2005; Van 
Weemen & Schuurs, 1971).  
A capture antibody is used to coat a stationary phase such as microtiter plate to 
bind with antigen of interest which increases specificity. Secondary biotinylated 
antibody is added after reaction of sample and primary antibody. Biotin-binding 
protein labelled with enzymes such as avidin-horse radish peroxidase is added 
before adding enzyme substrate to produce colour. The colour production is 
measured by spectrophotometry and compared to standard curve to determine the 
concentration of antigen. The absorbance reading is directly related to the 
concentration of antigen.  
In competitive ELISA, competition between unlabelled antigens with            
enzyme-labelled antigen will determine the concentration. Less amount of antigen 
in sample will increase the binding of enzyme-labelled antigen, increasing the 
absorbance values. Thus, absorbance reading is inversely related to antigen 
concentration.  
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Study population 
3.1.1 Beta-thalassaemia major patients  
Participation of patients and control subjects were on a voluntary basis. The                    
β-thalassaemia major patients were recruited from Paediatric Ward 6 Day Care, 
Level 4, Women and Children Health Complex, University Malaya Medical Centre 
(UMMC). Patients with ages ranging from 4 to 25 years old were recruited during 
their monthly visits for blood transfusion.  
3.1.2 Normal controls  
Normal and healthy volunteers with ages within the β-thalassaemia patient study 
group were recruited as control subjects.  Subjects with severe anaemia due to other 
causes, serious and chronic diseases and those following serious drug treatments 
were excluded.  
Participants were briefed about the objectives of the study, method of sample 
collection and any risks associated with the sample collection procedures. Informed 
and written consent was obtained from all patients and control subjects. In patients 
and control subjects below 18-years old, informed and written consent was obtained 
from their parents/guardians. Patients and control subjects were asked about their 
history of ancestry, intake of supplements, medication and health status.  
This project was approved by the Medical Ethics Committee of University 
Malaya Medical Centre (MEC Ref. No: 727.1). 
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3.1.3 Recruitment of β-thalassaemia major patients for molecular analysis 
of β-thalassaemia using mouthwash, saliva and buccal cytobrush 
samples 
For optimisation of DNA extraction protocols and molecular analysis of                  
β-thalassaemia, mouthwash, saliva and buccal cytobrush samples were collected 
from 50 β-thalassaemia major patients. The patients include 27 Malays, 14 Chinese 
and 9 from other ethnic groups. Patients classified from other ethnic groups include 
Indians and patients with a history of interracial marriage in their ancestry. The      
β-thalassaemia major patients group consisted of 24 males and 26 females. Three of 
the patients were aged below 5-years, 17 patients with ages ranging from                 
6 – 10-years, 21 patients were aged 11 – 15-years and 9 patients with ages ranging 
from 16 – 20-years. The summary of the ages of the patients are shown in Table 3.1.  
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Table 3.1 Age group of β-thalassaemia major patients recruited in the study for 
optimisation of DNA extraction protocols and molecular analysis of       
β-thalassaemia 
Age 
(years) 
Number of patients                                    
(n)  
< 5 3 
6 – 10 17 
11 – 15 21 
16 – 20 9 
Total 50 
 
The β-globin gene mutations in all β-thalassaemia major patients in this study 
had been previously characterised using blood samples. Table 3.2 shows the list of 
patients with their genotype in this study.  
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Table 3.2 List of patients, ethnic groups and β-thalassaemia mutations 
 
Ethnicity Βeta-thalassaemia mutations 
 
Ethnicity Βeta-thalassaemia mutations 
1 Malay Hb Lepore/Hb Lepore 16 Chinese IVS2-654/CD41/42 
2 Malay CD26/CD71/72 17 Malay CD26/IVS1-5 
3 Malay CD26/CD35 18 Malay CD26/IVS1-5 
4 Malay IVS1-5/IVS1-5 19 Malay CD26/IVS1-5 
5 Chinese IVS2-654/IVS2-654 20 Chinese CD41/42/CD17 
6 Malay/Chinese CD26/CD71/72 21 Malay CD26/IVS1-5 
7 Malay CD26/IVS1-5 22 Malay CD26/IVS1-5 
8 Indian IVS1-5/Poly A 23 Malay CD26/IVS1-1 
9 Malay/Chinese IVS1-5/IVS2-654 24 Chinese CD41/42/CD41/42 
10 Chinese CD41/42/CD27/28 25 Malay CD26/IVS1-5 
11 Chinese CD26/Filipino β-deletion  26 Malay CD26/IVS2-654 
12 Chinese CD41/42/CD41/42 27 Chinese CD41/42/CD41/42 
13 Chinese/Siamese CD41/42/IVS1-1 28 Malay/Siamese CD41/42/CD26 
14 Chinese CD41/42/CD41/42 29 Malay CD26/IVS1-5 
15 Malay CD26/IVS1-5 30 Malay CD26/IVS1-1 
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Table 3.2  List of patients, ethnic groups and β-thalassaemia mutations (cont.)  
 
Ethnicity Βeta-thalassaemia mutations 
 
Ethnicity Βeta-thalassaemia mutations 
31 Indian IVS1-5/Cap+1 41 Malay CD26/IVS1-1 
32 Malay CD26/IVS1-5 42 Malay CD26/IVS1-5 
33 Chinese CD41/42/
G(A)o 43 Malay CD26/IVS2-654 
34 Chinese CD41/42/-28 44 Malay CD26/IVS2-654 
35 Chinese IVS2-654/IVS2-654 45 Malay CD26/IVS1-5 
36 Chinese -28/-28 46 Malay IVS1-5/IVS1-1 
37 Chinese IVS2-654/-28 47 Malay CD19/CD8/9 
38 Chinese/Siamese CD26/CD17 48 Malay CD26/IVS1-5 
39 Chinese/Siamese CD26/CD41/42 49 Malay CD26/IVS1-5 
40 Pakistani CD8/9/CD16 50 Malay IVS1-5/CD19 
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3.1.4 Recruitment of β-thalassaemia major patients and healthy controls for 
biochemical analysis using saliva samples  
For the analysis of biochemical parameters, saliva samples were collected from              
65 patients and 55 healthy controls. Beta-thalassaemia major patients consisted of       
37 Malays, 20 Chinese and 8 from other ethnic groups. With regards to gender, 25 
out of the 65 patients were males. In aspects of age distribution, 20 patients were 
below 10-years, 34 patients were between 11 – 20-years and 11 patients were 
between 21 – 30-years.  
With regards to genetic classifications of β-thalassaemia major, the                    
β-thalassaemia major patients were further divided into three groups based on their 
β-globin gene mutations. Group 1 consisted of patients who have been characterised 
as β+-thalassaemia homozygotes (β+/β+) which consisted of 9 patients, Group 2 was        
β+/β0-compound heterozygotes with 39 patients and Group 3 was β0-thalassaemia 
homozygotes (β0/β0) with 17 patients.  
Healthy controls were recruited from the public, with age matching the age range 
of the β-thalassaemia major patients. The healthy controls consisted of 35 Malays, 
16 Chinese and 4 individuals from other ethnic groups. Twenty-three out of the 55 
healthy individuals were males. In aspects of age distribution, 7 individuals were 
with aged below 10-years, 18 were between 11 – 20-years and 30 were between    
21 – 30-years. Summary of the ages of the patients and the healthy individuals are 
shown in Table 3.3.  
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Table 3.3 Age group of participants recruited in the study for analysis of 
biochemical parameters using non-invasive samples 
Age 
(years) 
Number of participants (n)  
Patients  Healthy controls 
< 10 20 6 
11 – 20 34 15 
21 – 30  11 34 
Total 65 55 
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3.2 Sample collection  
Patients were given four sample containers which were clearly labeled prior to 
sample collection: (1) and (2) – are two wide-mouth containers containing 15 mL of 
sterile normal saline (0.85% NaCl) for mouthwash sample collection, (3) – one 
empty 50 mL centrifuge tube (Labcon, USA) for saliva sample collection and       
(4) – one 15 mL centrifuge tube (Labcon, USA) containing 5 mL normal saline with 
one sterile, individually packed cytological brush (Cross Protection, Malaysia) for 
buccal cytobrush sample collection. The procedures for sample collection were 
explained and demonstrated to the patients.  
Healthy individuals were given container (3) for saliva sample collection for 
biochemical analysis.  
Containers used for sample collection are shown in Figure 3.1.  
 
Figure 3.1 Containers 1, 2, 3 and 4 used for sample collection with sterile 
individually packed buccal cytobrush 
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3.2.1 Mouthwash samples  
Patients were asked to rinse their mouth with sterile normal saline in container 
(1) as provided to remove food debris from their oral cavity. They were then 
instructed to rub their cheeks against their molars for 30 seconds. They were then 
required to rinse their mouth for the second time with fresh sterile normal saline 
solution in container (2) for  1 minute while rubbing the cheeks against their molars 
occasionally. The mouthwash solution was then expectorated into the container.  
3.2.2 Salivary fluid collection  
Patients were asked to spit at least 5 mL of saliva slowly into container (3) 
without forcing the fluid flow. They were allowed to drink if they felt their mouth 
becoming dry during the process. However, they were reminded to gargle and swish 
the oral cavity with clean water prior to continuing. They were asked to minimise 
the time needed to collect the samples to prevent loss of analytes in the samples.  
For healthy controls, collection of saliva samples was performed after initial 
mouth rinsing using sterile normal saline in container (1).  
3.2.3 Buccal cytobrush samples  
Buccal cytobrush samples were collected using the sterile cytological brush 
provided with container (4). Patient’s inner cheeks were rubbed by twirling the 
brush up and down for at least 15 seconds on each side. The brush was then dipped 
and agitated in 5 ml of fresh sterile normal saline in the container to loosen the 
buccal cells obtained. The process was repeated three times. 
After the final collection, the brush was agitated and left in the solution and the 
tube was sealed. 
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3.2.4 Sample storage and processing  
All samples were immediately kept on ice after collection was completed. 
Sample processing was carried out on the same day as sample arrival in the 
laboratory.  
The saliva samples were centrifuged at 2,500 x g for 10 minutes at 4°C to pellet 
the cells or any residue present. Supernatant of the samples were aliquoted into 
several microcentrifuge tubes and kept frozen at -70°C until required for 
biochemical analysis.  
The pellet from saliva was rehydrated and resuspended with Tris-EDTA (TE,                 
10 mM/10 mM) buffer pH 8.0. Pellet suspensions were kept frozen in -20°C until 
DNA extraction was carried out.  
The mouthwash and buccal cytobrush samples were directly frozen in -20°C 
until DNA extraction was carried out.  
Summary on the procedures of sample collection and processing is presented in 
Figure 3.2.  
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Figure 3.2 Flow chart of sample collection and sample processing procedures 
for mouthwash, saliva and buccal cytobrush samples 
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3.3 Preparation of cell pellets for DNA extraction 
Mouthwash, saliva cell pellet and buccal cytobrush samples were thawed quickly 
in a 37°C waterbath (Shel Lab, USA) prior to DNA extraction.  
The mouthwash samples were transferred into new 50 mL centrifuge tubes. 
Cytological brushes from buccal cytobrush samples were agitated for 30 seconds to 
dislodge the buccal cells from the bristles into the saline solution. The cytological 
brushes were then discarded.  
The mouthwash and buccal cytobrush samples were centrifuged at 3,500 rpm for   
15 minutes at 4°C to pellet the cells present. The supernatant was carefully 
discarded.  
The mouthwash and saliva samples pellets were resuspended with 24 mL         
TE buffer, while the buccal cytobrush samples pellet was resuspended in 10 mL   
TE buffer. The cell suspensions were divided evenly into two separate tubes. The 
suspensions from mouthwash and saliva samples were brought to a final volume of 
25 mL with TE buffer and the suspension from buccal cytobrush samples were 
brought to a final volume of  15 mL with TE buffer. All samples were incubated for 
10 minutes in ice. Samples were then centrifuged at 3,500 rpm for 15 minutes at 
4°C. The supernatant was carefully discarded.  
Flow chart for collection of cell pellet for DNA extraction from mouthwash, 
saliva and buccal cytobrush is summarised in Figure 3.3.  
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Figure 3.3 Flow chart of cell pellet collection from mouthwash, saliva and 
buccal cytobrush samples prior to DNA extraction 
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3.3.1 DNA extraction – Method 1  
The pellets obtained were resuspended in 400 µL lysis buffer (0.1M NaCl and      
2% w/v SDS in TE buffer) and transferred into 2 ml microcentrifuge tubes (Axygen, 
USA) containing 70 µL of 10 mg/mL Proteinase K (Invitrogen, USA). The pellets 
were incubated at 37°C overnight in a shaking incubator.  
On Day 2, DNA in solution was purified with equal volumes of 
phenol:chloroform (ratio 1:1, Merck, Germany). The DNA-phenol-chloroform 
mixtures were gently inverted and were centrifuged at 14,000 rpm, 25°C for            
5 minutes. The lower phenol:chloroform and interphase layers were aspirated using 
a pipettor. The purification steps were carried out twice.   
DNA was precipitated with 1/10 volume of 4 M NaCl (Merck, Germany) and 
two volumes of ice-cold absolute ethanol and incubated overnight at -70°C. The 
samples were thawed at 25°C the following day and centrifuged at 14,000 rpm for  
5 minutes at 4°C. Purification was carried out using ice-cold 70% ethanol followed 
by absolute ethanol (Merck, Germany). DNA tubes were centrifuged at 14,000 rpm 
for 5 minutes at 4°C.  
DNA was air-dried in a laminar flow cabinet and solubilised with sterile 
deionised water. Solubilisation was carried out at 37°C for two hours with shaking. 
Extracted DNA samples were stored at -20°C.  
Summary of Method 1 DNA extraction is presented in Figure 3.4a. 
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3.3.2 DNA extraction – Method 2  
The pellets for mouthwash and buccal cytobrush samples were resuspended in     
700 µL lysis buffer and transferred into 2 mL microcentrifuge tubes containing     
35 µL of 20 mg/mL Proteinase K.  
The pellets for saliva samples were resuspended in 700 µL lysis buffer and 
transferred into 15 mL centrifuge tubes containing 1 mL of 10 mg/mL dithiotrietol 
(DTT, Sigma-Aldrich, USA) and 35 µL of 20 mg/mL Proteinase K.  
All samples were incubated in a waterbath at 65°C for one hour, followed by 
58°C incubation for two hours with shaking. A final incubation at 37°C was carried 
out overnight in a shaking incubator.  
DNA was then purified with an equal volumes of phenol:chloroform             
(ratio 1:1, Merck, Germany) and the mixtures were inverted gently. The           
DNA-phenol-chloroform mixtures in 2 mL microcentrifuge tubes were centrifuged 
at 14,000 rpm, 25°C for 2 minutes. The DNA-phenol-chloroform mixtures in 15 mL 
centrifuge tubes were centrifuged at 3500 rpm, 25°C for 10 minutes.  
The lower phenol:chloroform and interphase layers were aspirated with a 
pipettor. Purification steps were carried out three times. The top aqueous layer 
containing DNA was transferred into new 15 mL centrifuge tubes (Labcon, USA).  
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DNA was precipitated with 1/10 volume of 3 M NaOAc pH 5.6 and two volumes 
of ice-cold absolute ethanol. The solution was incubated at -70°C overnight. The 
samples were thawed to 25°C the following day and centrifuged at 14,000 rpm for  
5 minutes at 4°C. DNA dehydration was carried out with ice-cold 70% ethanol 
followed by absolute ethanol. DNA tubes were centrifuged at 14,000 rpm for           
5 minutes at 4°C.  
DNA was air-dried in a laminar flow cabinet and solubilised in 200 µL of sterile 
deionised water. Solubilisation was carried out at 37°C for two hours. Extracted 
DNA samples were stored at -20°C.  
Summary of Method 2 DNA extraction is presented in Figure 3.4b. 
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Figure 3.4a & b Flow chart of DNA extraction Methods 1 and 2 for 
mouthwash, saliva and buccal cytobrush samples 
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3.3.3 DNA quantification and statistical analysis 
DNA quantification was performed in duplicates. Two aliquots of purified DNA 
were diluted 100X with sterile deionised water. The diluted DNA solution was 
transferred into a quartz cuvette with 1 cm path length and measured using a UV 
spectrophotometer (PerkinElmer, USA) at wavelengths of A260nm and A280nm.  
The concentration of purified DNA in µg/µL was determined by the formula:  
 
[DNA] (µg/µL) = (A260nm X Dilution Factor X 50 µg/mL) / 1000 µL/mL 
 
Each 1.0 absorbance in 260nm corresponded to 50 µg/mL of double stranded 
DNA. 
Protein contamination was determined by calculating A260nm/A280nm. Purified 
DNA with A260nm/A280nm ratio in the range of 1.8 – 2.0 is considered as highly pure 
DNA.  
Measurement of DNA concentration and purity was carried out for all sampling 
methods and DNA extraction techniques.  
The data from DNA quantification was used in statistical analysis using SPSS 17 
(SPSS Inc., Chicago, IL). The data was tested for normality with Shapiro-Wilk test. 
Significance of difference in the purified DNA concentration and purity were 
analysed with Friedman test. The analysis was followed by post hoc test using 
Wilcoxon signed-rank test for confirmation of the most optimum method for sample 
collection and DNA extraction (Jaykaran, 2010).  
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3.4 Archived DNA  
Archived DNA extracted from blood samples from normal individuals,                    
β-thalassaemia carriers and β-thalassaemia major patients who were homozygous or 
compound heterozygous were also used in the study. DNA amplification using 
Amplification Refractory Mutation System (ARMS), Combine-ARMS (C-ARMS),   
gap-polymerase chain reaction (gap-PCR) and PCR-Restriction Fragment Length 
Polymorphism (PCR-RFLP) was carried out on the archived DNA.  
These results were compared with results using DNA from mouthwash, saliva 
and buccal cytobrush samples. Archived DNA samples were also used as positive 
controls in the molecular assays. Table 3.4 shows the list of the archived DNA from                  
β-thalassaemia carriers and β-thalassaemia major patients used in this study.   
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Table 3.4 List of archived DNA from β-thalassaemia carriers and                     
β-thalassaemia major patients used in the study 
i. No ii. Archived DNA from β-thalassaemia carriers 
iii. 1 Heterozygous for CAP+1 (A-C) 
iv. 2 Heterozygous for CD15 (G-A) 
v. 3 Heterozygous for CD19 (A-G) 
4 Heterozygous for CD26 (G-A) 
5 Heterozygous for Poly A (AATAAA-AATAGA) 
6 Heterozygous for IVS1-5 (G-C)  
7 Heterozygous for IVS1-1 (G-T) 
8 Heterozygous for CD8/9 (+G) 
9 Heterozygous for IVS2-654 (C-T) 
10 Heterozygous for -29 (A-G) 
11 Heterozygous for -28 (A-G) 
12 Heterozygous for Initiation Codon (T-G) 
13 Heterozygous for CD43 (G-T) 
14 Heterozygous for CD41/42 (-CTTT) 
15 Heterozygous for CD17 (A-T) 
16 Heterozygous for CD71/72 (+A) 
17 Heterozygous for Filipino β-deletion 
18 Heterozygous for 100 kb 
G(A)o-deletion 
19 Heterozygous for CD27/28 (+C) 
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Table 3.4  List of archived DNA from β-thalassaemia carriers and                    
β-thalassaemia major patients used in the study (cont.)  
vi. No vii. Archived DNA from β-thalassaemia major patients  
20 Compound heterozygous for CD41/42/CD17 
21 Homozygous for IVS1-5/IVS1-5 
22 Homozygous for IVS2-654/IVS2-654 
23 Homozygous for CD41/42/CD41/42 
24 Homozygous for -28/-28 
25 Homozygous for Filipino β-deletion  
26 Homozygous for Hb Lepore  
 
 
 
 
 
 
 
 
 
 
67 
3.5 Molecular analysis of β-thalassaemia using non-invasive DNA samples  
3.5.1 DNA analysis using the Amplification Refractory Mutation System 
(ARMS) 
DNA analysis using the ARMS was performed using DNA extracted from 
mouthwash, saliva and buccal cytobrush samples from 49 patients. DNA samples 
from the remaining one patient was not amplified using ARMS as the patient is 
homozygous for Haemoglobin Lepore, which was identified using gap-PCR (refer 
to section 3.5.3.3).  
Sixteen common and rare -globin gene mutations present in the Malay and 
Chinese ethnic groups were confirmed using the ARMS. The -globin gene 
mutations confirmed using ARMS are at the initiation codon for translation (T-G),   
-29 (A-G), -28 (A-G), CAP+1 (A-C), CD8/9 (+G), CD15 (G-A), CD17 (A-T), 
CD19 (A-G), CD26   (G-A), IVS1-1 (G-T), IVS1-5 (G-C), CD41/42 (-CTTT), 
CD71/72 (+A), IVS2-654   (C-T), CD43 (G-T) and Poly A (AATAAA-AATAGA).   
The sixteen mutant ARMS primers were matched with different β-globin gene 
common primers to detect the sixteen β-globin gene mutations (Tan et al., 2004). 
Internal controls were included in every PCR reaction. Internal control primers A 
and B amplified an 861 bp product and were used in ARMS for detection of every 
mutation except for the β-globin gene mutation at IVS2-654. The size of amplified 
product for IVS2-654 (830 bp) differed from the internal control product (861 bp 
product) by 31 base pairs. Thus, another set of internal control was used with   
IVS2-654.  
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Internal control primers E and F were used for the β-globin gene mutation at     
IVS2-654 in place of A and B. The amplification of the internal control for      
IVS2-654 was performed in a separate PCR reaction and produced an amplified 
product with a size of 323 bp.  
Four normal ARMS primers were included to exclude the normal gene sequence 
for IVS1-5, IVS2-654, CD41/42 and -28 in seven patients who were homozygous 
for these β-globin gene mutations.  
The common ARMS primer sequences are presented in Table 3.5 while the 
mutant and normal ARMS primer sequences and their amplified product size are 
listed in Table 3.6.  
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Table 3.5 Common primer sequences for ARMS for amplification of internal controls and the 16 common and rare β-globin gene mutations 
Common  
primers Primer direction Sequence (5’ to 3’) 
A Sense CAA TGT ATC ATG CCT CTT TGC ACC 
B Antisense GAG TCA AGG CTG AGA AGA TGC AGG  
C Sense ACC TCA CCC TGT GGA GCC AC 
D Antisense CCC CTT CCT ATG ACA TGA ACT TAA 
E Antisense CTC TGC ATC ATG GGC AGT GAG CTC 
F Sense AGT GCT GCA AGA AGA ACA ACT ACC  
G Antisense TTC GTC TGT TTC CCA TTC TAA ACT 
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Table 3.6 Mutant and normal primer sequences for ARMS for the detection of 16 β-globin gene mutations, common primers used and 
molecular weight of amplified product 
Primers Primer 
direction 
Primer 
type 
Sequence (5’ to 3’) 
Common 
Primer 
Amplified 
product size (bp) 
Primer sequences to detect β-globin gene mutations (Malay) at:  
CD26  Sense Mutant CGT GGA TGA AGT TGG TGG TA D 458 
IVS1-5 Antisense Mutant CTC CTT AAA CCT GTC TTG TAA CCT TGT TAG C 285 
 Antisense Normal CTC CTT AAA CCT GTC TTG TAA CCT TGT TAC C 285 
IVS1-1  Antisense Mutant TTA AAC CTG TCT TGT AAC CTT GAT ACG AAA C 281 
Poly A  Sense Mutant GGC CTT GAG CAT CTG GAT TCT GCC TAT TAG B 393 
CD15  Sense Mutant TGA GGA GAA GTC TGC CGT TAC TGC CCA GTA D 500 
CD19  Sense Mutant TGC CGT TAC TGC CCT GTG GGG CAA GGA GAG D 488 
CD8/9  Antisense Mutant CCT TGC CCC ACA GGG CAG TAA CGG CAC ACC C 215 
CAP (+1) Sense Mutant AAA AGT CAG GGC AGA GCC ATC TAT TGG TTC D 596 
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Table 3.6  Mutant and normal primer sequences for ARMS for the detection of 16 β-globin gene mutations, common primers used and 
molecular weight of amplified product (cont.) 
Primers Primer 
direction 
Primer 
type 
Sequence (5’ to 3’) 
Common 
Primer 
Amplified product 
size (bp) 
Primer sequences to detect β-globin gene mutations (Chinese) at:  
IVS2-654  Sense Mutant GAA TAA CAG TGA TAA TTT CTG GGT TAA CGT B 830 
 Sense Normal GAA TAA CAG TGA TAA TTT CTG GGT TAA CGC B 830 
CD41/42  Antisense Mutant GAG TGG ACA GAT CCC CAA AGG ACT CAA CCT C 439 
 Antisense Normal GAG TGG ACA GAT CCC CAA AGG ACT CAA AGA C 443 
CD17  Antisense Mutant CTC ACC ACC AAC TTC ATC CAC GTT CAG CTA C 240 
-28  Sense Mutant AGG GAG GGC AGG AGC CAG GGC TGG GCT TAG D 624 
 Sense Normal AGG GAG GGC AGG AGC CAG GGC TGG GCT TAA D 624 
CD43 Antisense Mutant ATC AGG AGT GGA CAG ATC CCC AAA GGA GTA C 448 
-29  Sense Mutant CAG GGA GGG CAG GAG CCA GGG CTG GGT ATG D 625 
CD71/72  Sense Mutant CAA GAA AGT GCT CGG TGC CTC TAA G 234 
Initiation 
Codon   
Sense Mutant TGT TCA CTA GCA ACC TCA AAC AGA CAG CAG D 545 
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All ARMS reaction mixture utilised 2.5 µL of 10X reaction buffer (200 mM 
Tris-HCl (pH 8.4), 500 mM KCl, Invitrogen, USA) and 200 µM of 
deoxyribonucleotide triphosphate (dNTP, Applied Biosystem, USA).  
The reaction mixture prepared for detection of β-globin gene mutation at CD26 
contained 1.2 mM magnesium chloride (MgCl2, Invitrogen, USA), 2.5 unit         
Taq DNA polymerase (Invitrogen, USA) and primers (Invitrogen, USA).  
For the detection of the other β-globin gene mutations, the concentrations of 
MgCl2 and Taq DNA polymerase were adjusted to 1.5 mM and 0.5 units 
respectively. However, for mutations at CD15 and CD19, the concentration of 
MgCl2 was reduced to 1.3 mM and 0.8 mM respectively to reduce non-specific 
primer hybridisation.  
Purified DNA (1 µg) was added into the reaction tubes. Sterile deionised water 
was added to bring the reaction mixture to a final volume of 25 µL. A non-template 
control or DNA blank, negative and positive controls for each β-globin gene 
mutation were included in each assay for validation. Negative control was obtained 
from DNA of a normal individual who did not posses any β-globin gene mutation. 
Positive control was obtained from archived DNA of the individuals who were 
confirmed to carry the specified β-globin gene mutation for the respective ARMS.  
Primer pairing, the final concentrations for every mutant and normal primers and 
their annealing temperatures are listed in Table 3.7 and Table 3.8, respectively. 
Common primers A and B and common primers E and F serve as internal control. 
Mutant and normal primers will pair with their respective common primers to 
produce the amplification product to determine the presence or absence of the 
respective β-globin gene mutations.  
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Table 3.7 Final concentrations of mutant primers and annealing temperatures 
for detection of the 16 β-globin gene mutations using ARMS 
β-globin gene 
mutation 
Primer pairs and final concentrations  
Annealing 
temperature 
(°C) 
Internal control  
(pmol) 
Mutant                         
(pmol) 
CD26  A  
B  
: 0.08 
: 0.08 
CD26  
D  
: 0.12 
: 0.12 
65 
IVS1-5  A  
B  
: 0.4 
: 0.32 
IVS1-5  
C  
: 0.36 
: 0.4 
65 
IVS1-1 A  
B  
: 0.24 
: 0.24 
IVS1-1  
C  
: 0.12 
: 0.12 
65 
Poly A  A  
B  
: 0.32 
: 0.32 
Poly A  
B 
: 0.12 
: 0.32 
65 
CD15 A  
B  
: 0.08 
: 0.12 
CD15  
D  
: 0.04 
: 0.04 
60 
CD19 A  
B  
: 0.16 
: 0.16 
CD19  
D  
: 0.06 
: 0.06 
60 
CD8/9  A  
B  
: 0.4 
: 0.4 
CD8/9  
C  
: 0.12 
: 0.32 
65 
CAP (+1)  A  
B  
: 0.24 
: 0.4 
CAP (+1)  
D  
: 0.4 
: 0.6 
65 
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Table 3.7  Final concentrations of mutant primers and annealing temperatures 
for detection of the 16 β-globin gene mutations using ARMS (cont.) 
β-globin gene 
mutation 
Primer pairs and final concentrations 
Annealing 
temperature 
(°C) 
Internal control  
(pmol) 
Mutant                         
(pmol) 
IVS2-654*  E  
F  
: 0.08 
: 0.08 
IVS2-654  
B  
: 0.08 
: 0.08 
60 
CD41/42  A  
B  
: 0.4 
: 0.24 
CD41/42  
C  
: 0.64 
: 0.2 
65 
CD17  A  
B  
: 0.24 
: 0.32 
CD17  
C  
: 0.32  
: 0.32 
65 
-28  A  
B  
: 0.24 
: 0.24 
-28  
D  
: 0.32 
: 0.64 
65 
CD43 A  
B  
: 0.32 
: 0.24 
CD43  
C  
: 0.16 
: 0.2 
65 
-29  A  
B  
: 0.4 
: 0.32 
-29  
D  
: 0.32 
: 0.8 
65 
CD71/72  A  
B  
: 0.24 
: 0.32 
CD71/72  
G  
: 0.16 
: 0.4 
60 
Initiation codon  A  
B  
: 0.4 
: 0.32 
Initiation codon  
D  
: 0.16  
: 0.16 
65 
Note: * - The internal control primers E and F amplified a 323 bp product in a 
separate reaction  
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Table 3.8 Final concentrations of normal primers and annealing temperatures 
for detection of 4 β-globin gene mutations using ARMS 
Primer  
Primer pairs and final concentrations  
Annealing 
temperature 
(°C) 
Internal control    
(pmol) 
Mutant                         
(pmol) 
IVS2-654N*  E 
F 
: 0.08 
: 0.08 
IVS2-654N  
B  
: 0.08  
: 0.08 
60 
IVS1-5N  A 
B 
: 0.4  
: 0.32 
IVS1-5N  
C  
: 0.36 
: 0.4 
65 
CD41/42N  A 
B 
: 0.4 
: 0.32 
CD41/42N  
C  
: 0.064  
: 0.064 
65 
-28N  A 
B 
: 0.24  
: 0.24 
-28N  
D 
: 0.32  
: 0.64 
65 
Note: * - The internal control primers E and F amplified a 323 bp product size in a 
separate reaction  
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PCR was carried out in an Applied Biosystem Veriti thermal cycler. The cycling 
conditions were 95°C for 5 minutes for complete denaturation of DNA, 93°C for    
1 minute (for denaturation of DNA), 60°C or 65°C for 1 minute (for annealing of 
primers), 72°C for 1.5 minutes (for extension of DNA) followed by 72°C for           
3 minutes for final extension. The denaturation-annealing-extension process was 
performed for 30 cycles.  
Using ARMS, DNA from normal individuals will produce an internal control 
amplified product of 861 bp. For ARMS using common primers E and F, the 
internal control amplified product will be 323 bp band. DNA of individuals with   
β-globin gene mutations will produce amplified products with sizes according to the 
respective β-globin gene mutations. For normal primers, the presence of normal    
β-globin gene sequence will allow primer annealing and produce the amplified 
normal β-globin gene sequence.  
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3.5.2 Combine-ARMS (C-ARMS) for rapid detection of the β-globin gene 
mutations at CD41/42 (-CTTT) and CD17 (A-T) 
For rapid detection of CD41/42 and CD17 in the Chinese patients, C-ARMS for 
CD41/42/CD17 was performed to detect the two mutations in a single reaction. 
Thirteen samples which have been identified to carry mutations at CD41/42 or 
CD17, or compound heterozygous for CD41/42/CD17 through single ARMS were 
analysed using the C-ARMS.  
The reaction mixture for C-ARMS CD41/42/CD17 utilised 2.5 µL of             
10X reaction buffer, 200 µM of dNTP, 1.5 mM of MgCl2 and 1.5 units of Taq DNA 
polymerase. Purified DNA (1 µg) was added into the reaction tubes. The reaction 
mixture was brought to a final volume of 25 µL with sterile deionised water. A         
non-template control, negative and positive controls for CD41/42, CD17 and 
CD41/42/CD17 were included in every assay for validation.  
The final concentrations of the primers used in the C-ARMS for CD41/42/CD17 
are listed in Table 3.9. Common primers A and B serve as internal control. Both 
CD41/42 and CD17 primers share the same common primer – common C.  
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Table 3.9 Final concentrations of primers used in C-ARMS for detection of the    
β-globin gene mutations at CD41/42 and CD17 
C-ARMS Primer pairs and final concentrations                  
(pmole) 
CD41/42/CD17 Common A  
Common B  
CD41/42   
CD17   
Common C  
: 0.4  
: 0.32 
: 0.08 
: 0.16 
: 0.16 
 
The reaction was initiated with complete denaturation at 95°C for 5 minutes, 
followed by 30 cycles of denaturation-annealing-extension (93°C for 1 minute, 
65°C for 1 minute and 72°C for 1.5 minutes) and a final extension at 72°C for         
3 minutes.  
Hybridisation between common primers A and B will produce an internal 
control amplified product of 861 bp. DNA with β-globin gene mutation at CD41/42 
will produce a 439 bp amplified product while DNA with the β-globin gene 
mutation at CD17 will produce a 240 bp amplified product. DNA from a compound 
heterozygous CD41/42/CD17 individual will produce both 439 bp and 240 bp 
amplified products.  
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3.5.3 Gap-PCR for detection of -thalassaemia  
The -thalassaemias caused by a large Filipino β-deletion, the Chinese 100 kb 
G(A)o-specific deletion and Hb Lepore were confirmed by DNA amplification 
across the deleted regions in the -globin gene complex (gap-PCR) using specific 
primers that flank the deleted sequences.  
3.5.3.1 Detection of the Filipino β-deletion  
Mouthwash, saliva and buccal cytobrush DNA samples from one patient was 
analysed using gap-PCR for detection of the Filipino β-deletion. The PCR mixture 
was prepared using 2.5 µL of 10X reaction buffer, 200 µM of dNTP, 5.0 µL of      
Q Solution (Qiagen, USA), 2.5 units of Taq DNA polymerase and 0.4 pmole of 
each of the primers P2, P4 and P5. DNA (1 µg) was added into the reaction tubes. 
The mixture was brought to a final volume of 25 µL with sterile deionised water. A 
non-template control, negative, heterozygous positive and homozygous positive 
controls were included for validation of each assay.  
The sequences of the primers are listed in Table 3.10. Primers P2 and P5 will 
anneal to the normal sequence in the DNA template and was used to detect the 
presence of the normal β-globin gene sequence. Primers P4 and P5 flank the deleted 
Filipino β-deletion and will detect the presence of the deletion-specific sequence.  
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Table 3.10 Primer sequences for gap-PCR to detect the Filipino β-deletion 
Primers Sequence (5’ to 3’) 
Amplified product 
size (bp) 
P2 TCA GAA GCA GAG CTA CTC AG 
482 
376 
P5 CAT TTA GCT CCC ACA CTC CT 
P4 GTC TAT GCA GGT GTG TAG ACA 
 
The amplification process involved 35 cycles of template denaturation at 95°C 
for 1 minute, primer annealing at 60°C for 1 minute and extension at 72°C for         
1 minute.  
The presence of the normal β-globin gene sequence allows amplification using 
primers P2 and P5 and produces a 482 bp amplified product. Absence of the normal 
β-globin gene sequence will only allow amplification of the primers P4 and P5, 
producing a 376 bp amplified deletion-specific product. After gel electrophoresis, 
DNA from a normal individual will show only the 482 bp amplified product. DNA 
from a homozygous β-thalassaemia individual for the Filipino β-deletion will only 
yield the 376 bp amplified product. A β-thalassaemia carrier with the Filipino        
β-deletion will show both the 482 bp and 376 bp amplified products.  
 
 
 
 
 
 
 
 
81 
3.5.3.2 Detection of the 100 kb Gγ(Aγδβ)0-deletion  
Mouthwash, saliva and buccal cytobrush DNA samples from one patient was 
analysed using gap-PCR for detection of the 100 kb 
G(A)o-specific deletion. 
The reaction mixture contained 2.5 µL of 10X reaction buffer, 200 µM of dNTP,    
3 µM of MgCl2, 2.5 units of Taq DNA polymerase, 0.2 pmole of primers G1 and 
G2 and 0.24 pmole of primer G3. Purified DNA (1 µg) was included in the reaction 
tubes. The total volume of the reaction mixture was 25 µL. For validation of assay, 
a non-template control, negative and heterozygous positive controls were included 
in each assay performed.  
The sequences of the primers used are listed in Table 3.11. Primers G1 and G2 
will anneal to the normal sequence in the DNA template and was used to detect the 
presence of the normal β-globin gene sequence. Primers G2 and G3 flank the 
deleted 100 kb 
Gγ(Aγδβ)0 sequence and will detect the presence of the          
deletion-specific sequence.  
 
Table 3.11 Primer sequences for gap-PCR to detect the 100 kb             
Gγ(Aγδβ)0-deletion 
Primers Sequence (5’ to 3’) 
Amplified product size                        
(bp) 
G1 GGC ATA TAT TGG CTC AGT CA 
682 
508 
G2 CTT GCA GAA TAA AGC CTA TC 
G3 TCA ACA ATT ATC AAC ATT ACA 
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The DNA amplification reaction was initiated with complete denaturation at 
95°C for 4 minutes, followed by 30 cycles of denaturation (93°C for 1 minute), 
annealing (58°C for 1 minute) and extension (72°C for 2 minutes) followed by a 
final extension at 72°C for 10 minutes.  
Amplification of primers G1 and G2 will produce a 682 bp amplified product 
which shows the presence of the normal β-globin gene sequence in the DNA 
template. The presence of the 
Gγ(Aγδβ)0-deletion will produce a 508 bp        
deletion-specific amplified product using primers G2 and G3. A normal individual 
will only amplify the 682 bp normal β-globin gene sequence. DNA from a 
homozygous individual will only amplify the 508 bp deletion-specific product. The 
presence of both amplified products after DNA amplification shows that the 
individual is heterozygous for the 
Gγ(Aγδβ)0-deletion.  
3.5.3.3 Detection of Haemoglobin Lepore  
Mouthwash, saliva and buccal cytobrush DNA samples from one patient was 
analysed using gap-PCR for detection of Hb Lepore. The reaction mixture for      
Hb Lepore was made up of 2.5 µL of 10X reaction buffer, 200 µM of dNTP,        
1.5 mM of MgCl2, 0.5 units Taq DNA polymerase 0.144 pmole primer LA,      
0.256 pmole primer LB and 0.8 pmole primer LC. Purified DNA (1 µg) was 
included in the reaction tubes. The final volume of the reaction mixture was 25 µL. 
For each assay performed, non-template control, negative and homozygous positive 
controls were included for validation.  
The sequence of primers LA, LB and LC are listed in Table 3.12. Primers LA 
and LB will anneal to the normal sequence in the DNA template and was used to 
detect the presence of the normal β-globin gene sequence. Primers LA and LC flank 
the deleted β-globin sequence and will detect the presence of the deletion-specific 
sequence. 
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Table 3.12 Primer sequences for gap-PCR to detect Haemoglobin Lepore 
Primers Sequence (5’ to 3’) 
Amplified product 
size (bp) 
LB CGA TCT TCA ATA TGC TTA CCA AG 
915 
775 
LA CAT TCG TCT GTT TCC CAT TCT A 
LC GAC ACA CAT GAC GGA ACA GCC AAT 
 
The amplification reaction involved complete denaturation at 94°C for                
4 minutes, followed by denaturation at 94°C for 1 minute, primer annealing at 58°C 
for 1 minute and extension at 72°C for 2 minutes. DNA amplification was carried 
out for 30 cycles before final extension at 72°C for 10 minutes.  
The presence of the normal β-globin gene sequence in a normal individual will 
be amplified as a 915 bp product using primers LA and LB. DNA from an 
individual homozygous for Hb Lepore will amplify a 775 bp deletion-specific 
sequence using primers LA and LC. DNA from an individual heterozygous for    
Hb Lepore will amplify both the 915 bp normal β-globin gene sequence and the  
775 bp Hb Lepore deletion-specific gene sequence.  
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3.5.4 Detection of β-globin gene mutation at CD27/28 (+C) using           
PCR-RFLP  
The detection of the β-globin gene mutation at CD27/28 was performed using 
PCR-RFLP. DNA from mouthwash, saliva and buccal cytobrush samples from one 
patient was analysed using the technique. The reaction mixture consisted of 2.5 µL 
of 10X reaction buffer, 200 µM of dNTP, 1.5 mM of MgCl2, 0.5 units Taq DNA 
polymerase, and 0.32 pmole of each forward (27/28F3) and reverse (27/28R) 
primer. Purified DNA (1 µg) was added into the reaction tubes. The reaction 
mixture was brought to a final volume of 25 µL with sterile deionised water.     
Non-template control, negative and heterozygous positive controls were included in 
each assay for validation purpose.  
The primer sequences are listed in Table 3.13. The primers 27/28F3 and 27/28R 
will flank the sequence where the β-globin gene mutation at CD27/28 is located. 
The amplified product will be obtained both from normal individuals and 
individuals with the β-globin gene mutation. The amplified product was subjected 
to subsequent restriction enzyme digestion.  
 
Table 3.13 Primer sequences for PCR-RFLP to detect the β-globin gene 
mutation at CD27/28 
Primers Sequence (5’ to 3’) 
Amplified product size    
(bp) 
27/28F3 CTG GGC ATA AAA GTC AGG G 
284 
27/28R GGC AGA GAG AGT CAG TGC CTA  
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Reaction was initiated with complete denaturation at 94°C for 5 minutes. DNA 
amplification was performed at 94°C for 2 minutes, followed by annealing at 55°C 
for 2 minutes, and extension at 72°C for 3 minutes. The denaturation-annealing-
extension cycles were repeated 35 times followed by additional incubation at 72°C 
for 3 minutes. After DNA amplification, the amplification product was 
electrophoresed in 1.5% w/v agarose gel at 70V for 40 minutes to confirm the 
presence of the 284 bp amplified product.  
For restriction enzyme digestion, the reaction mixture prepared contained 1 unit 
of NlaIV restriction enzyme (Cat: R0126, New England Biolabs, USA), 2.5 µL of 
10X NEBuffer 4 (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM 
magnesium acetate and 1 mM DTT at pH 7.9) and 0.25 µL of 100X bovine serum 
albumin (BSA, New England Biolabs). Amplification product (15 µL) was added 
into the reaction tubes. Sterile deionised water was added to bring the reaction 
mixture to a final volume of 25 µL. Restriction enzyme digestion was carried out at 
37°C overnight.  
The addition of a single base (+C) at CD27/28 creates a restriction site, which 
cleaves the DNA amplified product into two fragments with sizes of 170 bp and 
114 bp. DNA from a normal individual will only show the 284 bp amplified product 
after the restriction enzyme treatment and gel electrophoresis. DNA from a 
heterozygous individual with the β-globin gene mutation at CD27/28 will show the 
284 bp undigested amplified product and 170 bp and 114 bp digested products. 
Individuals homozygous for CD27/28 will only produce the 170 bp and 114 bp 
digested products.  
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3.5.5 Gel electrophoresis and visualisation 
Amplified DNA (10 µL) from single ARMS, C-ARMS and gap-PCR was 
electrophoresed in 1.5% w/v agarose gels (SeaKem LE) pre-stained with 2.0 µL 
ethidium bromide (Sigma-Aldrich, USA). PCR-RFLP products which have smaller 
molecular weight products was analysed in 2.0% w/v agarose gels. Loading of 
amplified DNA was carried out using 2 µL 5X loading buffer (3% v/v bromophenol 
blue, 15% v/v xylene cyanol in 10X Tris-Borate-EDTA (TBE):glycerol:2% w/v 
SDS solution in ratio of 50:49:1). Agarose gels were electrophoresed for 90 minutes 
at 70V in 1X TBE (Thermo Scientific) buffer. Electrophoresis of amplified DNA 
was carried out with molecular weight markers (Thermo Scientific) as reference. 
Separated fragments were visualised and photographed using the MultiDoc-it 
Digital Imaging System (UVP, USA).  
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3.6 Oxidative stress indices and cytokine measurement 
The frozen saliva samples were thawed and centrifuged at 10,000 x g for          
10 minutes in refrigerated microcentrifuge prior to assay to remove mucin. 
Supernatant was used directly without dilution for the measurement of the oxidative 
stress indices and cytokine level based on established methods and commercialised 
kits. All samples were assayed in triplicates.  
3.6.1 Ferric reducing antioxidant power   
Ferric reducing ability of metabolites in samples was measured using 
colorimetric method, ferric reducing antioxidant power (FRAP) assay. The FRAP 
reagent containing Fe
3+
 ion from ferric 2,4,6-tripyridyl-triazine complex          
(Fe
3+
-TPTZ) was added into the sample. The concentration of Fe
2+
 produced due to 
reduction-oxidation reaction between the sample and Fe
3+
-TPTZ complex was 
measured (Benzie & Strain, 1996).  
The FRAP reagent contains 300 mM acetate buffer pH 3.6, 10 mM TPTZ in     
40 mM hydrochloric acid (HCl) and 20 mM ferric chloride hexahydrate 
(FeCl3.6H2O), mixed in the ratio of 10:1:1. The TPTZ reagent is light sensitive and 
FRAP reagent was protected from light once prepared.  
Acetate buffer was prepared by mixing 0.31 g of sodium acetate trihydrate 
(NaOAc.3H2O) with 1.6 mL of glacial acetic acid and brought up to a final volume 
of 100 mL with deionised water. Six different concentrations of ferrous sulphate 
heptahydrate (FeSO4.7H2O) ranging from 0, 200, 400, 600, 800 and 1000 µM were 
used as standards.  
Reaction was initiated by mixing 10 µL of each sample or standards with 300 µL 
of FRAP reagent in flat bottom 96-well plate. Absorbance at 593 nm from 0 to        
4 minutes was measured and the difference was calculated. The FRAP values were 
expressed in µM.  
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3.6.2 Advanced oxidation protein product   
Advanced oxidation protein products (AOPP) were measured using colorimetric 
method. The sample absorbance was compared with the absorbance of   
chloramine-T after mixing them with potassium iodide (KI) in acidic condition 
(Witko-Sarsat et al., 1996).  
AOPP reagent was prepared by mixing phosphate buffered saline (PBS, Oxoid), 
50% acetic acid and 1.16 M KI in 81:15:4 ratios. Prepared reagent was protected 
from light. Six concentrations of chloramine-T in deionised water (0, 100, 200, 300, 
400 and 500 µM) were prepared as standard. 
Reaction was initiated by mixing 18 µL of each sample and standards with     
200 µL of reagent mixture in flat bottom 96-well plate. Absorbance at 340 nm was 
measured instantly and results were expressed in µM chloramine unit.  
3.6.3 Lipid hydroperoxide  
Assessment of lipid peroxidation was performed by measuring the level of lipid 
hydroperoxide (LOOH) in samples. Method used was based on procedures 
described by Esterbauer & Cheeseman (1990).  
Standards were prepared by diluting 1,1,3,3-tetraethoxypropane (TEP) in 
deionised water. Six concentrations of TEP (0, 2.5, 5, 10, 15 and 20 µM) were 
included in each assay to generate a standard curve.  
Each sample and standards (150 µL) were mixed with 375 µL of 10.3 mM MPI 
in acetonitrile and 225 µL of 5 M hydrochloric acid (HCl). Reaction was initiated 
by incubating the mixture in 45°C waterbath for 40 minutes. The mixture was then 
centrifuged at 10,000 x g for 5 minutes. Supernatant (200 µL) was transferred into 
flat bottom 96-well plate and absorbance reading at 586 nm was measured. Results 
were compared with standards to determine the LOOH concentration present in the 
samples and expressed in µM.  
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3.6.4 Glutathione peroxidase   
Measurement of glutathione peroxidase (GPx) activity was carried out using 
Glutathione Peroxidase Assay Kit (Cayman Chemical, USA, Cat: 703102). The 
assay involves measuring the rate of NADPH concentration reduction to determine 
GPx activity. The assay was carried out in flat bottom 96-well plate according to the 
procedure supplied with the kit.  
The reagents were brought to room temperature and diluted appropriately for 
each experiment. Blank, samples and control were included in each assay.  
Samples and control (20 µL) were added into each well. For blank, 20 µL of 
Assay buffer were loaded instead. Assay buffer (100 µL) and Co-Substrate mixture 
(50 µL) were loaded into each well. Reaction was initiated by adding 20 µL of 
Cumene Hydroperoxide. The plate was agitated to mix the solutions.  
Changes of absorbance at 340 nm were monitored for at least 5 minutes at          
1 minute interval. Mean of values obtained for each minute were plotted and linear 
equation is generated. The slope (rate) of the linear curve for each sample and 
control were subtracted from blank. Enzyme activity was calculated through the 
formula below.  
 
GPx activity (nmol/min/mL) =        Rate           x    0.19 mL x sample dilution 
        0.00373 µM-1         0.02 mL 
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3.6.5 Uric Acid   
Assay for measurement of uric acid (UA) level was carried out using Uric Acid 
Assay Kit (BioVision, Cat: K608-100). The kit was based on enzymatic method to 
estimate the amount of UA in samples. Preparations and assay were carried out 
according to the procedures supplied with the kit. The assay was performed in flat 
bottom 96-well plate. 
Blank, standards and samples were included for each assay carried out. Crude 
standard in dimethyl sulfoxide (DMSO) at concentration of 2 nmol/µL was diluted 
with assay buffer to produce series of standards with concentrations of 0, 8, 16, 24, 
32 and 40 nmol per well. Samples and standards (50 µL) were loaded into the 
corresponding wells.  
Reaction was initiated by adding 50 µL of reaction mix comprising 46 µL of 
assay buffer, 2 µL of UA probe and 2 µL of UA enzyme mix into each well. 
Mixtures were incubated at 37°C and protected from light for 30 minutes.  
Absorbance reading at 570 nm was carried out after the incubation. The average 
reading for samples and standards were subtracted from blank. Linear equation was 
generated from standard curve and the amounts of UA in sample wells were 
obtained. The UA concentration is calculated using the formula:  
 
[UA] (nmol/mL) = Amount of UA in sample well (nmol) x 1000 
Sample volume (µL) 
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3.6.6 Tumor necrosis factor-α and interleukin-6  
The levels of cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) 
were estimated using ELISA kits by BioLegend ELISA MAX (Cat: 43204 and 
43504, respectively).  
Assay was carried out according to the procedures provided with minor 
alteration. One day prior to performing the assay, Capture Antibody was diluted        
200 times in 1X Coating Buffer. Diluted antibody (200 µL) was added into each 
well of 96-well plate and incubated for 16-18 hours at 4°C.  
On the day the assay was performed, each well was washed twice with 300 µL of 
PBS with 0.05% Tween-20. The wells were further washed twice with 300 µL of 
PBS. Buffer residue was removed from the wells by tapping the plate upside down 
on an absorbent paper after each washing.  
Antigen blocking was carried out by incubating the wells with 200 µL of         
1X Assay Diluent for 1 hour. The plate was sealed and incubated at room 
temperature on a shaker prior to the washing steps.  
Samples and diluted standards (100 µL) were added into the corresponding wells 
and were incubated for 2 hours which was followed by washing steps. Diluted 
Detection Antibody (100 µL) was added into all wells and incubation was carried 
out for 1 hour. The plate was washed again before the addition of 100 µL of 
Avidin-HRP solution into each well and followed by further 30 minute incubation.  
For final washing, the plate was washed twice with 300 µL PBS with          
0.05% Tween-20 and thrice with PBS. For each round of washing, the wells were 
soaked in the buffer for 1 minute. After washing, 100 µL of TMB Substrate solution 
was added into each well and kept in the dark for 15 minutes to allow colour 
development.  
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Reaction was terminated by adding 100 µL of 2 N sulphuric acid (H2SO4). 
Absorbance at 450 nm was measured within 30 minutes. Standard curve was 
generated to determine the concentration of the cytokine in pg/mL.  
3.6.7 Statistical Analysis 
Results from biochemical assay were assessed using SPSS 17. The normality in 
data distribution was first assessed by Shapiro-Wilk test. The alpha level was set to 
0.05. Any significance in Shapiro-Wilk value indicates that the data was 
significantly deviated from normal distribution.  
As Shapiro-Wilk test confirmed deviation of data distribution, data was assessed 
using non-parametric statistical analyses. Significance of difference on the median 
of parameter levels between β-thalassaemia major patients and healthy individuals 
groups was also assessd using Mann-Whitney U test.  
Correlation between oxidative stress indices and cytokines were estimated using 
Spearman’s correlation.  
Analysis for significance of difference between demographic data sub-groups in 
β-thalassaemia major patients was performed using Kruskal-Wallis H test. Any 
significant differences observed were further analysed using Mann-Whitney U test 
to determine the actual groups with significant differences (Jaykaran, 2010).  
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CHAPTER 4: RESULTS 
4.1 Quantity and quality of extracted DNA from non-invasive samples  
The results for DNA concentration and purity were presented as median. 
Comparison of DNA concentration and purity between sampling methods was 
carried out using Friedman test. Results were presented in chi-square (χ2) value with 
degrees of freedom of 2. Friedman test was followed by post-hoc test using 
Wilcoxon signed-rank test to determine where the differences occurred. The results 
were reported using the Z statistics.  
Comparison of DNA concentration and purity between DNA extraction methods 
1 and 2 was performed using Wilcoxon signed-rank test. The results were reported 
using the Z statistics. 
Difference in DNA concentration and purity between sampling procedures and 
DNA extraction method was considered as statistically significant if p value is less 
than 0.05 and highly significant if p value is less than 0.01.  
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4.1.1 Concentration and purity of purified DNA extracted using Method 1 
Using Method 1, mouthwash samples produced purified DNA with a median 
concentration of 0.14 µg/µL. The mean DNA concentration of mouthwash samples 
was 0.17 ± 0.13 µg/µL (mean ± standard deviation (SD)) and the concentration 
ranged from 0.01 – 0.60 µg/µL. The median concentration of purified DNA from 
saliva samples was 0.28 µg/µL (mean: 0.38 ± 0.38 µg/µL, range:                         
0.07 – 2.14 µg/µL) while median concentration of DNA from buccal cytobrush 
samples was 0.09 µg/µL (mean: 0.19 ± 0.18 µg/µL, range: 0.04 – 0.80 µg/µL). 
Using Method 1, saliva samples produced the highest median of purified DNA 
concentration followed by mouthwash and buccal cytobrush samples.  
There was a significant difference on DNA concentration, with χ2(2) = 12.98,     
p < 0.05 depending on the sampling procedure. From the Wilcoxon signed-rank test 
performed, the median concentration of purified DNA extracted from saliva 
samples was significantly higher than mouthwash samples (Z = -3.88, p < 0.01) and 
buccal cytrobrush samples (Z = -3.40, p < 0.05).  
Figure 4.1 is a graphical representation of the comparison between median 
purified DNA concentrations for the three sampling procedures using Method 1. 
Table 4.1 summarise the median, mean, SD, minimum and maximum purified DNA 
concentration obtained from mouthwash samples.  
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Figure 4.1 Comparison of median of purified DNA concentrations for 
mouthwash, saliva and buccal cytobrush samples using Method 1 
 
Table 4.1 Comparison of median, mean, SD and range of DNA concentration 
obtained from mouthwash, saliva and buccal cytobrush samples 
extracted using Method 1
a
 
Concentration  
(µg/µL) 
Samples  
Mouthwash Saliva Buccal cytobrush 
Median  0.14 0.28
*,**
 0.09 
Mean  0.17 0.38 0.19 
SD 0.13 0.38 0.18 
Range  0.01 – 0.6 0.07 – 2.14 0.04 – 0.80 
a 
Wilcoxon signed-rank test 
 
*
 Significantly higher compared with buccal cytobrush samples (p < 0.05) 
**
 Significantly higher compared with mouthwash samples (p < 0.01)  
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In aspects of purity, DNA extracted from mouthwash samples has a median 
purity of 1.64 and mean purity of 1.60 ± 0.17. The DNA purity ranged from 1.15 to 
1.90. Saliva samples produced DNA with a median purity of 1.64 (mean:           
1.62 ± 0.16, range: 1.32 – 1.91), while the buccal cytobrush samples produced DNA 
with a median purity of 1.58 (mean: 1.57 ± 0.13, range: 1.27 – 1.87). DNA with the 
highest purity was obtained from the saliva samples, followed by mouthwash and 
buccal cytobrush samples using Method 1.  
There was a significant difference on DNA purity, with χ2(2) = 6.52, p < 0.05 
depending on the sampling procedure. Wilcoxon signed-rank test confirmed that the 
purity ratio of purified DNA extracted from saliva samples was significantly higher 
than buccal cytrobrush samples (Z = -2.29, p < 0.05). 
Figure 4.2 summarise of the difference in median purity of purified DNA 
obtained from the three samples; mouthwash, saliva and buccal cytobrush. The 
following Table 4.2 present the median, mean, SD and range of DNA purity.  
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Figure 4.2 Comparison of median of DNA purity between mouthwash, saliva 
and buccal cytobrush samples using Method 1 
 
Table 4.2 Comparison of median, mean, SD and range of DNA purity obtained 
from mouthwash, saliva and buccal cytobrush samples extracted 
using Method 1
a
 
Purity 
Samples  
Mouthwash Saliva Buccal cytobrush 
Median  1.64 1.64
*
 1.58 
Mean  1.60 1.62 1.57 
SD 0.17 0.16 0.13 
Range  1.15 – 1.90  1.32 – 1.91 1.27 – 1.87 
a 
Wilcoxon signed-rank test 
 
*
 Significantly higher compared with buccal cytobrush samples (p < 0.05) 
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4.1.2 Concentration and purity of purified DNA extracted using Method 2 
For DNA extraction using Method 2, saliva samples also produced purified DNA 
with the highest median concentration of 0.67 µg/µL (mean: 0.96 ± 0.96 µg/µL, 
range: 0.01 – 4.7 µg/µL). Mouthwash samples produced the second highest amount 
of purified DNA with a median concentration of 0.15 µg/µL (mean:                     
0.26 ± 0.39 µg/µL, range: 0.01 – 4.70). The lowest amount of DNA was obtained 
from buccal cytobrush samples, with median DNA concentration of 0.08 µg/µL 
(mean: 0.15 ± 0.33 µg/µL, range <0.01 – 2.14 µg/µL).  
Significant difference in DNA concentration was present depending on the 
sampling procedure, with χ2(2) = 40.44, p < 0.01. The concentration of purified 
DNA of saliva samples was significantly higher than the DNA concentration of 
mouthwash (Z = -5.16, p < 0.01) and buccal cytrobrush samples (Z = -5.70,             
p < 0.01).  
The DNA concentration from mouthwash samples was also significantly higher 
than the DNA concentration from buccal cytobrush samples with Z = -4.03            
(p < 0.01).  
A graphical representation of the difference in median purified DNA 
concentration is demonstrated in Figure 4.3. Table 4.3 summarise the median, 
mean, SD and range of DNA concentration obtained through Friedman test.  
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Figure 4.3 Comparison of median of purified DNA concentrations for 
mouthwash, saliva and buccal cytobrush samples using Method 2 
 
Table 4.3 Comparison of median, mean, SD and range of DNA concentration 
obtained from mouthwash, saliva and buccal cytobrush samples 
extracted using Method 2
a
 
Concentration  
(µg/µL) 
Samples  
Mouthwash Saliva Buccal cytobrush 
Median  0.15
##
 0.67
**
 0.08 
Mean  0.26 0.96 0.15 
SD 0.39 0.96 0.33 
Range  0.01 – 2.6 0.01 – 4.70 < 0.01 – 2.14 
a 
Wilcoxon signed-rank test 
 
##
 Significantly higher compared with buccal cytobrush samples (p < 0.01) 
**
 Significantly higher compared with mouthwash and buccal cytobrush 
samples (p < 0.01) 
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Using Method 2 DNA extraction, mouthwash samples produced purified DNA 
with the median purity of 1.75. The mean was 1.74 ± 0.14 with purity ranging from 
1.38 – 1.90. On the other hand, DNA extracted from saliva samples has a median 
purity of 1.70 (mean: 1.65 ± 0.20, range: 1.29 – 2.0). The purified DNA from 
buccal cytobrush samples have a median purity of 1.68 (mean: 1.62 ± 0.17, range: 
1.30 – 1.86). Mouthwash samples produced DNA with the highest purity, followed 
by saliva and buccal cytobrush samples. 
The non-invasive DNA purity was significantly different, with χ2(2) = 20.28,      
p < 0.01 depending on the sample used for extraction. From the post hoc test 
performed, the median purity of DNA from mouthwash was significantly higher 
when compared with purified DNA extracted from saliva (Z = -2.52, p < 0.01) and 
buccal cytobrush samples (Z = -4.11, p < 0.01).  
Figure 4.4 shows the summary of the difference in DNA purity based on 
A260nm/A280nm ratio between mouthwash, saliva and buccal cytobrush samples. 
Table 4.4 summarise the median, mean, SD and range of DNA purity obtained.  
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Figure 4.4 Comparison of median of DNA purity between mouthwash, saliva 
and buccal cytobrush samples using Method 2 
 
Table 4.4  Comparison of median, mean, SD and range of DNA purity obtained 
from mouthwash, saliva and buccal cytobrush samples extracted 
using Method 2
a
 
Purity  
Samples  
Mouthwash Saliva Buccal cytobrush 
Median  1.75
**
 1.70 1.68 
Mean  1.74 1.65 1.62 
SD 0.14 0.20 0.17 
Range  1.38 – 1.90  1.29 – 2.00 1.30 – 1.86 
a 
Wilcoxon signed-rank test 
 
**
 significantly higher compared with saliva and buccal cytobrush samples        
(p < 0.01) 
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4.1.3 Comparison of concentration of purified DNA extracted using 
Methods 1 and 2 
The comparison of DNA concentrations between Methods 1 and 2 was 
performed using Wilcoxon signed-rank test. The comparison indicates that Method 
2 was able to extract significantly higher concentration of DNA from saliva 
samples, with Z = -3.80 (p < 0.01).  
The difference in mouthwash DNA concentration between the methods was not 
significant (Z = -1.506, p = 0.132).  
However, the median concentration of purified DNA from buccal cytobrush was 
significantly reduced when the samples were extracted using Method 2 compared 
with Method 1 (Z = -2.00, p < 0.05).  
Figure 4.5 summarise the comparison in median purified DNA concentration 
obtained from mouthwash, saliva and buccal cytobrush samples when extracted 
using Method 1 and 2.  
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Figure 4.5 Comparison of median purified DNA concentrations between 
extraction Methods 1 and 2 for mouthwash, saliva and buccal 
cytobrush samples  
* p < 0.05 and ** p < 0.01 when compared between methods by 
Wilcoxon signed-rank test 
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4.1.4 Comparison of purity of purified DNA extracted using Methods 1 and 
2 
With regards to DNA purity, Method 2 was able to produce DNA with a higher 
median A260nm/A280nm ratio for all sampling procedures.  
Using Method 2, significant increase in DNA purity was observed in mouthwash 
(Z = -2.52, p < 0.05) and saliva samples (Z = 4.11, p < 0.01).  
However, no significant difference was observed in buccal cytobrush DNA 
samples purity (Z = -1.38, p = 0. 17).  
Figure 4.6 presents the comparison in median of DNA purity between the two 
extraction methods for mouthwash, saliva and buccal cytobrush samplings.  
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Figure 4.6 Comparison of median DNA purity between extraction Methods 1 
and 2 for mouthwash, saliva and buccal cytobrush samples  
* p < 0.05 and ** p < 0.01 when compared between methods by 
Wilcoxon signed-rank test 
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4.2 Amplification of purified DNA for molecular analysis of                      
β-thalassaemia  
The results for molecular analysis utilising purified non-invasive DNA from 
mouthwash, saliva and buccal cytobrush samples are presented as the percentage of 
successful DNA amplifications using the different molecular techniques – 
Amplification Refractory Mutation System (ARMS), Combine-ARMS, gap-PCR 
and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP).   
4.2.1 Amplification of purified DNA from archived and non-invasive 
samples using Amplification Refractory Mutation System (ARMS)  
Forty-nine purified DNA samples from each mouthwash, saliva and buccal 
cytobrush sample collection were analysed using ARMS. Using Method 1, 
successful DNA amplification was obtained in 55% of mouthwash samples, 65% of 
saliva samples and 81% of buccal cytobrush samples.  
Using Method 2, the successful DNA amplification was increased to 87% for 
mouthwash samples, 83% for saliva samples and 86% for buccal cytobrush 
samples. The results show that Method 2 produced purified DNA that produced 
more successful amplifications compared with Method 1. Archived DNA produced 
100% successful amplifications for ARMS.  
Results for archived DNA amplification using ARMS are shown in Figure 4.7, 
4.8 and 4.9. Results for mouthwash, saliva and buccal cytobrush DNA amplification 
using ARMS for the β-globin gene mutation at CD26 are shown in Figure 4.10.  
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Figure 4.7 shows the archived DNA amplified for β-globin gene mutations 
common in the Malays (lanes 2-9). Lane 1 is the internal control amplified as an 
861 bp band in DNA from a normal individual by using common primers A and B. 
The 861 bp internal control band can be observed in all the lanes 1-9 which contain 
amplified DNA from archived samples of heterozygous β-thalassaemia carriers.  
Using ARMS, the DNA with β-globin gene mutation at CAP+1 was amplified as 
a 596 bp band (lane 2), CD15 as a 500 bp band (lane 3), CD19 as a 488 bp band 
(lane 4), CD26 as a 458 bp band (lane 5), Poly A as a 393 bp band (lane 6), IVS1-5 
as a 285 bp band (lane 7), IVS1-1 as a 281 bp band (lane 8) and CD8/9 as a 215 bp 
band (lane 9)  
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Lane M: 100 bp molecular weight marker  
Lane 1: Common A and B internal control, 861 bp  
Lane 2: CAP+1, 596 bp  
Lane 3: CD15, 500 bp  
Lane 4: CD19, 488 bp  
Lane 5: CD26, 458 bp  
Lane 6: PolyA, 393 bp  
Lane 7: IVS1-5, 285 bp  
Lane 8: IVS1-1, 281 bp  
Lane 9: CD8/9, 215 bp  
 
 
 
 
 
Figure 4.7 Gel electrophoresis after ARMS amplification for confirmation of  
β-globin gene mutations common in the Malays 
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Figure 4.8 shows the archived DNA amplified for β-globin gene mutations 
common in the Chinese (lanes 2-7, 9 and 10). Lane 1 is the internal control 
amplified as an 861 bp band in DNA from a normal individual by using common 
primers A and B. The 861 bp internal control band can be observed in all the lanes 
3-7, 9 and 10 which contain amplified DNA from archived DNA samples of 
heterozygous β-thalassaemia carriers.  
Using ARMS, the β-globin gene mutation for IVS2-654 was amplified as a     
830 bp band (lane 2), -29 as a 625 bp band (lane 3), -28 as a 624 bp band (lane 4), 
Initiation codon as a 545 bp band (lane 5), CD43 as a 448 bp band (lane 6), 
CD41/42 as a 439 bp band (lane 7), CD17 as a 240 bp band (lane 9) and CD71/72 
as a 234 bp band (lane 10).  
In lane 8, DNA from a normal individual was amplified using common primers 
E and F producing a 323 bp internal control band. Since the DNA of β-thalassaemia 
carriers with the β-globin gene mutation at IVS2-654 amplified an 830 bp band, the 
common primers A and B which produce the 861 bp internal control was not used 
for this mutation due to the small difference in size of amplified products. Thus, the 
internal control for IVS2-654 mutation was amplified in a separate reaction using 
common primers E and F.  
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Lane M: 100 bp molecular weight marker  
Lane 1: Common primers A and B internal control, 861 bp  
Lane 2: IVS2-654, 830 bp  
Lane 3: -29, 625 bp  
Lane 4: -28, 624 bp  
Lane 5: Initiation Codon, 545 bp  
Lane 6: CD43, 448 bp  
Lane 7: CD41/42, 439 bp  
Lane 8: Common primers E and F internal control, 323 bp  
Lane 9: CD17, 240 bp  
Lane 10: CD71/72, 234 bp 
 
 
 
 
 
Figure 4.8 Gel electrophoresis after ARMS amplification for confirmation of   
β-globin gene mutations common in the Chinese 
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Homozygosity for β-thalassaemia mutations (IVS2-654, -28, CD41/42 and 
IVS1-5) in 7 patients was confirmed by amplification of the normal β-globin gene 
sequences. For example, using ARMS, a patient who is homozygous for the    
IVS2-654 mutation will not amplify the normal IVS2-654 gene sequence. DNA 
from normal individuals or compound heterozygous β-thalassaemia major 
individuals will amplify the normal gene sequence, producing an 830 bp amplified 
product band using a normal primer.  
Figure 4.9 shows the ARMS products after DNA amplification using normal 
primers for normal sequences at IVS2-654, -28, CD41/42 and IVS1-5. Lane 1 is the 
common A and B internal control amplified as 861 bp band in DNA from a                  
β-thalassaemia major individual who is homozygous for CD41/42/CD41/42. The 
861 bp internal control band can be observed in lanes 3-5. The 861 bp internal 
control was not used for amplification of normal gene sequence for IVS2-654 due 
to small difference in amplified product size.  
Using ARMS, normal gene sequence for IVS2-654 was amplified as a 830 bp 
band (lane 2), normal gene sequence for -28 was amplified as 624 bp band (lane 3), 
normal gene sequence for CD41/42 was amplified as 443 bp band (lane 4) and 
normal gene sequence for IVS1-5 was amplified as 285 bp band (lane 5). 
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Lane M: 100 bp molecular weight marker 
Lane 1: Common primers A and B internal control, 861 bp  
Lane 2: IVS2-654 normal sequence, 830 bp  
Lane 3: -28 normal sequence, 624 bp  
Lane 4: CD41/42 normal sequence, 443 bp  
Lane 5: IVS1-5 normal sequence, 285 bp  
 
 
 
 
 
 
  
Figure 4.9 Gel electrophoresis after ARMS amplification for the normal gene 
sequences for detection of homozygous patients 
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Figure 4.10 shows DNA amplification for ARMS for detection of the β-globin 
gene mutation at CD26. Lane 1 is the non-template control where DNA was not 
included in the reaction mixture. Lane 2 is the negative control which amplified the 
861 bp internal control band using the DNA from a normal individual. Lane 3 
contains the amplified product of a positive control which is a β-thalassaemia 
carrier with a β-globin gene mutation at CD26.  
Lanes 4-6 show amplification of purified DNA extracted using Method 1 while 
lanes 7-9 are amplified products of DNA extracted using Method 2. DNA from both 
methods was well amplified, but the intensity of the 458 bp CD26 band is slightly 
more distinct with DNA extracted using Method 2.  
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The β-globin gene mutation amplified is CD26  
Lane M: 100 bp molecular weight marker 
Lane 1: DNA blank  
Lane 2: Negative control; amplification of 861 bp product using 
DNA from a normal individual  
Lane 3: Positive control for CD26; amplification of the 861 bp and 
458 bp products   
Lanes 4-6: DNA extracted using Method 1 from mouthwash, saliva 
and buccal cytobrush samples; amplification of 861 bp and 458 bp 
products 
Lanes 7-9: DNA extracted using Method 2 from mouthwash, saliva 
and buccal cytobrush samples; amplification of 861 bp and 458 bp 
products   
 
 
Figure 4.10 Comparison of ARMS amplification products from DNA extracted 
from mouthwash, saliva and buccal cytobrush samples using both 
Methods 1 and 2  
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4.2.2 Molecular analysis using Combine-ARMS for CD41/42/CD17  
Thirteen samples from β-thalassaemia major patients confirmed to carry 
mutations at CD41/42 or CD17 or compound heterozygous for CD41/42/CD17 
were analysed using Combine-ARMS (C-ARMS).  
The C-ARMS specifically detects both β-globin gene mutations at CD41/42 and 
CD17 in a single reaction. Using Method 1, successful DNA amplification was 
obtained in 77% of mouthwash samples, 85% of saliva samples and 77% of buccal 
cytobrush samples. The same results were also obtained from mouthwash and saliva 
samples extracted using Method 2. Purified DNA from all buccal cytobrush 
samples extracted using Method 2 were successfully amplified.  
Figure 4.11 shows the amplified products from C-ARMS for CD41/42/CD17. 
Lane 1 is the non-template control where DNA was not included in the reaction. 
Lane 2 is the negative control where DNA of a normal individual was added into 
the reaction mixture. The DNA only amplified the 861 bp internal control band.  
Three positive controls were utilised in the reaction. In lane 3, amplified product 
of DNA from an individual with the β-globin gene mutation at CD41/42 amplified 
both the 861 bp internal control band and the 439 bp band. Lane 4 is positive 
control for β-globin gene mutation at CD17 which amplified both the 861 bp 
internal control band and the 240 bp band. In lane 5, the positive control for 
compound heterozygous CD41/42/CD17 amplified the 861 bp internal control 
band, 439 bp band for CD41/42 and 240 bp band for CD17.  
Lanes 6-8 show amplification of purified DNA extracted using Method 1 while 
lanes 9-11 are amplified product of DNA extracted using Method 2. All samples 
were successfully amplified.  
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Lane M: 100 bp molecular weight marker 
Lane 1: DNA blank   
Lane 2: Negative control; amplification of 861 bp product of DNA 
from a normal individual 
Lane 3: Positive control for CD41/42; amplification of 861 bp and 
439 bp products 
Lane 4: Positive control for CD17; amplification of 861 bp and    
240 bp products  
Lane 5: Positive control for compound heterozygous CD41/42/CD17 
individual; amplification of 861 bp, 439 bp and 240 bp products  
Lanes 6-8: DNA extracted from compound heterozygous using 
Method 1 from mouthwash, saliva and buccal cytobrush samples  
Lanes 9-11: DNA extracted from compound heterozygous individual 
using Method 2 from mouthwash, saliva and buccal cytobrush 
samples  
 
Figure 4.11 Amplification products of C-ARMS for CD41/42/CD17 for a 
Chinese patient using DNA samples extracted with Method 1 and 
Method 2 
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4.2.3 Characterisation of β-thalassaemia using gap-PCR  
4.2.3.1 Detection of the Filipino β-deletion  
Purified DNA from mouthwash, saliva and buccal cytobrush samples from one 
patient previously confirmed with the Filipino β-deletion was used in the gap-PCR 
along with negative, positive heterozygous and positive homozygous controls. The 
β-thalassaemia major patient was previously confirmed with the Filipino β-deletion 
and CD26 using DNA extracted from blood sample. The results of gel 
electrophoresis performed on the amplified samples are presented in Figure 4.12.  
Lane 1 is the DNA blank which will show no DNA amplification. Lane 2 is the 
DNA from a normal individual (negative control) which will only amplify the     
482 bp normal sequence. Lane 3 is the heterozygous positive control from a 
Filipino β-deletion carrier. This sample amplified both the 482 bp normal and     
376 bp deletion-specific sequences. Lane 4 shows the amplified product of a 
homozygous individual which amplified only the 376 bp deletion-specific 
sequence. The purified DNA from mouthwash, saliva and buccal cytobrush samples 
are shown in lanes 5 - 10.  
Purified patient DNA from mouthwash and buccal cytobrush samples isolated 
using both extraction methods amplified both the 482 bp normal and 376 bp 
deletion-specific sequence at the same product band intensity, as observed in lanes 
5, 7, 8 and 10.  
However, DNA from saliva extracted using both methods (lane 6 and 9) did not 
amplify the specified products. Smearing can be observed in lane 6 (saliva sample 
extracted with Method 1), suggesting that DNA is present in the sample, but the 
DNA may have been sheared during processing.  
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Lane M: 100 bp molecular weight marker 
Lane 1: DNA blank  
Lane 2: Negative control; 482 bp normal band (DNA from a normal 
individual)  
Lane 3: Heterozygous positive control; 482 bp and 376 bp bands 
(DNA from a 118 kb Filipino β-deletion carrier)  
Lane 4: Homozygous positive control; 376 bp deletion-specific band 
(DNA from a homozygous patient with the Filipino β-deletion) 
Lanes 5-7: DNA extracted using Method 1 from mouthwash, saliva 
and buccal cytobrush samples   
Lanes 8-10: DNA extracted using Method 2 from mouthwash, saliva 
and buccal cytobrush samples   
 
 
 
 
Figure 4.12 Gel electrophoresis after gap-PCR amplification for the detection of 
the Filipino β-deletion  
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4.2.3.2 Detection of the 100 kb Gγ(Aγδβ)0-deletion  
Purified DNA from one β-thalassaemia major patient previously characterised 
with CD41/42/
Gγ(Aγδβ)0-deletion was used in the gap-PCR. Gap-PCR was 
performed with negative (normal individual) and heterozygous positive controls. 
Results for the gap-PCR are shown in Figure 4.13.  
Lane 1 is the DNA blank. Lane 2 contains DNA from a normal individual which 
amplified only the 682 bp normal sequence. Lane 3 is DNA from a heterozygous 
individual (positive control) which amplified the 682 bp normal and 508 bp 
deletion-specific sequence. Lanes 4 - 9 are amplified products of purified DNA 
from mouthwash, saliva and buccal cytobrush samples.  
Amplification was successful for all samples except for the buccal cytobrush 
sample extracted using Method 1 (lane 6). Inadequate amount of DNA in the 
sample or reduced DNA purity may be the possible causes of the amplification 
failure. Amplification of DNA from mouthwash extracted with Method 1 (Lane 4) 
produced bands with better intensity when compared with the mouthwash sample 
extracted with Method 2 (lane 7).  
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Lane M: 100 bp molecular weight marker 
Lane 1: DNA blank  
Lane 2: Negative control; 682 bp band from DNA from normal 
individual  
Lane 3: Heterozygous positive control; 682 bp and 508 bp bands 
from DNA from 100 kb 
Gγ(Aγδβ)0-deletion carrier  
Lanes 4-6: PCR products from DNA extracted using Method 1 from 
mouthwash, saliva and buccal cytobrush samples; 682 bp and 508 bp 
bands  
Lanes 7-9: PCR products from DNA extracted using Method 2 from 
mouthwash, saliva and buccal cytobrush samples; 682 bp and 508 bp 
bands  
 
 
 
 
Figure 4.13 Gel electrophoresis of PCR products after gap-PCR amplification for 
the detection of the 100 kb 
Gγ(Aγδβ)0-deletion 
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4.2.3.3 Detection of Hb Lepore  
One β-thalassaemia major patient was previously confirmed with homozygous 
Hb Lepore. Purified DNA from mouthwash, saliva and buccal cytobrush samples 
was used for gap-PCR to detect Hb Lepore.  
As shown in Figure 4.14, lane 1 is the DNA blank. Lane 2 is the negative control 
using DNA from a normal individual which only amplify the 915 bp normal band. 
Lane 3 is the homozygous positive control using DNA from individual with 
homozygous Hb Lepore. This control only amplifies the 775 bp deletion-specific 
sequence. Lanes 4 – 9 are the amplification products of DNA from mouthwash, 
saliva and buccal cytobrush extracted using Methods 1 and 2.  
Purified DNA extracted with Method 1 from mouthwash and saliva samples 
(lanes 4 and 5) did not show any amplification. Only DNA from buccal cytobrush 
extracted with the same method amplified the targeted DNA sequence as observed 
in lane 6. On the other hand, all purified DNA extracted with Method 2 (lanes 7 – 9) 
amplified the 775 bp sequence, confirming that DNA extracted from mouthwash, 
saliva and buccal cytobrush can be used for molecular studies.  
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Lane M: 1000 bp molecular weight marker 
Lane M2: 100 bp molecular weight marker 
Lane 1: DNA blank  
Lane 2: Negative control; 915 bp band using DNA from normal 
individual  
Lane 3: Positive control; 775 bp deletion-specific band using DNA 
from homozygous Hb Lepore individual  
Lane 4-6: DNA extracted using Method 1 from mouthwash, saliva 
and buccal cytobrush samples; 775 bp deletion-specific band  
Lane 7-9: DNA extracted using Method 2 from mouthwash, saliva 
and buccal cytobrush samples; 775 bp deletion-specific band  
 
 
 
 
Figure 4.14 Gel electrophoresis of PCR products after gap-PCR for detection of 
Hb Lepore  
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4.2.4 Detection of mutation at CD27/28 using PCR-RFLP 
Purified DNA from one patient with compound heterozygosity for 
CD41/42/CD27/28 was analysed using PCR-RFLP to detect the β-globin gene 
mutation at CD27/28. Gel electrophoresis after treatment of amplification products 
with restriction endonuclease NlaIV is shown in Figure 4.15.  
Lane 1 is the DNA blank with no added DNA template. Lane 2 shows the 
products after restriction endonuclease treatment in DNA from a normal individual. 
The 284 bp amplified band is not digested as the restriction site is not present in 
normal individuals. Lane 3 shows the digestion products of positive control DNA 
from a heterozygous individual who carries the β-globin gene mutation at CD27/28. 
Restriction enzyme digestion produced the 170 bp and 114 bp digested fragments.  
Lanes 4 – 6 show restriction endonuclease digestion of amplified DNA from 
mouthwash, saliva and buccal cytobrush samples extracted using Method 1. Lanes  
7 – 9 show restriction endonuclease digestion of amplified DNA from mouthwash, 
saliva and buccal cytobrush using Method 2. All samples showed the 170 bp and 
114 bp digested products. The undigested 284 bp band was also present after 
restriction enzyme digestion as the patient was compound heterozygous for 
CD41/42/CD27/28.  
DNA from buccal cytobrush extracted with Method 2 (lane 9) produced a less 
distinct 284 bp undigested band and fainter 170 bp and 114 bp digested bands 
compared with the sample extracted with Method 1. This might be due to the lower 
DNA concentration of the sample extracted using Method 2.  
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Lane M: 100 bp molecular weight marker 
Lane 1: DNA blank   
Lane 2: Negative control; DNA from a normal individual (284 bp 
band) Lane 3: Positive control; DNA from an individual who is 
heterozygous for CD27/28 (284 bp, 170 bp and 114 bp bands) 
Lane 4-6: DNA extracted from mouthwash, saliva and buccal 
cytobrush samples of a compound heterozygous patient for 
CD41/42/CD27/28 using Method 1 (284 bp, 170 bp and 114 bp 
bands) 
Lane 7-9: DNA extracted from mouthwash, saliva and buccal 
cytobrush samples of a compound heterozygous patient for 
CD41/42/CD27/28 using Method 2 (284 bp, 170 bp and 114 bp 
bands)  
 
 
 
Figure 4.15 Gel electrophoresis after treatment of amplified DNA with 
restriction endonuclease NlaIV 
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4.3 Statistical analysis of salivary biochemical parameters  
Assessment by Shapiro-Wilk test indicated that the data for all biochemical 
parameters were not normally distributed. Thus, the non-parametric statistical 
analyses were performed on the data to determine the significance of difference 
between groups.  
Biochemical analysis results were expressed in median. Significance in 
difference were evaluated by Mann-Whitney U test. The difference is considered as 
statistically significant if the p value is less than 0.05 and highly significant if          
p value is less than 0.01.  
Correlation analysis was carried out using Spearman’s rank order correlation and 
presented as Spearman’s rho (rs). Comparison of parameters according to 
demographic data of β-thalassaemia major patients was performed using      
Kruskal-Wallis H test followed by Mann-Whitney U test as post-hoc test.  
4.3.1 Measurement of salivary oxidative stress indices and cytokine levels   
When expressed in median, the LOOH, GPx, UA and IL-6 levels were higher in 
the β-thalassaemia major patients group. On the other hand, FRAP value, AOPP 
and TNF-α levels were higher in the healthy controls group.  
From Mann-Whitney test performed, only GPx activity was observed to be 
significantly increased in the β-thalassaemia major patients group (U = 781.50,              
p < 0.01). The activity was increased by 35% in the patients group compared with 
the healthy controls.  
Table 4.5 summarises the median level of oxidative stress indices and cytokine 
levels analysed in the saliva samples. 
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Table 4.5 Comparison of median of oxidative stress indices and cytokine levels 
between β-thalassaemia major patients and healthy controlsa 
Parameters Unit 
Median 
Beta-thalassaemia 
major patients 
Healthy controls 
FRAP  μM 184.76 197.50 
AOPP  μM 71.51 76.67 
LOOH  μM 0.26 0.19 
GPx  nmol/min/mL 11.72
**
 8.66 
UA nmol/mL 97.26 82.72 
TNF-α pg/mL 7.13 7.98 
IL-6 pg/mL 18.24 13.89 
 
a
 Mann-Whitney U test   
**
 p < 0.01 when compared with healthy controls  group  
 
 
 
 
 
 
 
 
127 
4.3.2 Correlation analysis between salivary oxidative stress indices and 
cytokines in patient samples  
Five significant correlations were observed after correlation analysis was 
performed on the oxidative stress indices and cytokine levels in β-thalassaemia 
major patients group.  
Salivary AOPP shows moderate and highly significant correlation with FRAP 
value (rs(63) = 0.43, p < 0.01). On the other hand, UA show strong and highly 
significant correlation with FRAP value (rs(63) = 0.72, p < 0.01). No other 
significant correlation was obtained between FRAP value and other biochemical 
parameters.  
Weak positive and statistically significant correlation was observed between 
salivary AOPP level and UA level (rs(63) = 0.25, p < 0.05).  
For salivary LOOH, a weak negative and significant correlation was observed 
between LOOH and IL-6 (rs(63) = -0.25, p < 0.05).  
Another weak negative and statistically significant correlation was observed 
between UA and TNF-α which was statistically significant (rs(63) = -0.25,              
p < 0.05).  
Table 4.6 summarises the correlation between the salivary oxidative stress 
indices and salivary cytokines observed in this study.  
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Table 4.6 Spearman’s rho (rs) value for correlation analysis between salivary 
oxidative stress indices and cytokines in β-thalassaemia patients 
group
a
 
Parameters  FRAP AOPP LOOH GPx UA TNF-α 
AOPP 0.43
**
      
LOOH 0.17 -0.05     
GPx 0.14 0.19 0.13    
UA 0.72
**
 0.25
*
 0.19 0.14   
TNF-α -0.19 0.09 -0.21 -0.17 -0.25
*
  
IL-6 0.06 0.22 -0.25
*
 0.01 0.10 0.13 
 
a
 Spearman’s rank order correlation  
*
 Correlation is significant at the 0.05 level (2-tailed) by Spearman’s rank order 
correlation  
**
 Correlation is significant at the 0.01 level (2-tailed) by Spearman’s rank order 
correlation  
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4.3.3 Comparison of salivary oxidative stress indices and cytokine level 
according to demographic data of β-thalassaemia major patients  
No significant differences were observed in the oxidative stress indices and 
cytokine levels between the two genders in the β-thalassaemia major patients group.  
Significant difference was observed in AOPP level depending on the genetic 
classification of β-thalassaemia, χ2(2) = 6.38, p < 0.05 with mean ranks of 46.67 for                 
β+-thalassaemia homozygotes, 29.21 for β+/β0-compound heterozygotes and 34.47 
for β0-thalassaemia homozygotes.  
Mann-Whitney U test was performed and confirmed that the AOPP level in                   
β+-thalassaemia homozygotes patients was significantly higher than                  
β+/β0-compound heterozygotes patients (U = 90.00, p < 0.05) and β0-thalassaemia 
homozygotes patients (U = 39.00, p < 0.05) 
TNF-α level was significantly different between the age groups, χ2(2) = 7.74,     
p < 0.05 with mean ranks of 34.88 for patients below 10-years, 36.54 for patients 
between 11 – 20-years and 18.64 for patients aged between 21 – 30-years.  
Mann-Whitney U test performed confirmed that the TNF-α levels were 
significantly lower in patients aged between 21 – 30-years compared with patients 
below 10-years (U = 52.00, p < 0.05). The level of TNF-α in patients aged between       
21 – 30-years was also significantly lower than patients aged between 11 – 20-years 
(U = 87.00, p < 0.01).  
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Statistically significant difference in TNF-α level was observed depending on the 
ethnic group of β-thalassaemia major patients, χ2(2) = 6.27, p < 0.05 with mean 
ranks of 28.08 for Malay ethnicity, 37.98 for Chinese ethnicity and 43.31 for Other 
ethnicity.   
From the Mann-Whitney U test, the TNF-α level in β-thalassaemia major 
patients from Malay ethnicity is significantly higher from β-thalassaemia major 
patients from Other ethnicity (U = 81.50, p < 0.05). 
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CHAPTER 5: DISCUSSIONS 
5.1 Selection of methods and materials in sample collection  
Mouthwash, saliva and buccal cytobrush were successfully collected from         
β-thalassaemia major patients.  
5.1.1 Normal saline as mouthwash solution  
The present study used normal saline as the mouthwash solution as this allows 
the participation of younger toddlers. Normal saline is the most suitable mouthwash 
solution as it is simple and non-toxic, thus safe for the use in toddlers and young 
children (Lum & Marchand, 1998).   
Young children are not advised to use commercialised mouthwash. Alcohol 
poisoning by ingestion in children is more common in mouthwash compared with 
other solutions with higher alcohol content (Riordan et al., 2002). Although small 
amount of alcohol ingestion may not be fatal for children, it may result in severe 
intoxication due to their low body weight (Shulman & Wells, 1997).  
The restriction also applies to alcohol free mouthwash. Phenolic compounds 
present in the mouthwash may intoxicate a person if ingested in large amount (Hoo 
et al., 2003). Previous observation by Kolahi et al. (2006) also reported that 
ingestion of antimicrobial agents such as chlorhexidine in large quantity may 
produce inflammation (Cole et al., 2013). As reported by Whitford (1992), over 
consumption of sodium fluoride present in mouthwash solutions may also cause 
severe problems such as muscular cramps and cardiac arrest (Ozsvath, 2009).  
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In addition, commercialised mouthwash solution containing alcohol produces 
burning sensation in the oral cavity and may produce unpleasant taste (Garcia-
Closas et al., 2001; Mulot et al., 2005). Thus, additional rinsing is needed. 
Published report states that brushing teeth prior to sample collection reduce the 
amount of cells collected (Feigelson et al., 2001). Additional rinsing may also 
reduce the number of cells collected on the subsequent sample collection method.  
Previous reports by other investigators used other solutions such as sterile water 
and sucrose as mouthwash solution in place of commercialised mouthwash solution 
(Aidar & Line, 2007; Mulot et al., 2005). Commercialised mouthwash solution is 
only used for collection of buccal cells for participants with age above 20 years-old 
(Garcia-Closas et al., 2001; King et al., 2002; Lum & Marchand, 1998).  
Trials on mouthwash samples were tried out to prevent the co-purification of 
commercialised mouthwash dyes as it may disturb the DNA performance for 
molecular analysis (Heath et al., 2001). In the preliminary tests conducted prior to 
this study, mouthwash dye was observed in the extracted DNA solution without 
affecting the DNA amplification performance. However, the result may not be 
significant due to the small sample size. Hence, the use of commercialised 
mouthwash was not recommended for large scale studies.  
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5.1.2 Collection of saliva by direct expectoration   
The present study aims to obtain unstimulated saliva for molecular analysis and 
estimation of biochemical parameters. However, the presence of the salty taste from 
the mouthwash is considered as a stimulus for saliva flow. Thus, direct 
expectoration was selected as the means of sample collection to prevent additional 
stimulation of saliva flow as previous reports have observed a difference in analyte 
concentration due to induction of saliva flow (Dizgah & Hosseini, 2011; Moore et 
al., 2001; Sculley & Langley-Evans, 2002).  
The use of external materials such as chewing gum and cotton roll should be 
avoided to prevent buccal cell lost due to the attachment of the cells onto the 
materials. Other researchers also used direct expectoration as the initial method for 
collection of whole saliva samples before using additional materials such as 
antibiotic- or stabiliser-treated cards (Harty et al., 2000; Mulot et al., 2005). The 
extraction of chewing gum and cotton roll can be difficult during DNA extraction. 
Contaminant of the materials may be expected, thus affecting the concentration and 
purity of the sample. In addition, the amount of salivary fluid collected cannot be 
properly determined before the materials are extracted.  
5.1.3 Direct buccal cell collection with buccal cytobrush  
The use of sterile buccal cytobrush or cotton swabs was seen as the most 
economical method to collect buccal epithelial cells compared with the mouthwash 
sampling method (Cheng et al., 2010; Cozier et al., 2004; King et al., 2002). The 
method is easily performed and involves minimal amount of liquid, thus making it 
preferable for mailing.  
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The use of cytobrush was preferred over cotton swabs or other forms of swabs in 
the present study as it allowed maximising the amount of buccal cells during 
collection and reduced cost. When compared with swabs, brushes appear to be less 
dense and the collected cells will not be retained in the bristles. The use of other 
swabs such as foam swabs can be costly and may require more collection units to 
achieve a good DNA yield (Rogers et al., 2007).  
The suspension of cells in normal saline solution enabled the same cytobrush to 
be used again for second and third collection attempts for the same patient. Previous 
published investigations have reported that more than one collection is needed to 
obtain sufficient DNA using buccal cytobrush or swabs (Cozier et al., 2004; Rogers 
et al., 2007). In addition, previous investigation showed that delayed DNA 
extraction and keeping the swabs air-dried will reduce the amount of DNA 
recovered from the samples (Meulenbelt et al., 1995).  
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5.2 Concentration and purity of purified DNA from non-invasive samples  
High concentration and purity DNA samples were successfully extracted from 
mouthwash, saliva and buccal cytobrush samples collected from β-thalassaemia 
major patients.  
5.2.1 Comparison of the purified DNA concentration and purity between 
sampling and extraction methods  
Other published investigations mainly use DNA yield in their reports. Thus, 
direct comparison between the results of present study and published reports could 
not be performed. However, there was a similar trend that was observed in all 
reported investigations, which is the comparison in DNA yield and purity between 
sampling methods used by the investigators. Thus, this basis was used in the present 
study to determine which sampling method could provide extracted DNA with the 
most optimum quantity and quality.  
5.2.1.1 Mouthwash samples  
Comparison between Methods 1 and 2 showed no notable differences in 
concentration of DNA extracted from mouthwash samples. The DNA purity was 
slightly increased using Method 2 compared with Method 1.  
When compared between sampling procedures, mouthwash sample provided 
second highest concentration of DNA. In aspect of purity, highest DNA purity was 
obtained from mouthwash samples.  
The same observation has been reported where DNA yield and purity was 
compared between saliva and buccal swab samples and DNA from mouthwash was 
the second highest in amount and highest in purity (Rogers et al., 2007). In 
addition, the purity varied greatly between DNA from mouthwash and buccal swab 
samples (1.78 vs 1.10, respectively).  
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Other investigations also obtained higher DNA yield and purity from mouthwash 
samples ranging from 4.0 – 88.4 µg of DNA compared with buccal swab samples 
which was 3.5 – 15.8 µg (Garcia-Closas et al., 2001; King et al., 2002; Mulot et al., 
2005).  
5.2.1.2 Saliva samples  
In the present study, saliva samples DNA concentration was almost 2-times 
greater than mouthwash DNA and almost 3-times greater then buccal cytobrush 
DNA when extracted with Method 1. The concentration was improved using 
Method 2, where the concentration was more than 4-times of mouthwash DNA and 
more than 8-times of buccal cytobrush DNA.  
In return, the purity was compromised compared with mouthwash samples. 
Using Method 1, similar median purity was obtained from both mouthwash and 
saliva samples. The DNA purity was improved using Method 2. In both occasions, 
the purity values were higher than buccal cytobrush. 
There are limited investigations on direct comparison in DNA yield and purity 
involving saliva samples and other non-invasive samples. A report by a group of 
investigators shows that the similar pattern of DNA amount and purity was obtained 
in their investigation (Rogers et al., 2007). DNA yield of saliva samples obtained 
which was 154.9 µg was almost 3-fold higher compared with mouthwash samples 
(54.7 µg). When compared with buccal swab samples DNA yield (12.7 µg), the 
saliva samples produced 12-times more DNA.  
In aspects of purity, the purity of DNA from mouthwash and saliva from Rogers 
and team investigation did not differ greatly (1.78 vs 1.74, respectively). However, 
as observed in the present study, saliva samples DNA purity managed to surpass 
DNA purity of buccal swab samples.  
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5.2.1.3 Buccal cytobrush samples  
Buccal cytobrush samples provided the lowest concentration of DNA compared 
with other procedures. Median concentration of buccal cytobrush samples were 
slightly reduced when extracted with Method 2. The buccal cytobrush DNA purity 
was the lowest among the three sampling method – mouthwash, saliva and buccal 
cytobrush. In addition, the purity did not differ much when extracted using   
Method 2.  
Previous reports have also observed that buccal swabs could only provide small 
amount of DNA ranging from 3.5 – 15.8 µg (Garcia-Closas et al., 2001; King et al., 
2002; Mulot et al., 2005; Rogers et al., 2007). In all instances, buccal swab DNA 
yields were lower than mouthwash DNA yield. In addition and in accordance to the 
present study finding, the means of DNA purity from published reports were 
slightly lower by 0.1 than mouthwash DNA. There was one situation where the 
purity was on par with mouthwash samples DNA purity (Garcia-Closas et al., 
2001). In two other instances, the means of buccal swab DNA purity were 1.15 and 
1.10, which was lower than the means of saliva samples DNA purity, which were 
1.63 and 1.74, respectively (Hansen et al., 2007; Rogers et al., 2007).  
Observation from previous published works support that saliva sample may 
produce highest amount of DNA, followed by mouthwash and buccal cytobrush 
samples. When observed in the aspects of purity, mouthwash samples provide DNA 
with highest purity, followed by saliva and buccal cytobrush samples.  
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5.2.2 Factors affecting the quantity of the purified DNA 
A number of factors may have affected the concentration of DNA extracted from 
non-invasive samples. The factors are not specific to one type of sampling 
procedure, but present in all the samples at different level.  
5.2.2.1 Preparations and actions performed during sample collection  
The presence of microorganism – normal oral cavity flora – can reduce the 
amount of extracted DNA (Saftlas et al., 2004). Microbial metabolism can degrade 
nucleic acids, thus reducing the nucleic acid quantity. The degree of degradation 
depends on the storage conditions such as temperature and the presence of 
stabilising agents in the storage solution (Aidar & Line, 2007; Hansen et al., 2007; 
Ng et al., 2006). The use of mouthwash solutions or addition of buffers containing 
ethanol and storage at low temperatures can inhibit bacterial growth and reduce 
nucleic acid degradation.  
In this study, additional rinsing prior to sample collection was performed to 
reduce the bacteria load in the samples. However, this step may reduce the number 
of buccal cells (Feigelson et al., 2001). But prior rinsing was still performed to 
remove as much contaminants as possible including food debris. To further reduce 
nucleic acid degradation, all samples were stored directly in -20°C after collection 
until DNA extraction was performed. Published reports also confirmed that samples 
in normal saline are stable for up to 6 months when stored in -20°C (Lum & 
Marchand, 1998).  
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The amount of brush strokes and timing can also contribute to the DNA yield 
(King et al., 2002; London et al., 2001; Mulot et al., 2005). Although the brushing 
time was fixed in this study, the amount of strokes performed by the participants 
differs and thus may result in different quantities of buccal cells obtained. 
Increasing the number of brushes used or brush strokes will improve the purified 
DNA yield as reported by Cozier et al. (2004). Thus, in this study the sampling 
procedure for buccal cytobrush collection was repeated three times to increase the 
quantity of epithelial cells recovered.  
Motions in the oral cavity and cheek rubbing may also increased the number of 
exfoliating cells during the mouthwash sample collection (Aidar & Line, 2007). 
However, Shao et al. (2007) reported that cheek rubbing against the teeth prior to 
swishing of mouthwash solution did not produce any increase in DNA yield. Thus, 
cheek rubbing may not provide much different in the DNA quantity in this study.  
5.2.2.2 Surface area and level of desquamation of the sampling site  
When comparison was made between sampling procedures, the involvement of a 
larger surface area during mouthwash collection may contribute to the increased 
amount of buccal cells collected during the procedure.  
Swishing of mouthwash solution involves contact with the palate and tongue, 
including the gutter area, which is located between the gums and lips. The buccal 
cells collected from the gutter area can provide a 2-fold higher amount of purified 
DNA compared wtih rinsing only on the cheek area alone (Saftlas et al., 2004). 
Thus, the involvement of gutter area during mouth rinsing can increase the DNA 
concentration.  
Collection of saliva samples involves drooling which drives the fluid in contact 
with the tongue, part of cheek including the gutter area. Thus, the cells from gutter 
area were also collected indirectly in the saliva samples.  
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5.2.2.3 Sequence in sample collection procedures 
In this study, the sampling procedures were carried out consecutively, beginning 
with mouthwash, saliva to buccal cytobrush sampling. As a result, the numbers of 
cells suitable for DNA extraction may have reduced after each procedure. Two 
situations was observed previously by other researchers. Decrease of DNA yield 
was observed when immediate repeat sampling was carried out on the same area 
where previous sampling was performed (Burger et al., 2005). However, other 
investigators did not observed any decrease in recovered DNA after repeat sampling 
was performed on the same cheek (Meulenbelt et al., 1995).  
The results of this study finding were consistent with that of Burger et al. (2005). 
Buccal cytobrush sampling was the last to be performed after mouthwash and saliva 
sampling. The number of collectable epithelial cells may have been reduced by the 
time buccal cytobrush sampling was carried out. Even though the procedure was 
performed three times to achieve a better yield of purified DNA, the probable 
reduced number of epithelial cells has resulted in lower DNA concentrations.  
5.2.2.4 Presence of leukocytes 
Leukocytes are present in the salivary fluid and previous reports have confirmed 
the presence of leukocytes in whole saliva (Kaufman & Lamster, 2000; Kumar et 
al., 2014; Pandeshwar & Das, 2014; Schiott & Loe, 1970). The cells migrate from 
the blood circulation through the gingival crevices between the teeth into the 
salivary fluid. This may be the main factor to the high yield of purified DNA in 
saliva samples. Collection of whole salivary fluid directly collects the leukocytes 
present between the teeth during the fluid pooling process.  
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The function of salivary fluid is to maintain the moisture of the oral mucosa. 
Therefore, leukocytes can also be present on the surface of the oral cavity. As the 
mouthwash solution was in contact with the oral mucosa, leukocytes can be 
collected during swishing. In addition, salivary fluid was observed to be 
incorporated into the samples when the mouthwash solution was expectorated out 
by the participants. Thus, leukocytes from saliva can be introduced into the 
mouthwash sample. This factor may have increased the amount of purified DNA 
recovered after the extraction procedure.  
Leukocytes are also present in the buccal cytobrush samples as the brush is in 
contact with the oral mucosa. Trace amounts of salivary fluid will also be collected 
during the brushing procedure. However, buccal cytobrush sampling only relies on 
a limited surface area. The amount of leukocytes collected will be lower than the 
mouthwash samples. The salivary fluid collected on the brush bristles is also lower 
in amount. As a result, the additional cellular components do not provide much 
difference in increasing the DNA concentration in buccal cytobrush samples.  
5.2.2.5 Sample and reagent components  
Mucin is rich with cysteine and readily forms disulphide bonds which thicken 
the substance (Villar, 2007). The presence of mucin may hinder the action of lysis 
buffer and proteinase K during the process of DNA extraction. To overcome the 
problem, buffer containing EDTA was added prior to storage and EDTA was also 
incorporated into the lysis buffer (Aidar & Line, 2007). EDTA chelates calcium 
ions which prevent interchain links between the cysteine molecules (Villar, 2007).  
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The chelationg action of EDTA also aids in DNA preservation which prevents 
exonuclease activity in the sample (Cowan, 1998). This may also be a factor of 
increased amount of DNA in saliva samples compared with the mouthwash and 
buccal cytobrush samples, since the samples were stored in buffer containing 
EDTA.  
DTT have been used as mucolytic agent to liquefy sputum samples prior to the 
analysis (Hammerschlag et al., 1980; Loppow et al., 2000; Tockman et al., 1995). 
DTT reduce the disulfide bonds and maintained the sulphide groups in reduced state 
(Cleland, 1963). This results in reduction of mucin thickness. The addition of DTT 
in Method 2 during the extraction process may have enhanced the dilution of mucin 
and improved the action of lysis buffer and proteinase K (Dimitrakakis et al., 2010).  
5.2.2.6 Repetitive sample transfer  
When compared with saliva and buccal cytobrush samples, extraction of DNA 
from mouthwash samples involves transferring the mouthwash samples into fresh 
tubes. Although the initial containers were rinsed thoroughly during the transferring 
process, there are possibilities that the buccal cells collected were strongly adhered 
to the inner surface of the container. This may result in the reduction of the number 
of cells available for the extraction process. However, this may not be the major 
factor, since the DNA yield for mouthwash samples were significantly higher when 
compared with buccal cytobrush for both methods.  
5.2.2.7 Standardisation of solubilising medium volume 
When comparisons were made between extraction methods, the increase in DNA 
concentration in Method 2 may be due to the standardisation of the amount of 
sterile deionised water used during DNA solubilisation.  
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Compared with Method 2 where all DNA was solubilised in 200 µL of sterile 
deionised water, the amount of water used to solubilise the DNA in Method 1 was 
based on visual observation of the amount of precipitated DNA. Visual error may 
have occurred during observation which resulted overestimation of precipitated 
DNA. In the end, more sterile deionised water was added into for solubilisation and 
the DNA samples become diluted. This may have affected the average 
concentration of the purified DNA.  
5.2.2.8 Overestimation by spectrophotometry  
Despite the high yield of DNA from mouthwash and saliva samples, 
measurement by spectrophotometry at 260 nm may have overestimated the actual 
DNA yield. Spectrophotometry is not able to distinguish between human DNA and 
microbial DNA (Moore et al., 2001; Mulot et al., 2005). Thus, the final DNA 
concentration may encompass the two DNA.  
Measurement of DNA by using fluorochrome such as PicoGreen may also 
produce more accurate results for DNA amplifications (Rylander-Rudqvist et al., 
2006). PicoGreen specifically binds to double stranded DNA. The actual quantity of 
double stranded DNA usable for downstream application can thus be more 
accurately determined. However, since bacterial DNA is also double stranded DNA, 
PicoGreen is not able to discriminate the non-human DNA present in the sample. It 
was suggested that better quantification can be achieved by using specific probes to 
hybridise human DNA in collected samples (Feigelson et al., 2001). Nevertheless, 
hybridisation using specific probes can be expensive and labour intensive (Garcia-
Closas et al., 2001).  
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5.2.3 Factors affecting the quality of purified DNA  
5.2.3.1 Mucin content in samples  
In aspects of purity, the presence of glycoprotein such as of mucin may have 
reduced the DNA purity (Navazesh et al., 1992; Sanchez et al., 2011). Since the 
mucin content is higher in saliva, the purity of salivary DNA was reduced when 
compared with mouthwash DNA samples. Although the number of purification 
cycles was increased in Method 2, there was no enhancement in DNA purity.  
5.2.3.2 External factors  
Buccal cytobrush samples are the least contaminated with saliva. Hence, it 
should be expected that buccal cytobrush samples will have higher DNA purity 
when compared with the other sampling methods. In contrast, the results showed 
that the extracted DNA with the lowest purity was obtained from buccal cytobrush, 
which is in agreement with published data (Garcia-Closas et al., 2001; Hansen et 
al., 2007; King et al., 2002; Mulot et al., 2005; Rogers et al., 2007).  
Food debris present in the oral cavity include carbohydrates and protein. These 
substances will be digested and solubilised into the solution during extraction 
process. Unlike hydrophobic proteins which are readily removed by organic 
purification process, the hydrophilic proteins, polysaccharides, aromatic substances, 
buffer salt and even trace amount of phenol can be co-purified and present in the 
purified DNA (Hansen et al., 2007; Moreira, 1998; Philibert et al., 2008).  
Improper rinsing prior to sample collection can result in improper removal of 
food debris. Although mouthwash and saliva sample collections were performed 
earlier than buccal cytobrush sampling, the collection of smaller sized food debris is 
more likely to happen during cheek brushing. Compared with larger sized debris, 
small sized food debris can appear similar to cell collected after centrifugation.  
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5.2.4 Factors affecting the variation of purified DNA concentration and 
purity  
5.2.4.1 Improper procedure execution  
Improper mouth rinsing prior to sample collection by some participants may 
have affected the efficacy of the mouthwash to remove food debris. Large food 
particle prior to extraction process were removed but small particles may remain as 
they cannot be distinguished from the buccal cell pellet. These particles may have 
been digested and incorporated into the DNA solution, thus lowering the DNA 
purity.  
It was also observed in this study that improper brushing during buccal 
cytobrush process may have increased the amount of contaminants. A number of 
participants were observed to have their cytobrush in contact with their teeth more 
than with their cheeks especially in the younger participants. More food particles 
and microorganisms were collected compared with the buccal cells.  
5.2.4.2 Desquamation level of epithelial cells  
The variation in purified DNA yield may be due to differences in buccal cell 
desquamation levels between individuals (King et al., 2002; Zayats et al., 2009). 
Epithelial cells in certain individuals may detach more easily than others. Even 
though the force and amount of time used to swab or rub the cheeks are almost 
identical, the amount of cells collected may be substantially different. As a result, 
the final purified DNA yield may vary.  
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5.2.4.3 Intensity of actions during sample collection  
Instead of relying on cheek rubbing prior to mouthwash sample collection, 
rubbing while swishing may increase the amount of purified DNA in mouthwash 
samples (Shao et al., 2007). The force of rubbing and swishing may be different 
between individuals, and this factor may affect the final amount of purified DNA. 
The force of rubbing may also affect the amount of purified DNA collected from 
buccal cytobrush (Meulenbelt et al., 1995; Mulot et al., 2005; Nedel et al., 2009).  
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5.3 Molecular analysis of DNA extracted from non-invasive samples 
Purified DNA from non-invasive samples mouthwash, saliva and buccal 
cytobrush were successfully amplified using various methods for molecular analysis 
for β-thalassaemia.  
The successful amplification of extracted DNA samples in this study using 
ARMS increased when the samples were extracted using Method 2. DNA 
amplification of purified DNA from mouthwash samples increased from 55% 
(Method 1) to 87% (Method 2), while saliva samples amplification increased from 
65% to 83% and buccal cytobrush samples amplification increased from 81% to 
86%.  
In previous experiments, failures of DNA amplification and genotyping were 
mainly due to the degradation of the DNA samples which was confirmed by gel 
electrophoresis. High amount of high molecular weight DNA was detected in 
mouthwash compared with buccal cytobrush samples. This contributes to the ability 
of buccal cytobrush DNA to amplify large-sized sequence (Cheng et al., 2010; 
Garcia-Closas et al., 2001; Rogers et al., 2007). The targeted sequences in the 
present study are small and DNA amplification was observed in the three           
non-invasive samples.   
Failure in the DNA amplifications without degradation may be due to the 
presence of PCR inhibitors in the samples (Burger et al., 2005; Zayats et al., 2009). 
Inhibitors such as salts co-purified during purification process may not be 
detectable using spectrophotometry at 260 nm and 280 nm. Trace amount of salts 
and EDTA may still be present in the samples and affected the sample ability to 
amplify in PCR. This could be the main factor to the amplification failures 
occurred.  
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Other than the presence of contaminants, successful amplification could be 
affected by the amount purified DNA template used in the PCR preparation 
(Altshuler, 2006). The excessive amount of DNA sequence not targeted by the 
primer may lead to false priming and halt the DNA amplification process.  
For purified DNA obtained from Method 1, the DNA concentration in the saliva 
samples was higher compared with mouthwash samples. Thus, lower volume of 
saliva DNA sample was used in the reaction preparation. DNA template and the 
contaminant were readily diluted for the final mixture. False priming and reaction 
disturbance by contaminant were reduced.  
DNA extraction and purification using Method 2 have improved the DNA 
concentrations and purity for both mouthwash and saliva samples. As the DNA 
concentration and purity for both samples was improved, low volume of solubilised 
DNA was required for reaction preparation. Better DNA and contaminant dilution 
in reaction preparation was achieved for both sampling procedures. This was 
observed in the increase of amplification success percentage for both mouthwash 
(from 55% to 87%) and saliva samples (from 65% to 83%).  
On the other hand, the actual DNA concentration used from buccal cytobrush 
samples could be too low from the beginning for both Methods 1 and 2. Thus, 
inhibition of PCR by non-targetted DNA template was not prominent although the 
volume of solubilised DNA added into the reaction mixture was higher compared 
with saliva and mouthwash samples.  
The DNA concentration was reduced when buccal cytobrush samples were 
extracted with Method 2. This may reduce the amplification success due to 
excessive reduction of DNA template. However, the increase in DNA purity may 
have contributed in maintaining the successful DNA amplification percentage (81% 
for Method 1 compared with 86% for Method 2).  
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5.4 Cost comparison between DNA extraction methods  
DNA extraction cost comparison was made between Method 2 DNA extraction 
procedure and 4 other DNA extraction kits readily available in Malaysia. Table 5.1 
presents the cost comparison of one preparation of DNA extraction.  
 
Table 5.1 Cost comparison between Method 2 and DNA extraction kits readily 
available in Malaysia (per preparation) 
DNA extraction protocol 
Cost per preparation 
(RM) 
Method 2 11.00 
Brand E 9.20 
Brand Q 13.00 
Brand T 15.60 
Brand O 100.00 
 
Method 2 costs RM 11.00, which is the second lowest after Brand E              
(RM 9.20/preparation). The other brands cost more for one preparation, up to      
RM 100.00/preparation. Although Method 2 cost more compared with Brand E, 
Method 2 can be used for DNA extraction of samples collected from mouthwash, 
saliva and buccal cytobrush.  
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Even though the amount of sample fluid used in commercialised DNA extraction 
kits is usually small in volume, the entire cells collected may be resuspended in the 
buffer provided in the kit. However, the amount of lysis reagents may not be able to 
lyse and digest the cells properly. This will later cause clogging in the spin column 
in the later process during the extraction procedures as observed in the preliminary 
testing. Thus, it will be necessary for the sample to be separated into a number of 
aliquots prior to extraction process. This needs more than one preparation for a 
single sample for extraction. Thus, even though the cost of Brand E per preparation 
may be lower than Method 2 in this study, more than one preparation was required 
for DNA extraction.  
Other preliminary tests were carried out using preparations from Brand Q on 
aliquots of mouthwash, saliva and buccal cytobrush samples. The DNA samples 
collected were smaller in amount compared with Method 2. During quantification 
process, the measurement could not be obtained suggesting that the amount of DNA 
present in the sample was too low. Thus, extracted DNA quantity and quality could 
not be determined. More preparations may be needed to achieve the desirable 
amount of DNA from one sample.  
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5.5 Measurement of oxidative stress indices and cytokines in saliva 
samples  
Oxidative stress markers and cytokine levels were successfully measured using 
saliva samples from β-thalassaemia major patients and healthy controls. 
Concentrations of analyte of interest were within detectable limit.  
5.5.1 Comparison of parameters between β-thalassaemia major patients 
and healthy controls 
As presented in the previous chapter, when analysis was performed by 
considering the data distribution, increase in GPx activity was still observed in the 
patients group.  
The enzyme GPx is one of the enzymatic antioxidant present in blood circulation 
other than catalase and superoxide dismutase (Ghone et al., 2008; Sclafani et al., 
2013). The enzyme prevents erythrocytes breakdown caused by hydroxyl radicals. 
The hydroxyl radicals abstract hydrogen atom from polyunsaturated lipid molecules 
and form LOOH (Gutteridge, 1995). The example of polyunsaturated lipid 
molecules includes the phospholipid layer of the cell membrane. The increase in 
median GPx activity suggests the increase in enzymatic antioxidant activity to 
inactivate the presence of free radicals.  
Earlier published investigation on patients with renal failure has reported that the 
GPx activity could readily affects the level of AOPP and TNF-α in the patient 
system. Reduction in GPx activity could cause the increase in protein oxidation in 
patients (Witko-Sarsat et al., 1998).  
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The level of GPx activity is affected by the level of reduced glutathione (GSH). 
Depletion in GSH commonly occurred in patients with iron-overload such as 
transfusion dependent thalassaemia major patients. Due to the decrease in 
enzymatic antioxidant activity, non-enzymatic antioxidant activity may play a more 
significant role to reduce oxidative stress (Kuppusamy & Tan, 2011).  
FRAP assay measures the total non-enzymatic antioxidant activity involving 
electron transfer between sample and the reagent (Muller et al., 2011; Witko-Sarsat 
et al., 1998). In the present study, the non-enzymatic antioxidant activity did not 
differ much between β-thalassaemia major patients and healthy controls. This 
suggests that in the patients, the free radicals that may be inactivated by             
non-enzymatic antioxidant were not significantly different from the healthy 
controls. Nevertheless, the presence of oxidants such as H2O2 and lipid 
hydroperoxide may drive the enzymatic antioxidant, GPx.  
5.5.2 Correlation between biochemical parameters in patients  
As presented in the Result section, there was a strong positive correlation 
between patients salivary FRAP and UA level. Although UA is usually associated 
with oxidative damage, it could also exhibit antioxidant role (Soukup et al., 2012). 
As reported by Benzie & Strain (1996), UA is one of the non-enzymatic antioxidant 
which could react readily with the FRAP reagent. Thus, it was expected that the 
increase in salivary UA level will give a strong effect on the salivary FRAP value.  
Using non-parametric analysis, there was a weak positive correlation between 
salivary UA and AOPP level and moderate correlation between salivary FRAP and 
AOPP level. The increase in AOPP was reported to be associated with the increase 
in monocyte activation and inflammation (Witko-Sarsat et al., 1998). The increase 
in monocyte activation could also lead to cellular damage and increased amount of 
purines and UA due to purine metabolism.  
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As UA also exhibit antioxidant properties, the increase in UA may have helped 
in decelerating the speed of protein oxidation. Furthermore, urate, which is the 
physiological form of UA have been reported to have the ability to prevent protein 
nitration (Ames et al., 1981).  
Reported investigations show that excess plasma UA is able to induce 
inflammatory cytokines including TNF-α in medical conditions (di Giovine et al., 
1991 ; Zhou et al., 2012). However, the observation in the present study using both 
parametric and non-parametric analysis shows that the increase in salivary UA 
provide minimal contribution in reducing salivary TNF-α production. As the rate of 
protein oxidation may have been decreased by UA, the pro-inflammatory cytokine 
production can be reduced to prevent more cellular damage.  
According to various reports, increase in lipid peroxidation may activate the 
cascade of IL-6 secretion (Davì et al., 2003; Evereklioglu et al., 2002). In contrast, 
the non-parametric statistical analysis in the present study shows that reduction of 
LOOH provided a weak induction to increase the IL-6 secretion. IL-6 is also 
reported to exhibit anti-inflammatory properties, by preventing further destruction 
of epithelial cells (Scheller et al., 2011). This is possibly due to the IL-6 ability to 
induce cells to enter mitosis (Kishimoto, 2003). The reduction of cellular damage 
which was indicated by decreased in LOOH level may have triggered IL-6 to 
induce cell proliferation, especially for erythrocytes.  
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5.5.3 Comparison of parameters between demographic data of                    
β-thalassaemia major patients  
There are notable difference in TNF-α level between Other ethnicity and Malay 
ethnicity where the median level was higher in the Malay ethnicity compared with 
Other ethnicity.  
There is a possibility that the level of oxidative stress indices differ depending on 
the ethnicity as presented by other investigation (Fisher et al., 2012; Kuppusamy et 
al., 2005). In the report by Fisher et al. (2012), the level of oxidative stress indices 
can be affected by difference in muscle mitochondrial function and also food intake. 
In comparison with this study, there can be minor differences in the food intake 
preferences between the ethnicity in Malaysia. This may indirectly affect the level 
of antioxidants especially in patients.  
However, the number of samples may have played a major role in the 
observation. The number of samples for Other ethnicity was lower compared to 
Malay ethnicity (8 vs 37). Any irregularities may results in contradictory findings, 
since both parametric and non-parametric statistical analysis are sensitive to large 
difference in sample size (Moran & Solomon, 2002).  
When analysed according to age groups, the level of TNF-α was also higher in 
the patients below 20-years old. As observed in this study, all but 1 patient by this 
age have started chelation therapy. However, the total duration of therapy for these 
patients was not as long as the older patients. The extent of iron removal may not be 
as adequate as the patients from the older age group.  
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There are also possibilities that a number of these patients might not be 
compliant to the treatment. Poor compliance to chelation treatment will not remove 
the accumulated iron adequately and cause complications in patients (Galanello et 
al., 2010). Due to inadequate removal of excess iron, redox imbalance still occurs in 
the patients leading to increase in oxidative stress markers.  
As presented in Chapter 2, β0-thalassaemia homozygotes have zero production of           
β-globin chain, which totally nullifies HbA production. In comparison, with         
β0-thalassaemia homozygotes, β+/β0 compound heterozygotes and β+ homozygotes 
have different level of β-globin chain production (Telen & Kaufman, 1999). Thus, 
β0-thalassaemia homozygotes have higher amount of free α-globin chain which can 
precipitate and disrupt the erythrocyte membrane integrity and was expected to 
have higher oxidative stress indices levels.  
However, in the present study, AOPP level were higher in β+-thalassaemia 
homozygotes compared with β+/β0 compound heterozygotes and β0 homozygotes. 
Perhaps this is because AOPP is considered as more sensitive oxidative stress 
marker especially when compared with lipid peroxidation markers such as LOOH 
(Kuppusamy & Tan, 2011; Witko-Sarsat et al., 1998).  
Other than that, external factors which are not assessed such as co-inheritance of 
α-globin gene mutations may have ameliorate the oxidative stress severity by 
reducing the free α-globin chains production (Camaschella et al., 1995; Nadkarni et 
al., 2001). Polymorphism such as XmnI could also reduce the severity of the 
condition by promoting the production of γ-globin chains which bind with free      
α-globin chains in place of β-globin and reducing the α-globin chain toxicity 
(Chinelato et al., 2011; Thein, 2004).  
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5.5.4 Factors affecting the analytes concentration  
5.5.4.1 Dilution of analytes in saliva  
The oxidative stress markers and cytokines measured in saliva originated from 
gingival crevicular fluid (GCF) and tissue metabolites. Other than GCF, the fluid 
component of the whole saliva was made of fluids from salivary glands and nasal 
and bronchial secretions (Kaufman & Lamster, 2000; Sculley & Langley-Evans, 
2002). Due to this factor, it was expected that the concentration of analytes 
measured in saliva samples were lower compared with the analyte levels reported in 
other studies using plasma samples (Kuppusamy & Tan, 2011; Morabito et al., 
2007).  
5.5.4.2 Combination of chelating agent and compliance towards chelation 
therapy 
A study on oxidative stress in β-thalassaemia major patients attending monthly 
blood transfusion in UMMC has been reported (Kuppusamy & Tan, 2011). The 
study showed that despite undergoing iron chelation therapy, iron overload was still 
observed in the patients. Plasma oxidative stress indices of chelated and unchelated 
β-thalassaemia major patients measured in the study were compared with healthy 
controls. The results showed that chelated patients were also under oxidative stress 
and their oxidative stress markers were significantly elevated compared with 
healthy controls.  
However, the chelated β-thalassaemia major patients recruited in the study were 
on single iron chelation therapy using deferoxamine (DFO). Compared with the 
published report, during β-thalassaemia major patient recruitment for the present 
study, 23% of the patients had undergone combination iron chelation treatment. The 
treatment involved combination of DFO and deferiprone (DFP), DFO and 
deferasirox (DFX) or DFP and DFX.  
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Published data has reported better rate of iron secretion from the patients’ 
circulation due to combination of targeted iron pool by different iron chelators. The 
patient under combination therapy managed to discontinue hormone therapy after 
improvement of endocrine glands and have better cardiac function (Galanello et al., 
2010). In addition, recent clinical observation has reported that DFX alone may 
reduce oxidative stress in transfusion dependent patients (Saigo et al., 2013 ). These 
factors could be the contributors to the improvement of the oxidative stress status in 
β-thalassaemia major patients.  
Although the patients below 20-years old appeared to have higher level of 
inflammatory cytokines, the overall oxidative stress status may suggest that the 
compliance towards chelation therapy is improving as the patients grow older. In 
addition, the knowledge about the importance of chelation therapy in patients and 
support from responsible bodies in encouraging proper treatment for patients could 
have improved.  
5.5.4.3 Supplementary prescription   
Compared to healthy controls, almost 50% of the β-thalassaemia major patients 
were prescribed with additional supplementary vitamins including vitamins C, D 
and E other than iron chelators. As described by Benzie & Strain (1996), ascorbic 
acid and α-tocopherol could react effectively with FRAP assay reagent. It is 
possible that additional supplement may have boosted up their antioxidant level up 
to a level almost similar to healthy controls and reduced or attenuated oxidative 
stress indices levels and cytokine production in their system.  
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5.5.4.4 Involuntary stimulation  
Mouth rinsing with normal saline prior to sample collection may stimulate whole 
saliva flow the same way as citric acid due to the taste (Sculley & Langley-Evans, 
2002). Participants were reminded about minimising chewing and tongue 
movement to prevent additional stimulation. Even though participants were allowed 
to drink, this was only to prevent them from expectorating forced thick saliva due to 
dehydrated mouth. However, it was still possible that the participants performed 
such actions during the sample collection resulting in excessive stimulation of 
salivary fluid flow.  
Reports have confirmed that stimulated saliva samples have reduced amount of 
analyte due to increased secretion of salivary gland fluid (Miller et al., 2010). This 
factor further diluted the analyte of interest in the whole saliva. This could be 
further corrected by taking saliva flow rate into consideration (Moore et al., 2001; 
Sculley & Langley-Evans, 2002).  
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5.6 Limitations  
Malaysia has a multi-ethnic population with many different languages. 
Differences in language proficiency, especially in understanding the terminology 
used with paediatric patients may play a major role in differences in sample 
collection. Although laymen terms were used during recruitment of participants, the 
extent of understanding the terms explained may have lead to variations in sample 
collection.  
Non-invasive samples are painless and simple to collect. However, public 
perception towards samples originating from expectorates such as saliva are 
unavoidable. Participants tend to feel uneasy when handling the samples, probably 
due to unpleasant odour and appearances. This factor also resulted in rejection 
towards requests to participate in the research which limited the number of samples 
collected.  
Physiological factors may reduce and alter the appearance and the amount of 
sample collected. Dryness of mouth due to reduced water consumption can 
contribute to increased viscosity of saliva samples. Participants tend to refuse to 
drink although they were allowed to do so during sample collection. Increase in 
sample viscosity may limit the usable amount of sample and increase the amount of 
contaminants. In addition, the sample will be hard to handle especially during 
separation of the salivary fluid during sample processing and increase the amount of 
mucin in the sample.  
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Better precision in analyte measurement could be achieved if saliva flow rate 
was considered during sample collection. However, the procedure could be time 
consuming especially in achieving the desired amount of sample to accommodate 
the analysis requirements. In addition, strict observation may be required during 
sample collection to obtain the precise time to determine the saliva flow rate. 
Throughout the investigation, direct observation on the participants made them tend 
to force the saliva flow. This resulted in thick and mucinous saliva which was hard 
to be aliquoted during sample processing.  
Similar to collection of samples for molecular analysis, bacterial contamination 
may result in degradation of oxidative stress indices and the cytokines. Despite of 
the attempt to remove oral cavity flora by initial rinsing and freezing, there may still 
be possibility that trace amounts of bacteria present in the sample. The bacteria 
metabolic activities may affect the level of biochemical parameters in the samples.  
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5.7 Future recommendations 
Further improvement for DNA extraction and purification can be performed to 
increase successful amplification. DNA extraction using other materials such as 
agarose gel may reduce the amount of inhibitors present in the sample for better 
DNA amplification (Moreira, 1998). On the other hand, the use of a protein 
precipitation method may reduce the need to use organic solvent for non-invasive 
DNA sample purification (Heath et al., 2001). With better DNA extraction and 
purification methods, isolation of DNA from samples such as urine can be included 
as an option for non-invasive DNA samples.  
DNA from non-invasive samples can be further quantified using other methods 
to determine the human DNA yield and purity. This includes the use of 
fluorochromes, hybridisation technique and measurement at A230nm (Feigelson et 
al., 2001; Hansen et al., 2007; Philibert et al., 2008; Rylander-Rudqvist et al., 
2006). These methods have been reported to provide better results for DNA 
quantification. 
Biomarkers concentration in saliva samples is easily affected by participant’s 
actions during sample collection. For future studies, better procedures in whole 
saliva sample collection are required. Written sample collection procedures can be 
used for participant’s reference to prevent any confusion and variation in sample 
collection.  
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Saliva flow rate can be estimated to provide better information on analyte 
concentration (Moore et al., 2001; Sculley & Langley-Evans, 2002). Sample 
collection procedures can be modified to include determination of saliva volume 
collected within a specified time. Perhaps this way more samples could be collected 
without the risk of diluting the analyte concentrations due to over stimulating the 
saliva. Samples can also be used to analyse more antioxidants and oxidative stress 
markers.  
Other non-invasive sample such as urine can also be used for measurement of 
oxidative stress markers (Kirschbaum, 2001; Schwemmer et al., 2000). Although 
some of the oxidative stress indices and cytokines analysed in this study could not 
be analysed using urine samples, comparison and correlation between salivary and 
urinary FRAP, AOPP, LOOH and UA can be performed. In addition, other 
biomarkers like 8-iso-PGF2α, hepcidin and 8-hydroxydeoxyguanosine can be 
analysed using urine samples (Lin et al., 2015; Nemeth, 2010; Wu et al., 2004).  
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CHAPTER 6:  CONCLUSION 
In summary, mouthwash, saliva and buccal cytobrush samples can provide 
reasonable amounts of DNA with acceptable purity. The sample collection 
procedures are convenient and easy to perform by researchers and participants. The 
DNA extraction and purification procedures using Method 2 provided purified 
amplifiable DNA. The purified DNA is sufficient in amounts and can be used for 
molecular characterisation of β-globin gene mutations in β-thalassaemia major 
patients with reproducible results. Mouthwash and saliva samples may serve as the 
most suitable sampling procedures to be used to obtain high quantity and quality 
non-invasive DNA for molecular characterisation of disorders like thalasseamia.  
Saliva can also be used in biochemical analysis to estimate the levels of 
oxidative stress in β-thalassaemia major patients. The oxidative stress indices and 
cytokine levels in the saliva samples were detectable and can be measured using   
in-house methods and commercialised assay kits. However, only selected oxidative 
stress indices and cytokines are sensitive and readily detected in saliva samples.  
Through the current study, the oxidative stress status in the β-thalassaemia major 
patients has improved. This observation is mainly due to better compliance towards 
treatment regimes, combination iron chelation therapies, education, additional 
supplementation and better patient management.  
  
164 
REFERENCE 
Abdul Wahab, J., Naznin, M., Nora, M. Z., Suzanah, A. R., Zulaiha, M., Aidil 
Faszrul, A. R., & Kamaruzaman, W. S. (2011). Thalassaemia: A study on 
the perception of patients and family members. Med J Malaysia, 6(4), 326-
334.  
Aidar, M., & Line, S. R. P. (2007). A simple and cost-effective protocol for DNA 
isolation from buccal epithelial cells. Braz Dent J 18(2), 148-152.  
Al-Rawi, N. H. (2011). Oxidative stress, antioxidant status and lipid profile in the 
saliva of type 2 diabetics. Diab Vasc Dis Res, 8(1), 22-28.  
Aldave, A. J., Yellore, V. S., Self, C. A., Holsclaw, D., & Small, K. (2004). The 
usefulness of buccal swabs for mutation screening in patients with suspected 
corneal dystrophies. Ophthalmology 111, 1407-1409.  
Alfano, M. C. (1974). The origin of gingival fluid. J Theor Biol 47, 127-136.  
Altshuler, M. L. (2006). Pcr troubleshooting: The essential guide (pp. 80). United 
Kingdom: Caister Academic Press. 
Ames, B. N., Cathcart, R., Schwiers, E., & Hochstein, P. (1981). Uric acid provides 
an antioxidant defense in humans against oxidant- and radical-caused aging 
and cancer: A hypothesis. Proc Natl Acad Sci USA, 78(11), 6858-6862.  
Applegate, E. (2002). Tissues and membranes The anatomy and physiology 
learning system (2nd ed., pp. 59-74). USA: W.B. Saunders Company. 
Ash, A., Burnett, G. R., Parker, R., Ridout, M. J., Rigby, N. M., & Wilde, P. J. 
(2014). Structural characterisation of parotid and whole mouth salivary 
pellicles adsorbed onto dpi and qcmd hydroxyapatite sensors. Colloids Surf., 
B, 116, 603-611.  
Barr, W. G. (1990). Uric acid In H. K. Walker, W. D. Hall & J. W. Hurst (Eds.), 
Clinical methods: The history, physical, and laboratory examinations (3rd 
ed., pp. 770-772). Boston Butterworths  
Bates, I., & Bain, B. J. (2006). Approach to the diagnosis and classification of blood 
diseases. Dacie and lewis practical hematology (10th ed., pp. 609-624). 
Philadelphia: Churchill Livingstone Elsevier  
Bennet, L. C., Kraemer, R., & Liechti-Gallati, S. (2000). Buccal cell DNA analysis 
in premature and term neonates: Screening for the mutation of the complete 
coding region for the cystic fibrosis transmembrane conductance regulator 
Eur J Pediatr, 159, 99-102.  
165 
Benzie, I. F. F., & Strain, J. J. (1996). The ferric reducing ability of plasma (frap) as 
a measure of ‘‘antioxidant power’’: The frap assay. Anal Biochem 239, 70-
76.  
Berg, J. M., Tymoczko, J. L., & Stryer, L. (2002). Nucleotide biosynthesis 
Biochemistry (5th ed., pp. 693-712). New York: W. H. Freeman and 
Company. 
Berlett, B. S., & Stadtman, E. R. (1997). Protein oxidation in aging, disease and 
oxidative stress. J Biol Chem 272(33), 20313-20316.  
Besa, E. C., Catalano, P. M., Kant, J. A., & Jefferies, L. C. (1992). Hematology 
USA: Harwal Publishing. 
Beyaert, R., & Fiers, W. (1998). Tumor necrosis factor and lymphotoxin Cytokines 
(pp. 335-360): Academic Press Limited. 
Bibi, G., Green, Y., & Nagler, R. M. (2008 ). Compositional and oxidative analysis 
in the saliva and serum of predialysis chronic kidney disease patients and 
end-stage renal failure patients on peritoneal dialysis. Ther Apher Dial 
12(2), 164-170.  
Brill, N., & Krasse, B. (1958). The passage of tissue fluid into the clinically healthy 
gingival pocket. Acta Odontol Scand 16, 233-245.  
Bunn, F. H., & Forget, B. G. (1986). Hemoglobin: Molecular, genetic and clinical 
aspects. Philadelphia: WB Saunders Company  
Burger, M. F., Song, E. Y., & Schumm, J. W. (2005). Buccal DNA samples for 
DNA typing: New collection and processing methods. Biotechniques 39, 
257-261.  
Cadet, J., & Douki, T. (1999). Modification of DNA bases by photosensitized one-
electron oxidation. Int J Rad Biol 75(5), 571-581.  
Camaschella, C., Mazza, U., Roetto, A., Gottardi, E., Parziale, A., Travi, M., 
Fattore, S., Bacchiega, D., Fiorelli, G., & Cappellini, M. D. (1995). Genetic 
interaction in thalassemia intermedia: Analysis of  mutations,  genotype, 
 promoters and -lcr hypersensitive sites 2 and 4 in italian patients. Am J 
Hematol 48, 82–87.  
Cao, A., Galanello, R., & Origa, R. (2000 ). Beta-thalassemia. In R. A. Pagon, M. 
P. Adam, H. H. Ardinger, T. D. Bird, C. R. Dolan, C. T. Fong, R. J. H. 
Smith & K. Stephens (Eds.), GeneReviews® [Internet]. Seattle (WA) 
University of Washington, Seattle. Retrieved from 
http://www.ncbi.nlm.nih.gov/books/NBK1426/ (1993-2015).  
166 
Cao, A., & Kan, Y. W. (2012). The prevention of thalassemia. Cold Spring Harb 
Perspect Med 3, a011775.  
Chen, L. T., & Weiss, L. (1973). The role of the sinus wall in the passage of 
erythrocytes through the spleen Blood, 41(4), 529-537.  
Chen, Q., Lu, P., Jones, A. V., Cross, N. C. P., Silver, R. T., & Wang, Y. L. (2007). 
Amplification refractory mutation system, a highly sensitive and simple 
polymerase chain reaction assay, for the detection of jak2 v617f mutation in 
chronic myeloproliferative disorders. J Mol Diagn 9(2), 272-276.  
Cheng, T. H., Chen, S. P., Lu, T. C., Chen, W. C., Sher, J. S., & Shieh, Y. S. 
(2010). Optimal DNA extraction from buccal swab samples. J Med Sci 
30(4), 149-154.  
Chinelato, I. S., Carrocini, G. C. dS., & Bonini-Domingos, C. R. (2011). Xmni 
polymorphism frequency in heterozygote beta thalassemia subjects and its 
relation to fetal hemoglobin levels. Rev Bras Hematol Hemoter 33(6), 483.  
Clark, B. E., & Thein, S. L. (2005). Molecular diagnosis of haemoglobin disorders. 
Clin Lab Haem, 26, 159-176.  
Cleland, W. W. (1963). Dithiothreitol, a new protective reagent  for sh group. 
Biochemistry 3(4), 480-482.  
Cohen, A. R., Galanello, R., Piga, A., De Sanctis, V., & Tricta, F. (2003 ). Safety 
and effectiveness of long-term therapy with the oral iron chelator 
deferiprone. Blood 102, 1583-1587.  
Cohen, A.R. (2006). New advances in iron chelation therapy ASH Education 
Program Book (1), 42-47.  
Cole, M. R., Li, M., Jadeja, R., El-Zahab, B., Hayes, D., Hobden, J. A., Janes, M. 
E., & Warner, I. M. (2013). Minimizing human infection from escherichia 
coli o157:H7 using gumbos. J Antimicrob Chemother. doi: 
10.1093/jac/dkt010 
Cooke, M. S., Evans, M. D., Dizdaroglu, M., & Lunec, J. (2003). Oxidative DNA 
damage: Mechanisms, mutation, and disease. FASEB J 17, 1195-1214.  
Cooley, T. B., & Lee, P. (1925). A series of cases of splenomegaly in children with 
anemia and peculiar bone changes Trans Am Pediatr Soc 37, 29-30.  
Cowan, J. A. (1998). Metal activation of enzymes in nucleic acid biochemistry 
Chem Rev 98, 1067-1087  
167 
Cozier, Y. C., Palmer, J. R., & Rosenberg, L. (2004). Comparison of methods for 
collection of DNA samples by mail in the black women’s health study. Ann 
Epidemiol 14, 117-122.  
Dacie, J. V., & Lewis, S. M. (1994). Practical hematology (8th ed.): Churchill 
Livingstone  
Davì, G., Chiarelli, F., Santilli, F., Pomilio, M., Vigneri, S., Falco, A., Basili, S., 
Ciabattoni, G., & Patrono, C. (2003). Enhanced lipid peroxidation and 
platelet activation in the early phase of type 1 diabetes mellitus: Role of 
interleukin-6 and disease duration. Circulation, 107, 3199-3203.  
de Vries, T. W., Ajubi, N., Slomp, J., & Storm, H. (2006). Analyzing DNA from 
buccal cells is a reliable method for the exclusion of cystic fibrosis. Results 
of a pilot study. Genet Med 8(3), 175–177.  
Delima, A. J., & Van Dyke, T. E. (2003). Origin and function of the cellular 
components in the gingival crevice fluid. Periodontol 2000, 31, 55-76.  
di Giovine, F. S., Malawista, S. E., Thornton, E., & Duff, G. W. (1991 ). Urate 
crystals stimulate production of tumor necrosis factor alpha from human 
blood monocytes and synovial cells: Cytokine mrna and protein kinetics, 
and cellular distribution. J Clin Invest 87, 1375-1381.  
Dimitrakakis, C., Zava, D., Marinopoulos, S., Tsigginou, A., Antsaklis, A., & 
Glaser, R. (2010). Low salivary testosterone levels in patients with breast 
cancer. BMC Cancer, 10(1), 547.  
Dizgah, I. M., & Hosseini, F. A. (2011). Stimulated and unstimulated saliva 
progesterone in menopausal women with oral dryness feeling. Clin Oral 
Invest 15, 859–862.  
Eckes, E. J. (2011). Chelation therapy for iron overload: Nursing practice 
implications J Infus Nurs 34(6), 374-380.  
Eroschenko, V. P. (2008). Epithelial tissue Difiore's atlas of histology with 
functional correlation (11th ed., pp. 29): Lippincott Williams & Wilkins  
Esterbauer, H., & Cheeseman, K. H. (1990). Determination of aldehydic lipid 
peroxidation products: Malonaldehyde and 4-hydroxynonenal. Methods 
Enzymol, 186, 407-421.  
Evereklioglu, C., Er, H., Turkoz, Y., & Cekmen, M. (2002). Serum levels of tnf-  , 
sil-2r, il-6, and il-8 are increased and associated with elevated lipid 
peroxidation in patients with behçet’s disease. Mediat Inflamma, 11, 87-93.  
Feigelson, H. S., Rodriguez, C., Robertson, A. S., Jacobs, E. J., Calle, E. E., Reid, 
Y. A., & Thun, M. J. (2001). Determinants of DNA yield and quality from 
168 
buccal cell samples collected with mouthwash. Cancer Epidemiol 
Biomarkers Prev, 10, 1005-1008.  
Fisher, G., Man, C. D., Alvarez, J. A., Cobelli, C., Ellis, A. C., Granger, W. M., & 
Gower, B. A. (2012). Race differences in the association of oxidative stress 
with insulin sin african- and european-american women. Obesity 20, 972-
977.  
Forman, H. J., & Boveris, A. (1982). Superoxide radical and hydrogen peroxide in 
mitochondria. In W. A. Pryor (Ed.), Free radicals in biology (pp. 65-89). 
New York Academic Press Inc. 
Galanello, R., Agus, A., Campus, S., Danjou, F., Giardina, P. J., & Grady, R. W. 
(2010). Combined iron chelation therapy. Ann NY Acad Sci, 1202 79–86.  
Galanello, R., Melis, M. A., Ruggeri, R., Addis, M., Scalas, M. T., Maccioni, L., 
Furbetta, M., Angius, A., Tuveri, T., & Cao, A. (1979). Beta
0
 thalassemia 
trait in sardinia. Hemoglobin, 3, 33-46.  
Garcia-Closas, M., Egan, K. M., Abruzzo, J., Newcomb, P. A., Ernstoff, L. T., 
Franklin, T., Bender, P. K., Beck, J. C., Marchand, L. L., Lum, A., 
Alavanja, M., Hayes, R. B., Rutter, J., Buetow, K., Brinton, L. A., & 
Rothman, N. (2001). Collection of genomic DNA from adults in 
epidemiological studies by buccal cytobrush and mouthwash. Cancer 
Epidemiol Biomarkers Prev, 10 687–696.  
George, E. (2001). Beta-thalassemia major in malaysia, on-going public health 
problem Med J Malaysia, 56(4), 397-400.  
George, E., & Tan, J. A. M. A. (2010). Genotype-phenotype diversity of -
thalassemia in malaysia: Treatment options and emerging therapies. Med J 
Malaysia 65(4), 256-260.  
Ghone, R. A., Kumbar, K. M., Suryakar, A. N., Katkam, R. V., & Joshi, N. G. 
(2008). Oxidative stress and disturbance in antioxidant balance in b-
thalassemia major Indian J Clin Biochem, 23(4), 337-340.  
Girotti, A. W. (1998). Lipid hydroperoxide generation, turnover, and effector action 
in biological systems. J Lipid Res 39, 1529-1542.  
Griffiths, G. F. (2003). Formation, collection and significance of gingival crevice 
fluid. Periodontol 2000, 31, 32-42.  
Gutteridge, J. M. C. (1995). Lipid peroxidation and antioxidants as biomarkers of 
tissue damage. Clin Chem 41(12), 1819-1828.  
169 
Gutteridge, J. M. C., Paterson, S. K., Segal, A. W., & Halliwell, B. (1981). 
Inhibition of lipid peroxidation by the iron-binding protein lactoferrin. 
Biochem J, 199, 259-261.  
Haber, F., & Weiss, J. (1932). Über die katalyse des hydroperoxydes Naturwiss, 51, 
948-950.  
Halliwell, B., & Chirico, S. (1993). Lipid peroxidation: Its mechanism, 
measurement, and significance. Am J Clin Nutr, 57(5), 715S-724S.  
Halliwell, B., & Gutteridge, J. M. C. (1999). Free redicals in biology and medicine 
(3rd ed.): Oxford University Press  
Hammerschlag, M. R., Harding, L., Macone, A., Smith, A. L., & Goldmann, D. A. 
(1980). Bacteriology of sputum in cystic fibrosis: Evaluation of 
dithiothreitol as a mucolytic agent. J Clin Microbiol, 11(6), 552-557.  
Hammond, G. D., Ishikawa, A., & Keighley, G. (1962). Relationship between 
erythropoietin and severity of anemia in hypoplastic and hemolytic states 
Erythropoiesis (pp. 351). New York Grune & Stratton  
Hansen, T. V., Simonsen, M. K., Nielsen, F. C., & Hundrup, Y. A. (2007). 
Collection of blood, saliva, and buccal cell samples in a pilot study on the 
danish nurse cohort: Comparison of the response rate and quality of 
genomic DNA. Cancer Epidemiol Biomarkers Prev, 16, 2072-2076.  
Harty, L. C., Shields, P. G., Winn, D. M., Caporaso, N. E., & Hayes, R. B. (2000). 
Self-collection of oral epithelial cell DNA under instruction from 
epidemiologic interviewers. Am J Epidemiol 151(2), 199-205.  
Heath, E. M., Morken, N. W., Campbell, K. A., Tkach, D., Boyd, E. A., & Strom, 
D. A. (2001). Use of buccal cells collected in mouthwash as a source of 
DNA for clinical testing. Arch Pathol Lab Med, 125, 127-133.  
Hershko, C. (2010). Pathogenesis and management of iron toxicity in thalassemia. 
Ann NY Acad Sci, 1202, 1-9. doi: 10.1111/j.1749-6632.2010.05544.x 
Hershko, C., Abrahamov, A., Konijn, A. M., Breuer, W., Cabantchik, I. Z., 
Pootrakul, P., & Link, G. (2003). Objectives and methods of iron chelation 
therapy. Bioinorg Chem Appl, 1(2), 151-168.  
Hoffbrand, A. V., & Pettit, J. E. (2000). Essential haematology (3rd ed.). 
Massachusetts: Blackwell Science Inc. 
Hold, K. M., De Boer, D., Zuidema, J., & Maes, R. A. A. (1995). Saliva as 
analytical tool in toxicology Int J Drug Test, 1, 1-36.  
170 
Hoo, G. W. S, Hinds, R. L., Dinovo, E., & Renner, S. W. (2003). Fatal large-
volume mouthwash ingestion in an adult: A review and the possible role of 
phenolic compound toxicity J Intensive Care Med 18, 150-155.  
Jaykaran. (2010). How to select appropriate statistical test? J Pharm Negative 
Results, 1(2), 61-63.  
Johnson, R. J., Segal, M. S., Sautin, Y., Nakagawa, T., Feig, D. I., Kang, D. H., 
Gersch, M. S., Benner, S., & Sanchez-Lozada, L. G. (2007). Potential role 
of sugar (fructose) in the epidemic of hypertension, obesity and the 
metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. 
Am J Clin Nutr, 86, 899–906.  
Junqueira, L. C., & Carneiro, J. (2003). Epithelial tissue. In J. Foltin, H. Lebowitz 
& P. J. Boyle (Eds.), Basic histology: Text and atlas (10th ed., pp. 69-93). 
USA: McGraw-Hill Companies. 
Kashimura, M., & Fujita, T. (1987). A scanning electron microscope study of 
human spleen: Relationship between the microcirculation and functions 
Scanning Microsc 1, 841-851  
Kassab-Chekir, A., Laradi, S., Ferchichi, S., Khelil, A. H., Feki, M., Amri, F., 
Selmi, H., Bejaoui, M., & Miled, A. (2003). Oxidant, antioxidant status and 
metabolic data in patients with beta-thalassemia. Clin Chim Acta, 338(79-
86).  
Kaufman, E., & Lamster, I. B. (2000). Analysis of saliva for periodontal diagnosis. 
J Clin Periodontol 27, 453-465.  
King, I. B., Abouta, J. S., Thornquist, M. D., Bigler, J., Patterson, R. E., Kristal, A. 
R., Shattuck, A. L., Potter, J. D., & White, E. (2002). Buccal cell DNA 
yield, quality, and collection costs: Comparison of methods for large-scale 
studies. Cancer Epidemiol Biomarkers Prev, 11, 1130–1133.  
Kirschbaum, B. (2001). Total urine antioxidant capacity. Clin Chem Acta, 305 167-
173.  
Kishimoto, T. (2003). Interleukin-6 (il-6) In A. W. Thomson & M. T. Lotze (Eds.), 
The cytokine handbook (pp. 281-304). London Elsevier Science Ltd. 
Kitching, R., & Seth, A. (2005). Amplification refractory mutation system and 
molecular diagnostics. In J. M. Walker & R. Rapley (Eds.), Medical 
biomethods handbook (pp. 155-165). Totowa, NJ Humana Press, Inc. . 
Kohn, J. (1969). Separation of haemoglobins on cellulose acetate J Clin Pathol 
22(1), 109-111.  
171 
Kolahi, J., Ghalayani, P., & Varshosaz, J. (2006). Systemic toxicity following 
ingestion of the chlorhexidine gluconate solution: A case report. J Int Acad 
Periodontol 8, 45–46.  
Koppenol, W. H. (2001). The haber-weiss cycle – 70 years later. Redox Rep 6(4), 
229-234.  
Kumar, T. P. P, Deepa, M. S., & Kumar, K. N. (2014). Salivary proteomic 
biomarkers in the diagnosis of periodontal diseases. Health Sciences, 1(3), 
1-15.  
Kuppusamy, U. R., Indran, M., & Rokiah, P. (2005). Glycaemic control in relation 
to xanthine oxidase and antioxidant indices in malaysian ttype 2 diabetes 
patients. Diabet Med 22, 1343-1346.  
Kuppusamy, U. R., & Tan, J. A. M. A. (2011). Chelation therapy with 
desferrioxamine does not normalize ferritin level but attenuates oxidative 
damage and improves total antioxidant level in malaysian chinese β-
thalassaemia major patients. West Indian Med J, 60(1), 3-8.  
Lachenmeier, D. W., Keck-Wilhelm, A., Sauermann, A., & Mildau, G. (2008). 
Safety assessment of alcohol-containing mouthwashes and oral rinses. 
SOFW J, 134(10), 70-78.  
Lahiri, D. K., & Schnabel, B. (1993). DNA isolation by a rapid method from human 
blood samples: Effects of mgcl2, edta, storage time, and temperature on 
DNA yield and quality. Biochem Genet, 31(7-8), 321-328.  
Lequin, R. M. (2005). Enzyme immunoassay (eia)/enzyme-linked immunosorbent 
assay (elisa). Clin Chem, 51(12), 2415–2418.  
Li, H. Y., Hou, F. F., Zhang, X., Chen, P. Y., Liu, S. X., Feng, J. X., Liu, Z. Q., 
Shan, Y. X., Wang, G. B., Zhou, Z. M., Tian, J. W., & Xie, D. (2007). 
Advanced oxidation protein products accelerate renal fibrosis in a remnant 
kidney model. J Am Soc Nephrol 18(2), 528-538. doi: 
10.1681/ASN.2006070781 
Lin, H. J., Chen, S. T., Wu, H. Y., Hsu, H. C., Chen, M. F., Lee, Y. T., Wu, K. Y., 
& Chien, K. L. (2015). Urinary biomarkers of oxidative and nitrosative 
stress and the risk for incident stroke: A nested case–control study from a 
community-based cohort. Int J Cardiol 183, 214-220.  
Livrea, M. A., Tesoriere, L., Pintaudi, A. M., Calabrese, A., Maggio, A., Freisleben, 
H. J., D'Arpa, D., D'Anna, R., & Bongiorno, A. (1996). Oxidative stress and 
antioxidant status in -thalassemia major: Iron overload and depletion of 
lipid-soluble antioxidants. Blood 88(9), 3608-3614.  
172 
London, S. J., Xia, J., Lehman, T. A., Yang, J. H., Granada, E., Chunhong, L., 
Dubeau, L., Li, T., David-Beabes, G. L., & Li, Y. (2001). Collection of 
buccal cell DNA in seventh-grade children using water and a toothbrush. 
Cancer Epidemiol Biomarkers Prev, 10, 1227-1230.  
Loppow, D., Bottcher, M., Gercken, G., Magnussen, H., & Jorres, R. A. (2000). 
Flow cytometric analysis of the effect of dithiothreitol on leukocyte surface 
markers Eur Respir J, 16, 324-329.  
Low, L. C. K. (2005). Growth of children with b-thalassemia major. Indian J 
Pediatr 72(2), 159-164.  
Lum, A., & Marchand, L. L. (1998). A simple mouthwash method for obtaining 
genomic DNA in molecular epidemiological studies. Cancer Epidemiol 
Biomarkers Prev, 7, 719-724.  
Lynch, J. R., Brown, J. M., Best, S., Jennings, M. W., & Weatherall, D. J. (1991). 
Characterisation of the breakpoint of a 3.5 kb deletion of the -globin gene. 
Genomics 10, 509-511.  
Meulenbelt, I., Droog, S., Trommelen, G. J. M., Boomsma, D. I., & Slagboom, P. 
E. (1995). High-yield noninvasive human genomic DNA isolation method 
for genetic studies in geographically dispersed families and populations. Am 
J Hum Genet 57, 1252-1254.  
Michishige, F., Kanno, K., Yoshinaga, S., Hinode, D., Takehisa, Y., & Yasuoka, S. 
(2006). Effect of saliva collection method on the concentration of protein 
components in saliva. J Med Invest 53, 140-146.  
Miller, C. S., Foley, J. D., Bailey, A. L., Campell, C. L., Humphries, R. L., 
Christodoulides, N., Floriano, P. N., Simmons, G., Bhagwandin, B., 
Jacobson, J. W., Redding, S. W., Ebersole, J. L., & McDevitt, J. T. (2010). 
Current developments in salivary diagnostics. Biomark Med, 4(1), 171–189.  
Milne, E., van Bockxmeer, F. M., Robertson, L., Brisbane, J. M., Ashton, L. J., 
Scott, R. J., & Armstrong, B. K. (2006). Buccal DNA collection: 
Comparison of buccal swabs with fta cards. Cancer Epidemiol Biomarkers 
Prev 15(4), 816-819.  
Misra, H. P., & Fridovich, I. (1971). The generation of superoxide radical during 
the autoxidation of ferredoxins. J Biol Chem, 246(22), 6886-6890.  
Moghimi, S. M. (1995). Mechanisms of splenic clearance of blood cells and 
particles: Towards development of new splenotropic agents Adv Drug Deliv 
Rev  17, 103-115.  
173 
Moore, L., Wiencke, J., Eng, C., Zheng, S., & Smith, A. (2001). Evaluation of 
buccal cell collection protocols for genetic susceptibility studies. 
Biomarkers 6(6), 448-454.  
Morabito, N., Russo, G. T., Gaudio, A., Lasco, A., Catalano, A., Morini, E., 
Franchina, F., Maisano, D., La Rosa, M., Plota, M., Crifò, A., Meo, A., & 
Frisina, N. (2007). The “lively” cytokines network in β-thalassemia major-
related osteoporosis. Bone 40, 1588–1594.  
Moran, J. L., & Solomon, P. (2002). Worrying about normality. Crit Care Resusc, 
4, 316-319.  
Moreira, D. (1998). Efficient removal of pcr inhibitors using agarose-embedded 
DNA preparations. Nucleic Acids Res, 26(13), 3309–3310.  
Motum, P. I., Kearney, A., Hamilton, T. J., & Trent, R. J. (1993). Filipino 0-
thalassaemia: A high hb a2 0-thalassaemia resulting from a large deletion 
of the 5'  globin gene region J Med Genet 30, 240-244.  
Muller, L., Frohlich, K., & Bohm, V. (2011). Comparative antioxidant activities of 
carotenoids measured by ferric reducing antioxidant power (frap), abts 
bleaching assay (teac), dpph assay and peroxyl radical scavenging assay. 
Food Chem, 129, 139–148.  
Mulot, C., Stucker, I., Clavel, J., Beaune, P., & Loriot, M. A. (2005). Collection of 
human genomic DNA from buccal cells for genetics studies: Comparison 
between cytobrush, mouthwash, and treated card. J Biomed Biotechnol, 3, 
291-296.  
Nadkarni, A., Gorakshakar, A. C., Lu, C. Y., Krishnamoorthy, R., Ghosh, K., 
Colah, R., & Mohanty, D. (2001). Molecular pathogenesis and clinical 
variability of -thalassemia syndromes among indians. Am J Hematol 68, 
75-80.  
Navazesh, M., Mulligan, R. A., Kipnis, V., Denny, P. A., & Denny, P. C. (1992). 
Comparison of whole saliva flow rates and mucin concentrations in healthy 
caucasian young and aged adults. J Dent Res 71(6), 1275-1278.  
Nedel, F., Conde, M. C. M., de Oliveira, I. O., Tarquinio, S. B. C., & Demarco, F. 
F. (2009). Comparison between DNA obtained from buccal cells of the 
upper and lower gutter area. Braz Dent J 20(4), 275-278.  
Nemeth, E. (2010). Hepcidin in β-thalassemia Ann NY Acad Sci, 1202, 31-35.  
Newton, C. R., Graham, A., Hepstintall, L. E., Powell, S. J., Summers, C., 
Kalsheker, N., Smith, J. C., & Markham, A. F. (1989). Analysis of any point 
mutation in DNA. The amplification refractory mutation system (arms) 
Nucleic Acids Res, 7(7), 2503-2516.  
174 
Ng, D. P. K., Koh, D., Choo, S., & Chia, K. S. (2006). Saliva as a viable alternative 
source of human genomic DNA in genetic epidemiology. Clin Chim Acta 
367, 81 – 85.  
Niki, E., Yoshida, Y., Saito, Y., & Noguchi, N. (2005). Lipid peroxidation: 
Mechanisms, inhibition, and biological effect. Biochem Biophys Res 
Commun 338, 668-676.  
Old, J. M., Varawalla, N. Y., & Weatherall, D. J. (1990). Rapid detection and 
prenatal diagnosis of -thalassemia: Studies in india and cypriot 
populations in the uk Lancet, 336, 834-837.  
Olivieri, N. F., Koren, G., Matsui, D., Liu, P. P., Blendis, L., Cameron, R., 
McClelland, R. A., & Templeton, D. M. (1992). Reduction of tissue iron 
stores and normalization of serum ferritin during treatment with the oral iron 
chelator l1 in thalassemia intermedia. Blood 79(10), 2741-2748.  
Ozsvath, D. L. (2009). Fluoride and environmental health: A review. Rev Environ 
Sci Biotechnol 8, 59–79.  
Pandeshwar, P., & Das, R. (2014). Role of oral fluids in DNA investigations. J 
Forensic Leg Med, 22, 45-50.  
Philibert, R. A., Zadorozhnyaya, O., Beach, S. R. H., & Brody, G. H. (2008). A 
comparison of the genotyping results using DNA obtained from blood and 
saliva. Psychiatr Genet, 18(6), 275-281.  
Piomelli, S., Danoff, S. J., Becker, M. H., Lipera, M. J., & Travis, S. F. (1969). 
Prevention of bone malformations and cardiomegaly in cooley’s anemia by 
early hypertransfusion regimen. Ann N Y Acad Sci 165, 427-436.  
Pirastu, M., Ristaldi, M. S., & Cao, A. (1989). Prenatal diagnosis of -thalassaemia 
based on restriction endonuclease analysis of amplified fetal DNA. J Med 
Genet, 26, 363-367.  
Prabhu, R., Prabhu, V., & Prabhu, R. S. (2009). Iron overload in beta-thalassemia - 
a review J Biosci Tech, 1(1), 20-31.  
Raj, S. C. D. (2009). Role of interleukin-6 in the anemia of chronic disease. Semin 
Arthritis Rheum 38, 382-388.  
Rasmussen, H. B. (2012). Restriction fragment length polymorphism analysis of 
pcr-amplified fragments (pcr-rflp) and gel electrophoresis - valuable tool for 
genotyping and genetic fingerprinting. In S. Magdeldin (Ed.), Gel 
electrophoresis - principles and basics: InTech. Retrieved from 
http://www.intechopen.com/books/gel-electrophoresis-principles-and-
basics/restriction-fragment-length-polymorphism-analysis-of-pcr-amplified-
fragments-pcr-rflp-and-related-te.  
175 
Rayegani, S. M., & Azadi, A. (2007). Lateral antebrachial cutaneous nerve injury 
induced by phlebotomy. J Brachial Plex Peripher Nerve Inj, 2, 6-8.  
Riordan, M., Rylance, G., & Berry, K. (2002). Poisoning in children 4: Household 
products, plants, and mushrooms. Arch Dis Child, 87, 403-406.  
Rogers, N. L., Cole, S. A., Lan, H. C., Crossa, A., & Demerath, E. W. (2007). New 
saliva DNA collection method compared to buccal cell collection techniques 
for epidemiological studies. Am J Hum Biol, 19(3), 319-326.  
Roussou, P., Tsagarakis, N. J., Kountouras, D., Livadas, S., & Kandarakis, E. D. 
(2013). Beta-thalassemia major and female fertility: The role of iron and 
iron-induced oxidative stress. Anemia, 1-9. doi: 10.1155/2013/617204 
Rylander-Rudqvist, T., Hakansson, N., Tybring, G., & Wolk, A. (2006). Quality 
and quantity of saliva DNA obtained from the self-administrated oragene 
method − a pilot study on the cohort of swedish men. Cancer Epidemiol 
Biomarkers Prev, 15 1742-1745.  
Saftlas, A. F., Waldschmidt, M., Sackett, N. L., Triche, E., & Field, E. (2004). 
Optimizing buccal cell DNA yields in mothers and infants for human 
leukocyte antigen genotyping. Am J Epidemiol, 160, 77-84.  
Said, M., Cappiello, C., Devaney, J. M., Podini, D., Beres, A. L., Vukmanovic, S., 
Rais-Bahrami, K., Luban, N. C., Sandler, A. D., & Tatari-Calderone, Z. 
(2014). Genomics in premature infants: A non-invasive strategy to obtain 
high-quality DNA. Sci Rep 4(4286). doi: 10.1038/srep04286 
Saigo, K., Kono, M., Takagi, Y., Takenokuchi, M., Hiramatsu, Y., Tada, H., 
Hishita, T., Misawa, M., Imoto, S., & Imashuku, S. (2013 ). Deferasirox 
reduces oxidative stress in patients with transfusion dependency. J Clin Med 
Res 5(1), 57-60.  
Sanchez, G. A., Miozza, V., Delgado, A., & Busch, L. (2011). Determination of 
salivary levels of mucin and amylase in chronic periodontitis patients. J 
Periodontal Res 46, 221-227.  
Scheller, J., Chalaris, A., Arras, D. S., & John, S. R. (2011). The pro- and anti-
inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 
1813, 878–888.  
Schiott, R. C., & Loe, H. (1970). The origin and variation in number of leukocytes 
in the human saliva. J Periodontal Res, 5, 36-41.  
Schwemmer, M., Fink, B., Kockerbauer, R., & Bassenge, E. (2000). How urine 
analysis reflects oxidative stress - nitrotyrosine as a potential marker Clin 
Chem Acta 297, 207-216.  
176 
Sclafani, S., Calvaruso, G., Agrigento, V., Maggio, A., Lo Nigro V., & D'Alcamo, 
E. (2013 ). Glutathione s transferase polymorphisms influence on iron 
overload in -thalassemia patients Thalassemia Reports 3(1), 6.  
Sculley, D. V., & Langley-Evans, S. C. (2002). Salivary antioxidants and 
periodontal disease status. Proc Nutr Soc, 61, 137-143.  
Shao, W., Closas, M. G., Alguacil, J., Rothman, N., Schatzkin, A., Vaught, J., 
Sigurdson, A., & Cosentino, M. (2007). Modifications to a standard buccal 
collection protocol: Effects on human DNA yield. Cell Preserv Technol, 
5(4), 216-224.  
Shulman, J. D., & Wells, L. M. (1997). Acute ethanol toxicity from ingesting 
mouthwash in children younger than 6 years of age Pediatr Dent, 19, 405-
408.  
Soukup, M., Biesiada, I., Henderson, A., Idowu, B., Rodeback, D., Ridpath, L., 
Bridges, E. G., Nazar, A. M., & Bridges, K. G. (2012). Salivary uric acid as 
a noninvasive biomarker of metabolic syndrome. Diabetol Metab Syndr, 4, 
14. doi: 10.1186/1758-5996-4-14 
Stitik, T. P., Foye, P. M., Nadler, S. F., & Brachman, G. O. (2001). Phlebotomy-
related lateral antebrachial cutaneous nerve injury. Am J Phys Med Rehabil, 
80, 230-234.  
Swinfield, C. E., Grahama, E. A. M., Nuttall, D., Maguire, S., Kemp, A., & Rutty, 
G. N. (2009). The use of DNA stabilizing solution to enable room 
temperature storage and transportation of buccal and trace sample swabs. 
Forensic Sci Int-Gen 183-184.  
Tan, J. A. M. A., George, E., Tan, K. L., Chow, T., Tan, P. C., Hassan, J., Chia, P., 
Subramanium, R., Chandran, R., & Yap, S. F. (2004). Molecular defects in 
the β-globin gene identified in different ethnic groups/populations during 
prenatal diagnosis for β-thalassemia: A malaysian experience. Clin Exp Med 
4, 142-147.  
Tan, K. L., Tan, J. A. M. A., Wong, Y. C., Wee, Y. C., Thong, M. K., & Yap, S. F. 
(2001). Combine-arms: A rapid and cost-effective protocol for molecular 
characterization of β-thalasaemia in malaysia. Genet Test, 5, 17-22.  
Telen, M. J., & Kaufman, R. E. (1999). The mature erythrocyte. In G. R. Lee, F. 
Paraskevas, J. Foerster & J. Lukens (Eds.), Wintrobe’s clinical hematology 
(10th ed., pp. 207). Baltimore, MD: Lippincott Williams & Wilkins. 
Thedsawad, A., Jindadamrongwech, S., Chuncharunee, S., & Butthep, P. (2012). 
Multiplex arms-pcr analysis for nineteen -thalassemia mutations. J 
Hematol Transfus Med 22, 31-40.  
177 
Thein, S. L. (1998). -thalassaemia. Bailliere Clin Haem 11(1), 91-126.  
Thein, S. L. (2004). Genetic insights into the clinical diversity of thalassaemia. 
Br J Haematol, 124, 264–274.  
Tockman, M. S., Qiao, Y., Li, L., Zhao, G. Z., Sharma, R., Cavenaugh, L. L., & 
Erozan, Y.S. (1995). Safe separation of sputum cells from mucoid 
glycoprotein Acta Cytol, 39, 1128-1136.  
Turgeon, M. L. (2005). Clinical hematology: Theory and procedures (4th ed.). 
USA: Lippincott Williams & Wilkins. 
Uitto, V. J. (2003). Gingival crevice fluid – an introduction. Periodontol 2000, 31, 
9-11.  
Van Weemen, B. K., & Schuurs, A. H. W. M. (1971). Immunoassay using antigen-
enzyme conjugates FEBS Lett, 15(3), 232-236.  
Villar, J. P. (2007). Mucin granule intraluminal organization. Am J Respir Cell Mol 
Biol 36, 183–190.  
Wandenvik, H., & Kutti, J. (1988). The spleen and pooling of blood cells Eur J 
Haematol, 41, 1-5.  
Wang, H., Czura, C. J., & Tracey, K. J. (2003). Tumor necrosis factor In A. W. 
Thomson & M. T. Lotze (Eds.), The cytokines handbook (4th ed., pp. 837-
860). London Elsevier Science Ltd. 
Weatherall, D. J., & Clegg, J. B. (1979). Recent developments in the molecular 
genetics of human hemoglobin. Cell 16(3), 467-479.  
Weatherall, D. J., & Clegg, J. B. (2001). The thalassaemia syndromes (4th ed.). 
Oxford: Blackwell Science Ltd. 
Wee, Y. C., Tan, K. L., Chua, K. H., George, E., & Tan, J. A. M. A. (2009). 
Molecular characterisation of haemoglobin constant spring and haemoglobin 
quong sze with a combine-amplification refractory mutation system. Malays 
J Med Sci, 16(3), 23-30.  
Whitford, G. M. (1992). Acute and chronic fluoride toxicity. J Dent Res 71 (5), 
1249–1254.  
Witko-Sarsat, V., Friedlander, M., Capeillere-Blandin, C., Nguyen-Khoa, T., 
Nguyen, A. T., Zingraff, J., Jungers, P., & Descamps-Latscha, B. (1996). 
Advanced oxidation protein products as a novel marker of oxidative stress in 
uremia. Kidney Int, 49, 1304—1313.  
178 
Witko-Sarsat, V., Friedlander, M., Nguyen-Khoa, T., Capeillere-Blandin, C, ., 
Nguyen, A. T., Canteloup, S., Dayer, J. M., Jungers, P., Drueke, T., & 
Descamps-Latscha, B. (1998). Advanced oxidation protein products as 
novel mediators of inflammation and monocyte activation in chronic renal 
failure. J Immunol, 161, 2524–2532.  
Wolfram, R., Oguogho, A., Palumbo, B., & Sinzinger, H. (2005). Enhanced 
oxidative stress in coronary heart disease and chronic heart failure as 
indicated by an increased 8-epi-pgf2. Eur J Heart Fail 7, 167–172.  
Wu, L. L., Chiou, C. C., Chang, P. Y., & Wu, J. T. (2004). Urinary 8-ohdg: A 
marker of oxidative stress to DNA and a risk factor for cancer, 
atherosclerosis and diabetics. Clin Chem Acta, 339 1-9.  
Zalewska, A., Knas, M., Sieskiewicz, E. G., Waszkiewicz, N., Klimiuk, A., Litwin, 
K., Sierakowski, S., & Waszkiel, D. (2014). Salivary antioxidants in patients 
with sistemic sclerosis J Oral Pathol Med 43, 61-68.  
Zayats, T., Young, T. L., Mackey, D. A., Malecaze, F., Calvas, P., & Guggenheim, 
J. A. (2009). Quality of DNA extracted from mouthwashes. PLoS ONE 4(7), 
e6165. doi: 10.1371/journal.pone.0006165 
Zhou, Y., Fang, L., Jiang, L., Wen, P., Cao, H., He, W., Dai, C., & Yang, J. (2012). 
Uric acid induces renal inflammation via activating tubular nf-kb signaling 
pathway. PLoS ONE 7(6), e39738. doi: 10.1371/journal.pone.0039738 
Ziffle, J. V., Yang, W., & Chehab, F. F. (2011). Homozygous deletion of six 
olfactory receptor genes in a subset of individuals with -thalassemia. PLoS 
ONE, 6(3). doi: 10.1371/journal.pone.0017327 
 
 
  
179 
LIST OF PUBLICATIONS AND PAPERS PRESENTED 
1. DNA genotyping and antioxidant status in β-thalassaemia major patients 
using non-invasive sampling techniques. International Anatomical Sciences 
and Cell Biology Conference, 26
th
 -29
th
 May 2010. National University of 
Singapore, Singapore (Poster presentation).  
2. Assessment of DNA extracted from non-invasive samples – mouthwash, 
saliva and buccal cells – for molecular analysis of β-thalsssaemia. National 
Postgraduate Conference in Molecular Medicine, 13
th
 -14
th
 April 2011. 
Universiti Sains Malaysia, Kota Bahru, Kelantan, Malaysia (Poster 
presentation).  
3. Evaluation of concentration and purity of DNA extracted from mouthwash, 
saliva and buccal cytobrush samples. 1
st
 International Conference on 
Molecular Diagnostics and Biomarker Discovery, 23
rd
 -25
th
 October 2013. 
Universiti Sains Malaysia, Penang, Malaysia (Poster presentation).  
4. Rahim, MRA, Kho, SL, Tan, JAMA and Kuppusamy, UR. Non-invasive 
DNA sampling for molecular analysis of beta-thalassemia: Amiable 
alternative sampling methods with accurate results for pediatric patients. 
Clin Lab. (Accepted).  
5. Rahim, MRA, Kuppusamy, UR and Tan, JAMA. Salivary oxidative stress 
indices and cytokine levels in beta-thalassaemia major patients. (Manuscript 
in preparation).  
 
 
 
  
180 
APPENDIX 
Appendix A  
Figure A1: Patient information sheet (Bahasa Malaysia)  
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Figure A2: Patient information sheet (English)  
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Figure A3: Informed consent form (Bahasa Malaysia)  
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Figure A4: Informed consent form (English)  
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Figure A5: Questionnaire form  
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Figure A6: Transfusion dependent thalassaemia flow sheet  
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Appendix B 
1) Reagent for sample collection  
a. Normal saline (0.85% NaCl) 
 8.5 g NaCl (MW: 58.44 g/mol) 
 Filtered water  
NaCl powder was dissolved in 1000 mL of water. The solution was autoclaved. 
 
2) Reagents for DNA extraction  
a. 1 M Tris(hydroxymethyl)aminomethane (Tris, pH 8.0)  
 121.1 g Tris (MW: 121.1 g/mol) 
 Sterile deionised water  
 Concentrated hydrochloric acid (HCl)  
Tris powder was dissolved in 800 mL of water. Concentrated HCl was added to 
adjust the pH to 8.0. Water was added to make up the volume to 1000 mL. The 
solution was filtered and autoclaved.  
 
b. 0.5 M ethylenediaminetetraacetic acid (EDTA, pH 8.0) 
 186.1 g sodium EDTA (Na2EDTA.2H2O,MW: 372.24 g/mol) 
 Sterile deionised water  
 10 M sodium hydroxide (NaOH)  
EDTA powder was dissolved in 800 mL of water. NaOH was added to adjust the 
pH to 8.0. Water was added to make up the volume to 1000 mL. The solution 
was filtered and autoclaved. 
 
c. 10 M sodium hydroxide (NaOH) 
 40 g NaOH (MW: 40 g/mol) 
 Sterile deionised water  
NaOH pellets were left to dissolve in 100 mL of water. Additional precaution 
was needed as the reaction was exothermic.  
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d. Tris-EDTA buffer (TE 10 mM/10 mM, pH 8.0) 
 10 mL 1 M Tris 
 20 mL 0.5 M EDTA  
 Sterile deionised water   
Both solution were mixed and diluted with deionised water up to 1000 mL. The 
solution was autoclaved. 
 
e. 4 M sodium chloride (NaCl) 
 23.38 g NaCl (MW: 58.44 g/mol) 
 Sterile deionised water  
NaCl powder was dissolved in 100 mL of water. The solution was filtered and 
autoclaved. 
 
f. 10% sodium dodecyl sulphate (SDS) 
 10 g SDS (MW: 288.37 g/mol) 
 Sterile deionised water  
SDS powder was dissolved in 100 mL of water. The solution was filter sterilised. 
 
g. Lysis buffer  
 1.25 mL of 4 M NaCl 
 10 mL of 10% SDS  
 TE buffer  
NaCl and SDS were mixed with TE buffer and the solution was made up to 50 
mL.  
 
h. 10 mg/mL proteinase K  
 100 mg of lyophilised proteinase K (fungal) (Invitrogen, Cat: 25530-015) 
 10 mL ultrapure water  
The enzyme was reconstituted with the ultrapure water. The solution was 
aliquoted into several tubes and stored at -20°C until needed.  
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i. 20 mg/mL proteinase K  
 100 mg of lyophilised proteinase K 
 5 mL ultrapure water  
The enzyme was reconstituted with the ultrapure water. The solution was 
aliquoted into several tubes and stored at -20°C until needed. 
 
j. 10 mg/mL dithiothreitol (DTT)  
 500 mg of DTT  
 50 mL sterile deionised water 
The powder was reconstituted with the sterile water and stored at 4°C until 
needed. 
 
k. Tris buffered phenol  
 1 kg phenol (crystal form)  
 0.5 M Tris (pH 8.0) 
 1 g 8-hydroxyquinolin  
Phenol crystals were allowed to liquefy in its amber bottle at 68°C waterbath.   
8-hydroxyquinolin was added into the phenol liquid. Phenol was mixed with 
equal volume of 0.5 M Tris and the bottle was agitated vigorously. The solution 
mixture was allowed to separate overnight.  
The aqueous layer was removed on the following day. New 0.5 M Tris was 
added and the mixture was agitated vigorously and allowed to separate.  
The mixing step was repeated until the phenol has reached the pH of 7.6 – 8.0.  
A portion of the aqueous layer was left on top of the phenol liquid to prevent 
phenol oxidation. The solution was stored at 4°C 
 
l. Phenol: chloroform (1:1) 
 500 mL Tris buffered phenol 
 500 mL chloroform   
Both solution was mixed in a amber bottle and stored at 4°C. 
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m. 3 M sodium acetate (NaOAc, pH 5.6) 
 24.61 g NaOAc (MW: 82.03 g/mol) 
 Sterile deionised water 
 Glacial acetic acid 
NaOAc powder was dissolved in 50 mL of water. Glacial acetic acid was added 
to adjust the pH to 5.6. The solution was filtered and autoclaved. 
 
3) Reagents for gel electrophoresis  
a. 10X Tris-Borate-EDTA buffer (TBE, pH 8.3) 
 108 g Tris 
 55 g boric acid (MW: 61.8 g/mol) 
 40 mL 0.5 M EDTA  
 Sterile deionised water   
All powders and solution were mixed and diluted with deionised water up to 
1000 mL. The solution was filtered and autoclaved.  
 
b. 5X TBE loading buffer 
 10 mL 10X TBE 
 9.8 mL glycerol  
 0.2 mL of 10% SDS  
 6 mg bromophenol blue  
 30 mg xylene cyanol  
All components were mixed in sterile reagent bottle and stored protected from 
light. 
 
4) Reagents for FRAP assay  
a. 1000 µM ferrous sulphate (FeSO4, standard stock solution)  
 0.0028 g FeSO4.7H2O 
 10 mL deionised water   
The powder was dissolved in water. The stock solution was used to produce 200, 
400, 600 and 800 µM solutions.  
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b. 300 mM acetate buffer (pH 3.6) 
 0.31 g NaOAc 
 1.6 mL acetic acid  
 Deionised water   
NaOAc was dissolved in 90 mL of water. Acetic acid was added and the solution 
was brought to final volume of 100 mL 
 
c. 10 mM TPTZ in 40 mM HCl  
 0.0156 g TPTZ 
 0.2 mL of 1 M HCl 
 Deionised water   
TPTZ was added into HCl and brought up to final volume of 5 mL with water. 
The solution was protected from light.  
 
d. 20 mM ferric chloride (FeCl3.6H2O)  
 0.0541 g FeCl3.6H2O 
 10 mL deionised water   
The powder was dissolved in water.  
 
e. FRAP reagent  
 50 mL acetate buffer 
 5 mL TPTZ 
 5 mL FeCl3  
All solutions were combined together. The final solution was protected from 
light.  
 
5) Reagents for AOPP assay  
a. 500 µM chloramine-T (standard stock solution) 
 0.0028 g chloramine-T 
 25 mL deionised water   
Chloramine-T was dissolved in water and further used to produce 100, 200, 300 
and 400 µM solutions. The solution was protected from light.  
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b. Phosphate buffered saline (PBS) 
 1 PBS tablet  
 100 mL deionised water   
The tablet was dissolved in water and stored at 4°C until needed.  
 
c. 50% acetic acid  
 50 mL glacial acetic acid 
 50 mL deionised water   
The acid was diluted with water. The solution can be kept for later use at room 
temperature.  
 
d. 1.16 M potassium iodide (KI)  
 0.9628 g KI  
 5 mL deionised water   
The KI powder was dissolved in water. The solution was protected from light.  
 
e. AOPP reagent  
 81% of PBS 
 15% of 50% acetic acid 
 4% of KI 
All solutions were combined together. The final solution was protected from 
light.  
 
6) Reagents for LOOH assay  
a. 1 mM 1,1,3,3-tetraethoxypropane (TEP, standard stock solution) 
 12.5 µL TEP 
 50 mL deionised water   
Water (12.5 µL) was removed from the tube. TEP was added and vortexed to 
mix. The stock solution was further used to produce 20, 15, 10, 5 and 2.5 µM 
solutions. The solution was protected from light.  
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b. 10.3 mM 1-methyl-2-phenylindole (MPI) in acetonitrile  
 0.0213 g MPI 
 10 mL acetonitrile  
The powder was dissolved in the solvent and protected from light.  
 
c. 5 M HCl  
 50 mL of stock HCl (37%)  
 50 mL deionised water  
The acid was diluted with water. The solution can be kept for later use at room 
temperature and protected from light.  
 
7) Reagents for ELISA  
a. Phosphate buffered saline (PBS) 
 10 PBS tablet  
 1000 mL deionised water   
The tablet was dissolved in water and stored at 4°C until needed.  
 
b. Washing buffer 
 50 mL PBS 
 25 µL Tween-20 
PBS (25 µL) was removed and Tween-20 was added. The solution was mixed 
gently.   
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Appendix C 
Figure C1: Standard curve for FRAP assay  
 
 
Figure C2: Standard curve for AOPP assay 
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Figure C3: Standard curve for LOOH assay 
 
 
Figure C4: Activity curve for control in GPx assay 
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Figure C5: Standard curve for UA assay 
 
 
Figure C6: Standard curve for ELISA 
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